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Head and neck cancer (HNC) confers a poor prognosis and patients face complex 
treatment decisions.  As with every cancer in the UK, recommendations for treatment 
are made through a multidisciplinary team (MDT).  This thesis critically analyses the 
working of the MDT: data are presented from an ethnographic study across three head 
and neck cancer treatment centres. 
Data collection comprised non-participant observation of 35 MDT meetings and 37 
MDT clinic appointments and semi-structured interviews with 19 patients pre- and post-
treatment and nine staff members of the MDT.  Data generated were analysed using a 
Constructionist Grounded Theory approach, drawing on symbolic interactionism and 
dramaturgical analysis. 
This thesis provides an in depth account of the backstage behaviour of the MDT 
members.  Although an assessment of which treatment is considered ‘best’ drives their 
discussion, there is often disagreement or uncertainty surrounding this assessment.  On 
delivering the recommendation to the patient, this backstage work often remains hidden, 
contributing to problems when offering treatment choice.  Even when a choice of 
treatment is acknowledged, the MDT faces barriers in delivering and supporting this in 
the MDT clinic.  For the patient, the majority of the work of decision making takes 
place away from the MDT clinic, a process which is not always supported by the MDT 
The difficulties of actively involving patients in the MDT decision process have never 
been explored, but the complexities of offering treatment choice in the MDT need to be 
recognised to support patients in this setting.  The guiding principles, purpose and 
limitations of the MDT meeting and the resultant treatment recommendation need to be 
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clear.  A process of collaborative MDT decision making should allow effective 
communication of treatment risk and uncertainty, structured elicitation of patient 
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Chapter 1: Head and Neck Cancer 
Head and neck cancer (HNC) is a group of tumours which may arise from multiple 
anatomical sites.  In this chapter I provide an introduction and overview of the disease, 
how it presents and how it is investigated and staged.  I then discuss the multiple 
treatment options which are available to patients and clinicians, the trade-offs associated 
with radical treatment and the difficulties of engaging patients in treatment decisions 
which make this disease uniquely challenging.  
1.1 Definition 
HNC is a large group of cancers originating from sites including the voice box (larynx), 
throat (oropharynx, hypopharynx and upper oesophagus), mouth (oral cavity), nose 
(nasal cavity, sinus and nasopharynx) and salivary glands.  Over 90% of HNC are 
squamous cell carcinomas (SCC) (DAHNO 2011). 
1.2 Epidemiology 
The World Health Organisation estimates that worldwide there are 560,000 new cases 
of HNC each year, and 300,000 deaths (WHO 2008).  In 2011 there were an estimated 
7354 new cases in the UK DAHNO 2011 with incidence rates in England varying from 
0.39 per 100,000 population for nasopharyngeal cancer (208 cases per year) to 3.01 per 
100,000 for laryngeal cancer (1729 cases per year) (OCIU 2010).  Depending on the site 
of the disease, the male:female ratio varies between 2:1 and 15:1.  Most patients are 
older, with 98% of cancers being diagnosed in the over 40s, and 50% in the over 60s 
(Mehanna et al. 2010).  The recent rise in the incidence of disease secondary to human 
papilloma virus (HPV) infection (discussed later) has led to HNC being diagnosed more 
commonly in younger patients (Mehanna et al. 2010; OCIU 2010).  HNC is more 
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commonly diagnosed in patients with characteristics associated with lower 
socioeconomic status such as unemployment or lower educational attainment, but much 
of this difference is due to increased rates of smoking (Conway et al. 2010a; Conway et 
al. 2010b). 
1.3 Risk Factors 
Tobacco and alcohol use account for around 75% of cases of HNC.  Their effects are 
not isolated but multiplicative (Mehanna et al. 2010).  Smoking alone has a clear dose-
response relationship for the frequency, duration, and number of pack-years of cigarette 
smoking. When drinkers are compared to never-drinkers, people who take more than 
three drinks per day have twice the risk of pharyngeal and laryngeal cancer (Hashibe et 
al. 2007); this effect is found to be more pronounced if drinking beers and spirits than if 
drinking wine (Purdue et al. 2009). A family history of HNC in first-degree relatives, 
especially siblings, also increases the risk of HNC (Negri et al. 2008).   
Despite an overall decline in the incidence of all head and neck cancers in recent years 
(NCI 2013), in the UK, the incidence of oropharyngeal tumours has increased by 51% 
(CRUK 2013).  This rise is thought to be a consequence of the increased incidence of 
tumours secondary to HPV infection.  There has been a significant increase in the 
proportion of oropharyngeal cancer biopsies which show evidence of HPV (Nasman et 
al. 2009).  HPV related HNC is viewed as a distinct disease entity which has a better 
prognosis (Fakhry et al. 2008; Worden et al. 2008) however smoking decreases survival 
in oropharyngeal cancer, and this effect is independent of the HPV status.  This means 
that patients with HPV positive disease who smoke have a similar survival to those with 
HPV negative disease (Gillison et al. 2012).    Sexual transmission is considered to be 
the primary route of HPV transmission – there is an increased rate of oropharyngeal 
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cancer in those with a history of six or more  lifetime sexual partners, four or more 
lifetime oral sex partners or an earlier age at first sexual intercourse (Heck et al. 2010).  
The emergence of HPV related disease has cast doubt over previous research in 
oropharyngeal SCC which did not stratify for HPV infection.  Additionally there has 
been debate about a standardised test or cut-off point for reliably detecting HPV in 
oropharyngeal biopsies and specimens (Mehanna et al. 2010), with the most widely 
used methods being in situ hybridisation and identification of p16, a downstream 
product of HPV expression (Singhi and Westra 2010).  Although HPV testing is now 
routinely used in HNC practice, there is limited evidence that these patients should have 
substantially different treatment regimens to non-HPV patients (Mehanna et al. 2010) 
and trials for optimal treatment are ongoing. 
1.4 Presentation 
UK Guidelines from the National Institute for Health and Clinical Excellence (NICE 
2005) state that patients should be referred for specialist assessment if they have more 
than three weeks’ of symptoms of sore throat, hoarseness, difficulty swallowing, lump 
in the neck or unilateral ear pain.  Doctors should also refer if they find a persistent red 
or white patch in the mouth, oral ulceration, cranial nerve palsy or effusion in the ear.  
Patients in the UK who fit these criteria are referred for an urgent specialist opinion via 
the two week wait rule (NICE 2005).  Once referred, patients are assessed by full 
history, examination and a flexible nasolaryngoscopy.  Formal endoscopy under general 
anaesthetic for examination of the site and biopsy is arranged if cancer is suspected, and 
all patients have a CT and/or MRI scan to improve the accuracy of tumour staging 
(Mehanna et al. 2010). 
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1.5 Investigation and staging 
All head and neck tumours are graded using the tumour, nodal status, metastases (TNM) 
grading system (AJCC 2010).  The tumour (T) stage concerns the size, position and 
local invasion of the tumour, and is graded between T1 (small tumours) and T4 (large, 
invasive tumours).  HNC is locally invasive, and commonly spread via lymph.  The 
nodal (N) stage depends on the number, position and size of the lymph nodes that the 
cancer has spread to and is graded between N0 (delineates no detectable spread to 
lymph nodes) and N3.  Patients with HNC rarely have a distant metastasis at first 
presentation.  If no metastasis is present, the tumour is graded M0, if the cancer has 
spread to distant structures (most often the lung) it is graded M1. 
Pathological features which are associated with a poorer survival are histological grade 
of the cancer, pattern of invasion, proximity of the surgically resected cancer to the 
resection margins and presence of extranodal spread (RCP 2005).  Extranodal spread is 
spread of the cancer through the outer capsule of an affected lymph node; this more than 
halves a patient’s chance of surviving five years (Dunne et al. 2006).  Concomitant 
disease also leads to a poorer prognosis, with this effect being more pronounced in 
younger patients.  Additionally, comorbidity is associated with a higher incidence of 
complications following treatment, and a poorer quality of life after treatment has 
finished (Paleri et al. 2010). 
1.6 Treatment 
The survival associated with HNC varies globally (WHO 2008), but in the UK, the five 
year survival is around 65%.  Just over 20% of patients die within a year of treatment 
and 30% die within two years (DAHNO 2011). Curative treatment of HNC is difficult 
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to achieve, and often requires radical treatment regimens which have profound effects 
on a patient’s quality of life, most notably swallow and voice function.  Good quality, 
randomised evidence to guide treatment decisions is severely lacking.  Treatments can 
be broadly divided into surgical and non-surgical regimes.  I shall divide the discussion 
of treatment into early disease and advanced disease and focus on laryngeal and 
pharyngeal cancer.                                                                                                                                                                                                                                                                                                                                                                                                                     
1.6.1 Early disease 
Early cancers of the larynx and pharynx were traditionally treated with radiotherapy or 
cold surgical excision, however the management of early cancers has been 
revolutionised by the advent of laser surgery.  In early oropharyngeal cancer, evidence 
comparing the use of laser with  radiotherapy is lacking,  but survival is thought to be 
similar (Robson and Paleri 2010).  Evidence supporting the use of laser in early 
pharyngeal cancer is limited mainly to retrospective case series (Grant et al. 2009; 
Karatzanis et al. 2010). 
In early laryngeal cancer, a recent Cochrane review found there to be no good quality 
randomised controlled trials available comparing mortality, disease-free survival, 
quality of life or voice outcomes for laser resection or radiotherapy (Dey et al. 2002).  
Clinical practice has been informed by a number of case series and other non-
randomised research (Hirano et al. 1985; Ton-Van et al. 1991; McGuirt et al. 1994; 
Keilmann et al. 1996) which suggest that survival is similar between the two treatments, 
but with a different side effect profile and a slightly better voice outcome with 
radiotherapy (Higgins et al. 2009).  Treatment pathways between the two options are 
also very different; radiotherapy involves travelling every day to hospital for treatment 
for 4-6 weeks, whereas laser surgery can be performed in one day.  This difference in 
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treatment process is one of the main barriers to recruitment to randomised trials and the 
most recent attempt to conduct a UK randomised controlled trial failed as a result 
(Hamilton et al. 2013).   
1.6.2 Advanced disease 
In advanced disease, single modality treatment is generally associated with a poorer 
survival (1991; Bhalavat et al. 2003) but improved quality of life (Bjordal et al. 2001).  
Patients are usually treated with a combination of surgery and radiotherapy or 
radiotherapy and chemotherapy.  Often, the choice between radiotherapy, 
chemoradiotherapy and surgery, on the face of it, seems simple: surgery has obvious 
detrimental effects on speech and appearance, whereas radiotherapy allows the patient 
to retain their voice box and produce speech normally, and the addition of 
chemotherapy increases survival.  Survival (1991) and quality of life (Hanna et al. 
2004) are reported to be the same between the two treatment options.  However, the 
choice of treatment in advanced disease necessitates trade-offs between survival and 
function with the treatment selected affecting aesthetics, communication, nutrition and 
psychosocial functioning. 
Radiotherapy to the larynx or pharynx allows preservation of the voice box which has 
the obvious benefits of improved cosmesis and normal speech production.  Dry mouth 
can be one of the most troublesome side effects, but is significantly reduced by the use 
of intensity modulated radiotherapy (IMRT) (Nutting et al. 2011).   Although other 
methods of delivery of external beam radiation such as accelerated or hyperfractionated 
radiotherapy have shown improvements in local tumour control (Fu et al. 2000), the 
lack of effect on overall survival, and the increased local toxicity have meant they have 
not been adopted widely in the UK.   Survival is increased if chemotherapy is added to 
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radiotherapy (Pignon et al. 2000; Bonner et al. 2006), as is the rate of organ 
preservation (Lefebvre 2006).  Survival is also increased for post-surgical patients who 
have positive resection margins or extracapsular lymph node spread, who go on to be 
treated with a combination of cisplatin and radiotherapy (Bernier et al. 2004; Cooper et 
al. 2004).  However, radiotherapy has significant side effects which are dose dependent 
and worsened when combined with chemotherapy (Abendstein et al. 2005).  The main 
short term side effects include skin reactions, inflammation of the lining of the mouth 
and throat and infection; in the long term pharyngeal stenosis leads to difficulty 
swallowing and laryngeal scarring causing hoarse voice.  In the most severe cases this 
may lead to a requirement for tracheostomy.  Difficulties with teeth and oral hygiene, 
mouth opening, dry mouth or sticky saliva (Abendstein et al. 2005) may be severe and 
debilitating.  Difficulty swallowing is now recognised as one of the major side effects of 
non-surgical management (Wilson et al. 2011) and many patients require supplementary 
enteral feeding or nutritional assistance with permanent gastrostomy or naso-gastric 
tube (Moor et al. 2010; Paleri and Patterson 2010).  Severe late radiation toxicity can be 
present in as many as 82% of patients at 5 years and may result in dry mouth, scarring 
of soft tissues and osteo-radionecrosis of the mandible (Denis et al. 2003).  In the 
Radiation Therapy Oncology Group 91-11 trial, 82% of patients treated with 
radiotherapy and cisplatin-based chemotherapy experienced a severe toxic effect 
(Forastiere et al. 2003). 
There are many potential surgical treatments of advanced HNC and a lack of consensus 
amongst clinicians about how much functional loss is considered ‘unacceptable’ to 
achieve complete resection of the tumour (Kreeft et al. 2009).  Large resections are 
commonplace, and microvascular free flaps are often used to improve post-operative 
function, cosmesis and quality of life (Schliephake and Jamil 2002; Genden et al. 2003).  
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Advanced oropharyngeal cancer is traditionally treated with radiotherapy (Forastiere 
and Trotti 1999; Finnegan et al. 2009) which is thought to produce improved functional 
outcomes (Parsons et al. 2002), however there are many advocates of surgery for these 
tumours (Rich et al. 2009; Haughey et al. 2011).  Again, decision making in advanced 
oropharyngeal cancer is limited by a lack of good quality, randomised, supportive 
evidence, leaving the choice of optimal management open to debate. 
In advanced laryngeal cancer, the standard of care was traditionally complete removal 
of the voice box (total laryngectomy).  Total laryngectomy renders the patient a neck 
breather with a tracheal stoma in the midline of the lower part of the anterior neck.  This 
has obvious cosmetic consequences, but can also cause problems with mucus 
production, crusting, sputum production and daily activities (in particular bathing and 
swimming).  After total laryngectomy, a patient speaks by occluding the stoma with a 
finger or thumb and forcing air through a one way valve, surgically created between the 
tracheal stoma and the gullet, thus creating a voice. Total laryngectomy patients are now 
offered primary surgical voice restoration, and their voice scores have been shown at 
least in one series to be no worse than those of patients with mild functional voice 
dysfunction  referred to voice clinics (Robertson et al. 2012).  Surgery also has 
significant potential complications: due to comorbidities, many patients pose a 
significant anaesthetic risk.  Post-operative infection rates can be as high as 20-40% 
(Liu et al. 2007; Varghese et al. 2009).   The advent of chemoradiotherapy means that 
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surgery is increasingly being undertaken on previously irradiated patients, a situation 
which leads to a fistula
1
 rate of up to a third (Weber et al. 2003).  
Almost 30 years ago, McNeil et al (1981) published a study scrutinising the trade-off 
between quantity and quality of life faced by patients with T3 laryngeal cancer.  They 
performed a simple time trade-off between speech and survival asking small groups of 
firemen and executives how many survival years they would “trade-off” in order to 
maintain a near normal voice with non- surgical management.  The premise of the 
utility analysis presented to participants, none of whom was a laryngeal cancer sufferer, 
was that radiotherapy was associated with a poorer survival, but a better voice.  Using 
expected utility theory they suggested that on this basis, 20% of healthy controls would 
opt for the non-surgical management.   The results of this work were widely accepted by 
the clinical community and so began a sea change in clinical opinion.  Today, the 
standard of care for the treatment of advanced laryngeal cancer is radiotherapy with or 
without chemotherapy (Paleri and Roland 2011). 
Practice has been heavily influenced in laryngeal cancer by large randomised controlled 
trials comparing surgery and radiotherapy and chemotherapy.  The first of these, 
conducted by the Department of Veterans Affairs Laryngeal Cancer Study Group  
showed similar short term survival between radiotherapy and TL (1991).  However, 
                                                 
1
 A fistula is a communication between the larynx, pharynx or oral cavity and the neck 
tissues or skin surface which causes leakage of saliva and has obvious cosmetic 




only estimated survivals for 2 years were ever reported and informal data presentation 
suggests  a longer term surgical survival advantage, which failed to achieve statistical 
significance due to sample size attrition (Wolf 2010).   Subsequently, the concurrent 
administration of chemotherapy was found to provide an added survival advantage to 
radiotherapy alone (Forastiere et al. 2003).  Again, analysis of the long-term survival 
results shows that the concurrent chemoradiotherapy group had a lower overall survival, 
although many of these deaths were not attributable to larynx cancer (Forastiere et al. 
2013).  This led some recently to advocate the selection of patients on the basis of 
response to a single dose of induction chemotherapy, a strategy which has demonstrated 
encouraging results (Urba et al. 2006).  Survival in laryngeal cancer has been found to 
be decreasing in the United States in the past two decades, coinciding with the steady 
increase in the use of non-surgical treatments (Hoffman et al. 2006).  It is hypothesised 
by a number of authors that survival may be higher in those patients who are treated 
surgically (Hashibe et al. 2007; Olsen 2010; Dziegielewski et al. 2012), but the 
difference may be insufficient to support the performance of further substantive, 
randomised comparisons. Thus some recent commentators argue that we should 
extrapolate the results of early,  closely controlled trials to the general patient population 
with caution (Olsen 2010).   
As a result of these findings, recent research has now come to focus on quality of life as 
a treatment outcome (Abendstein et al. 2005; Rogers et al. 2007) and even as a 
predictor of survival (Mehanna and Morton 2006). Treatment for advanced HNC has 
profound effects on a patient’s quality of life, especially their voice and swallow 
function.  Quality of life is greatly reduced during treatment and starts to improve about 
3 months following this.  This improvement in quality of life persists until around two 
years, at which point there is no further improvement (Bjordal et al. 2001); in fact there 
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may be a further deterioration in quality of life in the long term (Mehanna and Morton 
2006).  Despite the obvious difference in treatment regimes, quality of life does not 
seem to be significantly different for patients treated surgically and non-surgically in 
early (Goor et al. 2007) or advanced disease (List et al. 1996; Hanna et al. 2004); 
however, this population based data may obscure wide variations between individual 
patients.  Quality of life is significantly reduced in those patients who have salvage 
surgery after the failure of non-surgical treatment (Weber et al. 2003). 
So far in this chapter, I have outlined the complexities of treatment choice in HNC.  
Many treatments, especially in advanced disease, have a limited chance of survival and 
a profound effect on many aspects of a patient’s quality of life.  For this reason, 
information giving is an important part of involving patients in decisions about their 
care and preparing patients for the treatments which lie ahead.  In the next section, I 
discuss the difficulties in delivering information effectively, and through this, outline 
some of the initial challenges of patient involvement in decision making. 
1.7 Patient information about treatment 
The diagnosis of and treatment for HNC is known to cause significant psychological 
morbidity (Rapoport et al. 1993; de Leeuw et al. 2001) which can persist in the long 
term (Bjordal and Kaasa 1995).  Psychological distress is almost three fold more than 
that found in other cancers (Singer et al. 2011).  Anxiety levels are associated  with the 
ability to cope (Elani and Allison 2011) which in turn can be affected by degree of 
perceived control (de Maddalena and Zenner 1991; Dropkin 1999). Quality of life has 
been considered as the extent to which “the hopes of an individual are matched and 
fulfilled by experience” (Calman 1984, page 124-125).  In this paper, Calman argued 
that to improve quality of life, health care professionals should “narrow the gap between 
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a patient’s hopes and aspirations and what actually happens” (ibid, page 125).  Through 
tailoring information to the individual, the mismatch between unrealistic expectations 
and experience could be narrowed thus potentially improving outcome. 
The expectations that patients have about their treatment are largely based on the 
information that they receive.  In a qualitative study of 15 HNC patients, treatment 
expectations were clearly linked to the information given by health professionals before 
therapy began.  Participants described a ‘knowledge gap’ between a full understanding 
of what was going to happen and what information can convey (Llewellyn et al. 2005).  
In turn, expected symptom severity rated before oral surgery was the primary predictor 
of symptom severity immediately post-operatively and at follow up.  Pre-operative 
expectations predicted not only symptom severity, but also psychological distress, speed 
of return to work and healing ratings after oral surgery (McCarthy et al. 2003).  The 
perception of adequate information from the specialist can be associated with a better 
long term rehabilitation outcome in laryngeal cancer (de Boer et al. 1995) and improved 
quality of life in oropharyngeal cancer (Moore et al. 1996).  Less satisfaction with 
information provision pre-treatment has also shown correlation with lower emotional 
functioning and higher levels of depression at follow up (Llewellyn et al. 2006).  
Satisfaction with information is a significant predictor of quality of life in patients 
undergoing radiotherapy for nasopharyngeal carcinoma. In a simple questionnaire 
study, the score from the five item Medical Interview Satisfaction Scale (MISS) 
questionnaire (a questionnaire designed to assess the satisfaction of a patient with a 
consultation) was found to significantly predict the Functional Assessment of Cancer 
Therapy, General Scale (FACT-G) score, suggesting that those patients who had more 
satisfaction with the medical information provided had a better quality of life 4 months 
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later.  This finding maintained significance when adjusted for disease stage (Yu et al. 
2001). 
The amount of information regarding surgery required by an individual patient varies 
enormously and patients express the need for information individualised to their 
particular case (NCA 2002; Newell et al. 2004; Llewellyn et al. 2005).  The information 
received from professionals often does not reflect the diversity of their needs.  This 
means that many patients turn to alternative sources of information to help them 
understand what they have been told.  Patients report that they are ill-prepared for the 
functional changes associated with surgery (Newell et al. 2004) and express a 
requirement for more information on communication and swallowing, length of time in 
hospital, psychological adjustment (Newell et al. 2004), side effects and prognosis of 
surgery (Chen et al. 2009) financial support, access to support groups and how the 
treatment would affect quality of life and the ability to work  (Llewellyn et al. 2006).  
After treatment for HNC, patient requirement for information changes, with the most 
common topics requested for discussion at follow up being fear of recurrence, dental 
health, chewing, pain and fatigue (Ghazali et al. 2013).  Nonetheless, before treatment, 
clinicians often focus  on the technical specifications of the operation (Edwards 1998).  
Patients report that they often have too little information or information that they cannot 
understand (Newell et al. 2004; Llewellyn et al. 2006).  On the other hand, too much 
information about the effects of treatment may lead to a perceived fear and lack of 
ability to cope (Llewellyn et al. 2005).  Half of the 82 HNC patients investigated by one 
group of researchers stated that they required more information than that provided pre-
treatment.  Post-treatment this figure had risen to two thirds, with 48% of patients 
reporting lower satisfaction with information post-treatment and in the follow up period  
than pre-treatment (Llewellyn et al. 2006).  This may be because patients often prefer 
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verbal over written information, but verbal information diminishes during follow-up, as 
contact with clinicians becomes less frequent (Pollock et al. 2008).  Patients often report 
a poor experience of involvement in their treatment decision and a large number of 
patients say that they were given no choice in the choice of treatment (Edwards 1998; 
Newell et al. 2004).  Many patients feel that the choice of treatment is the responsibility 
of the doctor (Newell et al. 2004; Pollock et al. 2008), while others want to be more 
involved in decisions about their care than they are currently,  but lack the requisite 
information (Edwards 1998).   
An inherent problem with assessing the information needs of HNC patients is that the 
concept of information need is difficult to define.  Various techniques are employed in 
an attempt to address this, resulting in an abundance of questionnaires assessing 
satisfaction with the consultation, treatment decision or information provision.  
Qualitative research allows a deeper understanding of the patient experience, but 
comparison and combination of study findings is difficult.  When qualitative and 
quantitative techniques are used on the same cohort of patients at different time-points it 
is found that patients’ claims of “satisfaction” with information was largely a result of 
the questionnaire methods rather than real, lived experience.  Negative experiences 
gleaned through interview were not expressed adequately via questionnaire; in fact, it 
was suggested that “information satisfaction” holds little importance to patients who are 
facing life-threatening illness and treatment (Pollock et al. 2011).  
1.8 Current practice 
A nationwide survey of information giving prior to laryngectomy demonstrated a large 
variation in the information giving practices among different clinicians.  Surgeons 
reported taking an average of 15 minutes to discuss the treatment options (range 1 to 45 
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minutes); all discussed the effect on voice and communication, but fewer discussed 
effects such as psychological sequelae (38%) and effect on relationships (22%); 84% of 
surgeon respondents discussed the diagnosis and treatment options at the same 
consultation; 79% agreed that there should be a second consultation to discuss treatment 
options, however only 64% reported its routine provision.  Worse, 40% of the surgeons 
failed routinely to discuss cure and survival rates for the treatment available, possibly 
calling into question the quality and validity of the informed consent for the procedure 
(Stafford et al. 2001).  Patients prefer their information to be delivered verbally by a 
health care professional (Pollock et al. 2008; Davies et al. 2010) and the relationship 
with the doctor and trust in their experience is an important part of the treatment 
decision making process.  Patients often exercise a positive choice to delegate 
responsibility for the treatment decision to the doctor (Pollock et al. 2008; Davies et al. 
2010; Pollock et al. 2011); however it is important that such delegation is not presumed 
by the clinician, nor used as a reason not to involve the patient in decisions regarding 
their care.  In a focus group study of 33 HNC health-care professionals, most found it 
difficult to impart information in the limited time available.  They agreed that, whilst 
patients should be involved in decisions regarding rehabilitation and palliative care, 
those about the choice of primary treatment were regarded as the province of the 
consultant in charge. Patients stated that they found talking to health professionals with 
experience of managing the disease helpful, but professionals often ‘protected’ their 
patient by underplaying the severity or longevity of side effects, leading to anxiety 
when the symptoms arise.  Many patients are therefore steered towards a particular 
treatment course by the consultant (NCA 2002).  This presents the patient and clinician 
with a difficult problem: the choice of treatment has profound effects on a patient’s 
survival and quality of life, but there are barriers to effective information provision.  
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There is a dearth of good quality research to guide decisions and the choice of treatment 
is not a value free exercise: important trade-offs are faced between survival, speech and 
swallow.  
1.9 Values and preferences 
To make a decision on behalf of a patient a clinician assumes that they hold shared 
values and priorities for treatment.  Gill et al (2011) argue that this is the case: in a 
small study of 30 patients, 30 companions and 25 members of the MDT, all groups 
ranked ‘being cured of my cancer', 'living as long as possible', 'having no pain' and 
'being able to swallow all foods and drinks’ as their top priorities.  However this finding 
is contested by many other groups: for example, when Mohide et al (1992) compared 
the treatment priorities of 20 HNC health care professionals and 20 patients, they did 
not match.  Professionals rated communication, self-image and esteem as most 
important, whereas patients were more concerned about the physical consequences of 
surgery such as tracheal mucus production (Mohide et al. 1992).  Other authors have 
found significant differences in ratings for the work and social functioning or pain 
(Grossman et al. 1991; Jalukar et al. 1998).  A comparison of the views of patients who 
had undergone laryngectomy with those of  health care providers found that more than 
twice the proportion of health care providers would compromise survival in order to 
preserve voice and quality of life compared to patients (Otto et al. 1997).  In a similar 
study, 130 newly diagnosed stage II to IV HNC patients were asked to rank a series of 
12 potential HNC treatment outcomes.  As expected, three quarters of patients ranked 
“being cured” as the top priority of treatment, however one fifth ranked it as second or 
third.  Rankings given were highly variable and generally unrelated to patient or disease 
characteristics, except for the perhaps unsurprising observation that older patients 
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generally placed a lower priority on cure and living longer, and a higher priority on 
avoidance of pain (List et al. 2000).  When patient findings were compared with the 
responses given by non-patients, it was concluded that non-patients also valued survival 
highly; however patients were more likely than non-patients to accept aggressive 
treatment in order to achieve survival benefit (List et al. 2004).  This is in agreement 
with another study of attitudes towards chemotherapy which demonstrated that a group 
of newly diagnosed cancer patients expressed willingness to undergo very aggressive 
chemotherapy with an extremely limited survival advantage.  In contrast, non-patients, 
oncology doctors and nurses were much less likely to opt for such a treatment with the 
expectation of minimal gain (Slevin et al. 1990).    
1.10 Decision making    
The majority of the work around decision making in HNC thus far has concentrated on 
expected utility theory.  One of the first applications of decision analysis to a clinical 
situation explored whether radical neck dissection was beneficial to patients with oral 
cancer with no local spread of disease  (Henschke and Flehinger 1967).  Paleri and 
Kelly (2008) constructed a decision tree for patients presenting with recurrent disease, 
analysing the decision between re-irradiation and chemotherapy and symptom 
palliation.  One of the most widely quoted uses of expected utility theory was the work 
undertaken by McNeil et al (1981). In her study, 37 normal participants (firefighters and 
middle managers) were asked to “trade-off” years of survival against retaining a normal 
voice.  The authors concluded that 20% of these volunteers would choose radiation to 
treat a T3 laryngeal tumour despite the treatment having a poorer survival rate than 
laryngectomy at the time.   However, the primary aim of these studies was to assign 
utility values to HNC treatment outcomes.  They draw on a ‘normative theory’ of 
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decision making, based on the philosophy that under ideal conditions, an individual will 
make the choice with the maximum expected utility: this however is arguably not a 
reflection of the real-life process of decision making for patient or clinician (Edwards et 
al. 2006).  Thus, although they provide a useful insight into the trade-offs which HNC 
patients face when choosing treatment modalities, they do not provide significant 
insight into the actual process of decision making. 
1.11 Conclusion 
HNC is a broad term which incorporates cancers from multiple anatomical sites.  A 
diagnosis of HNC is often associated with a poor prognosis and almost a third of 
patients will die of their disease within two years.  Not only this, but successful 
treatment may cause persistent and debilitating effects on swallow, voice and quality of 
life: patients and clinicians are therefore forced to trade-off function against survival.  
Research underpinning the effectiveness of the treatments available is open to criticism, 
interpretation and debate.  The patient population are often long term drinkers, with 
concomitant health problems and lower educational attainment, presenting patients and 
clinicians with a unique challenge in effectively engaging patients in treatment 
decisions.   This combination of factors makes treatment decision making in HNC 
fraught with difficulty.  The requirement for patients to contribute to decision making 
seems clear: many decisions are based on values and attitudes to survival and quality of 
life, but when the values of patients and clinicians are compared, they differ.  Although 
the provision of treatment related information is related to patient expectations and 
quality of life, there are significant challenges in delivering information to patients 
which is effective and individualised.  Some patients express a requirement for more of 
a role in the treatment decision, whereas others actively delegate the responsibility of 
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decision making to the clinical team.  Thus, the degree of desired involvement in 
decision making varies from patient to patient, and this should be acknowledged in the 
decision making process.  In the next chapter I shall describe the increasing role of the 
patient in treatment decisions and outline the rationale for effective patient engagement 
in healthcare decision making.  
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Chapter 2: Decision Making in Healthcare 
The relationship between doctor and patient is complex (Ong et al. 1995) and has been 
the subject of many reports (Roter and Hall 1992).  In cancer management, treatment 
decisions can have far-reaching effects on survival and quality of life. As I discussed in 
the previous chapter, HNC in particular presents the patient and doctor with multiple, 
complicated treatment options and little high-quality research evidence to act as 
guidance.  Not only does this make treatment choice difficult; it also places further 
importance on effective communication and decision making between clinician and 
patient. 
In this chapter, I discuss how treatment decisions are made in medicine.  Through the 
course of the chapter, I do not aim to give an in depth view of all of the different types 
of physician-patient encounter, as these are discussed in detail elsewhere (Emanuel and 
Emanuel 1992).  I shall provide a history of the rise of patient involvement in healthcare 
decisions, as well as the drivers for this.  I will then define and discuss shared decision 
making (SDM) and its use in making healthcare decisions. 
2.1 Paternalism 
Since the era of Hippocrates there has been a generally accepted view that doctors make 
decisions on behalf of their patients; they decide what is in their best interests, and 
patients are sometimes informed of these decisions. “The old Hippocratic ethic saw the 
patient as a weak, debilitated, childlike victim, incapable of functioning as a real moral 
agent” (Veatch 1987, cited in Miles 2009, page 1322) 
The description of the paternalistic model of decision making emerged from the account 
of the “sick role” (Parsons 1951).  In this, Parsons viewed the doctor-patient 
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relationship as one which is similar to that between parent and child.  The temporary 
sick role status is granted to the patient and its award involved both rights and 
obligations on the part of the patient.  The patient is excused from usual responsibilities 
and duties, including family and work, but must attempt to return to health by seeking 
medical help and complying with the recommendations of the physician.  Although 
there are examples of this role in society today, this model does not serve modern 
medicine well.  We attend our doctors for many things other than solely when we are ill 
(e.g. pregnancy, disease screening) and many chronic conditions cannot be assumed to 
be temporary (Maguire 2002).   
However, the paternalistic model of healthcare decision making was widely practiced.  
In this model, the physician, on behalf of the patient, assessed the stage and degree of 
disease, and formulated a treatment plan which he believed was most likely to lead to 
cure of, or improvement in the condition.  The amount of patient involvement in this 
process varied, from being delivered selected information to enable agreement and 
consent, to where the clinician “authoritatively informs the patient when the 
intervention will be initiated” (Emanuel and Emanuel 1992 page 2221).  It was 
assumed, for this model to be successful, that the physician was knowledgeable and up 
to date, leading to the correct treatment being applied consistently to patients with the 
same problem.  Physicians were considered to be best placed to evaluate the trade-offs 
and pitfalls of treatment, and applied these to the decision process based on their 
evaluation of the best interests of the patient (Charles et al. 1999). 
There are situations where it is still appropriate to employ the paternalistic decision 
making model.  It is often used in emergency situations, or when the patient is 
unconscious or cannot make their wishes known.  As medicine has evolved, however, 
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its shortcomings have been exposed (Charles et al. 1997).  This model cannot 
adequately incorporate the wishes and autonomy of a patient, and to practice using 
paternalism assumes that that the physician and patient place the same value on clinical 
outcomes (Deber 1994).  Although paternalistic decision making relies on the 
beneficence of the physician, physicians may give limited information in order to 
influence the patient to agree with their assessment of best interests (Emanuel and 
Emanuel 1992).  Not only this, but there have been several driving forces to increase the 
role of the patient in the medical encounter away from that of a passive recipient.  In the 
following section, I shall discuss in turn the major influences on increasing patient 
involvement in decision making. 
2.2 Evolution of medicine 
Modern medicine has witnessed an explosion in the number of treatments available for 
existing conditions and an increase in the number of conditions for which treatments 
may be administered.  For example, it has been long recognised that a profoundly 
elevated blood pressure is damaging to health, however the increased cardiovascular 
risk associated with mild to moderate hypertension have only been more recently 
realised (Kannel et al. 1972).  Hypertension is usually asymptomatic and gives sufferers 
an increased risk of future negative health events.  Treatment options were once limited 
but now there is a huge number of drugs available, organized into five main classes.  
Published guidelines are complicated, stratifying patients by age and comorbidity 
(NICE and BHS 2011), and have, over time, recommended treatment of increasing 
proportions of the population (Thomson et al. 2005).  The development of guidelines 
however creates a bias towards effectiveness and places less importance on adverse 
effects.  Clinical practice guidelines may rarely take account of patient preferences 
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(McAlister et al. 2000; Thomson et al. 2005; Joyce et al. 2013), or not concentrate on 
outcomes which are important to patients (Joyce et al. 2013).  Even when published, the 
content and recommendations of the guidelines are often the subject of scrutiny and 
debate (Sofat et al. 2012).  Thus a consultation deciding on the appropriate treatment for 
a hypertensive patient involves complex skills in clinical evaluation, critical appraisal 
and risk communication.  Each potential treatment has effects on mortality and 
morbidity, making an assessment of ‘best’ far more complex.  If guidelines’ 
recommendations are applied without consideration of patient preference, a large 
proportion of patients may receive treatment which is not in line with their preference 
(Protheroe et al. 2000).  Guidelines which take into account the values of the patient for 
complex decisions can be more responsive to the individual preference of the patient 
(Thomson et al. 2000).  Despite this, professionals often feel pressure to adhere to them 
(Matlock et al. 2011) which has led to suggestions to adapt guidelines to include the 
patient more effectively (van der Weijden et al. 2013), or even be developed in 
conjunction with decision support tools (van der Weijden et al. 2012). 
2.3 Variation in care 
Wide geographical variation in the treatments administered for common medical 
conditions have previously been noted (Roos 1984; Chassin et al. 1986) and this 
variation was often found to be independent of population and disease characteristics.  
Wennberg described this as ‘unwarranted variation’ as it cannot be explained by illness 
or patient preference (Wennberg 2010).  Although this variation is dependent on 
geography to an extent, it is more dependent on clinical uncertainty related to the 
outcome of the treatment (McPherson et al. 1982).  Unwarranted variation in care is 
particularly evident in ‘preference sensitive’ decisions: those which have more than one 
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generally accepted treatment option, such as elective surgery.  Unwarranted variation 
can be significant; the rate of knee replacement can vary by a factor of 4.7 and the rate 
of mastectomy by 7.3 across regions of the United States.  In England the rate of 
variation is lower but occurs in procedures such hysterectomy or hip or knee 
replacements (Wennberg 2011).  The UK Atlas of Variation documents variation across 
a range of outcomes in England: for example the length of admission following an 
elective breast procedure has a six-fold variation across the country (RightCare 2011).  
Policy makers and clinicians have attempted to reduce this variation in care by tackling 
clinical uncertainty. Research is performed to quantify and measure clinical outcomes 
and these are then used to produce management guidelines with the intention of 
standardising disease treatment.  Although this seems to makes sense, it is not wholly 
effective.  When producing a practice guideline based on research on clinical outcomes, 
the importance that a particular patient places on that clinical outcome and its risks and 
consequences may be ignored (Joyce et al. 2013) and therefore variation may persist as 
a result.  For example the rate of surgery for benign prostatic hypertrophy is not dictated 
by the severity of symptoms, rather by the extent to which the patient is troubled 
thereby (Barry et al. 1995).  Also, in a population study of 2,128 individuals, time to 
joint replacement was more strongly predicted by “willingness to consider surgery” than 
symptom severity (Hawker et al. 2006).  Clinical guidelines may act to mask the 
uncertainty which often underlies the treatment decision for many conditions (Mulley 
2009), which clouds risk communication. Not only this, but whilst central planning and 
delivery of healthcare might be expected to reduce variation across countries, this is not 
the case (Westert et al. 2010).  Rates of tonsillectomy are particularly affected by 
variations in care, famously noted by Glover in 1938 (Glover 2008).  The publication of 
guidelines based on ample good quality evidence (SIGN 2010) clearly outline the risks 
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and benefits of intervention but have failed to eradicate the variation in operation rate 
which persists over 70 years after the publication of Glover’s findings (Burton 2008; 
Suleman et al. 2010).   
If healthcare delivery variation cannot be explained by difference in disease patterns, 
geography or patient population alone, it must represent unwarranted variation in 
clinical practice between regions.  If the balance of power in the treatment decision lies 
with the healthcare provider, then this  variation will persist (Wennberg 2010).  Ideally, 
variation should depend on the clinical characteristics of the population and the attitude 
and preferences of the patient (Wennberg 2011); so called warranted variation.  The use 
of decisions aids significantly changes the rates of intervention across a broad range of 
conditions (Mulley 2009). Thus informing and empowering patients by involving them 
in decisions about their care should act to lessen this clinician-driven unwarranted 
variation in care. 
2.4 Legislation 
The increasing recognition of the role of patients in the medical consultation has 
gradually been recognised by the legislative and regulatory authorities. In June 2008 the 
General Medical Council (the regulatory body for UK doctors) changed the guidance on 
informed consent.  The old booklet “Seeking patients’ consent: the ethical 
considerations” (GMC 1998)  was replaced with “Consent: patients and doctors making 
decisions together” (GMC 2008).   The guidance extended the concept of consenting 
patients beyond informing patients of the alternatives, risks and benefits of interventions 
and instead instructed doctors to work in partnership with patients and “maximise 
patients’ opportunities, and their ability, to make decisions for themselves” (ibid, page 
6).  In the same way, successive governments have placed more and more emphasis on 
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patient choice, culminating in the recent proposed NHS reforms championing “No 
Decision About Me Without Me” (DoH 2010A; DoH 2010B).  These documents not 
only support the involvement of patients in decision about their care, but recommend a 
wholesale change of culture of the NHS where patient involvement in every decision is 
ingrained as routine practice.  Implementation of such recommendations requires more 
than documents alone: for culture change to come about the traditional view of the 
doctor patient relationship is challenged.  For this reason, implementation is slow, as it 
is difficult to embed patient involvement into routine practice (Elwyn et al. 2010).  
Professionals and clinicians may need to be incentivised to involve patients or the 
quality of decision making should be measured to provide feedback (Coulter and 
Collins 2011).  Each approach faces challenges, however, not least the difficulty in 
defining and measuring decision quality (discussed later).  Nurses and doctors 
sometimes feel that they are already involving their patients in decisions (Gravel et al. 
2006) and hence that there is no need to change; however, this view is not always 
echoed by the patients they treat (Stevenson et al. 2000).  Nevertheless, real 
implementation of patient involvement in all treatment decisions requires effective 
leadership, good quality care commissioning and substantial investment (Elwyn et al. 
2010). 
2.5 Patient preference 
One of the main driving forces behind greater patient involvement in the medical 
encounter has come from the patients themselves (Stevenson et al. 2004).  Patients 
expressed an unmet need for information about their care and value information about 
treatment choices (Waitzkin 1984; Beisecker and Beisecker 1990; CQC 2010).    This 
strong desire for information was independent of the socioeconomic status of the 
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patient, and the need for health information appeared less dependent on patient factors 
than on situational factors, such as the length of consultation and the cues from the 
doctor (Haug and Lavin 1979; Beisecker and Beisecker 1990), all of which were 
modifiable in the consultation.  Bringing a patient viewpoint into the consultation 
involved two separate but interlinked concepts: patient information about the disease 
and treatments, and patient involvement in the treatment decision.  These two concepts 
were not always correlated and at first it seemed there was a need for one and not the 
other.  Ende et al (1989) measured patient preference with a scale of 0 to 100, where 0 
is very low, 50 a neutral attitude and 100 a very high preference.  Their 303 patients 
reported a mean score of 33.2 +/- 12.6 with regard to involvement in the treatment 
decision, however they expressed a higher information requirement of 79.5+/-11.5.  It 
was also found that the level of preferred involvement in decisions decreased with 
increasing severity of the illness.  This work was supported by others: in a study of 210 
patients with hypertension, 47% felt that they preferred the clinician to make the 
therapeutic decisions, 31% felt that the clinicians should make the decision after taking 
an opinion from the patient and 19% felt that decisions should be made on an equal 
basis (Strull et al. 1984). This was supported by work performed in college students 
(Krantz et al. 1980) and low income diabetes sufferers (Pendleton and House 1984).  
Even if patients did express a desire to be involved in medical decisions, this failed to 
predict their actual behaviour in the consultation (Haug and Lavin 1981).  Larsson 
showed that 73% of patients were as involved in decisions as much as they wished to be 
(Larsson et al. 1989).   
It would be simple to conclude from this research that although patients were expressing 
a need for information about their disease process, the majority were happy for the 
doctor to lead the decision process.  This conclusion however has its flaws: in order to 
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understand the issue of patient participation in the consultation, it must be clear what 
“participate” means. Two processes are required in order to make a decision: “problem 
solving” and “decision making”.  Problem solving requires the doctor to know the 
problem, and have knowledge of the options which are available to solve it.  Decision 
making requires the ascertainment of values and preferences to decide which of the 
options is preferred for that specific patient.  Patients often cannot be involved with the 
“problem solving” stage – they will not be aware of the range, effectiveness and 
associated morbidity and mortality of the treatment options available, but they could be 
central to the “decision making” (Deber 1994).  A variation on this model was also 
described by Eddy: he divided the consultation into two stages, an “objective” stage 
where the treatment options are presented and the prognosis, mortality, morbidity and 
risk associated with the options are discussed.  This is followed by the “subjective” 
phase, where the values and preferences of the patient are discussed in order for a 
decision to be made (Eddy 1990).   
In more recent years, patients have expressed an increasing (often unmet) requirement 
for involvement in treatment decisions.  One in three patients in primary care and one in 
two following inpatient hospital treatment state that they would prefer more engagement 
in decisions about their care (Garratt and Boyd 2008; Martin 2008).  In a large, 
qualitative study of HNC patients and professionals, Edwards found that most patients 
wanted to be more involved in the decisions about their care than they currently were 
(Edwards 1998).  Not only this, but patients’ perception of their own involvement does 
not always correlate well with that observed by researchers (Martin et al. 2003); some 
patients felt that they had been involved in the decision process but were not given a 
menu of options or did not significantly influence the course of action (Beaver et al. 
2005).  In a study videotaping consultations, doctors appeared poor at eliciting the 
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concerns or priorities of the patient, and even when elicited, these were often not acted 
upon (Campion et al. 2002).  Importantly, this is not to argue that all patients want more 
involvement in decisions about their care; more that desire for involvement is 
individual, and thus varies from patient to patient.  Indeed, desire of a patient to be 
actually involved (so called ‘meta-preference’) varies according to many patient 
characteristics such as age, education, experience of ill health and relationship with the 
clinician (Say et al. 2006).  Hence if treatment decisions are to be patient centred, 
clinicians must be able to respond to this variation and adapt the decision process 
accordingly. 
2.6 Variations on paternalism 
Waterworth and Loker (1990) expressed concern that involving patients in decisions 
may be inadvertently forcing them to “toe the line” in order to please the practitioner, 
and therefore patient involvement should be resisted.  This gave rise to forms of 
“sensitive paternalism” (Deber 1994) where the patient actively gives permission for the 
practitioner to make a decision on their behalf (“paternalism with permission”) (Cross 
and Churchill 1982) or the practitioner makes the decision, and then provides the patient 
with information about the benefits, risks and alternatives in order to allow them to 
potentially withdraw permission.  Hence, although sensitive paternalism seems to 
increase the amount of information conveyed to a  patient, it does not allow active 
participation in the decision making process (Deber 1994).  To achieve decision 
participation, patients need to have knowledge not only of the option being presented, 
but alternative options, as well as the uncertainty which may underpin the decision 
(Birke et al. 1990). 
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The driving forces which I have outlined so far in this chapter meant that the importance 
of involving patients in decisions was beginning to be recognised.  In breast cancer, 
Ashcroft was one of the first to look at not only the psychological impact of choice of 
treatment, but also the effect that patient choice had on this, providing a clinical 
psychologist to guide patients through the decision process.  It was noted that the 
feeling of personal control over outcome was expressed by the participants as being 
important and concluded that: 
The best predictor of a good psychological adjustment to breast cancer 
treatment is to establish, before surgery, the importance to the woman 
of a complete body image.  Treatment, preferably with consultation 
with the patient herself, can be adjusted accordingly (Ashcroft et al. 
1985 page 45, 46).  
This was echoed by work in 1988 which concluded that patient involvement in the 
choice of treatment had greater relevance to the psychosocial outcomes than the type of 
operation performed (Morris and Ingham 1988).  Much of the debate centred on 
whether a patient should be involved in healthcare decisions and, if they were involved, 
how much of a role should they have and how this should be achieved. 
2.7 Informed choice 
It has been proposed that patients should have complete control over the decision, 
sometimes described as informed choice.  The patient overcomes the problem of 
information deficit by receiving information, and therefore is able to make the decision 
alone and no longer needs to share the process or have decisions made for them (Levine 
et al. 1992).  In this model, the physician’s preferences for the treatment options do not 
come into the discussion and the decision relies on information provision as the sole 
basis of the decision making process.  Although this means that a patient is better 
informed, patients may not necessarily want all the responsibility for the decision (Ende 
31 
 
et al. 1989; Beisecker and Beisecker 1990).  Informed choice allows control for patients 
if they choose to assume the role of “agent” (Bishop and Yardley 2004), but is 
problematic as it assumes the patient is a “rational actor” in the relationship – due to the 
emotional and complex nature of the decision, this is not always the case. 
Thus began an endeavour to shift the paradigm of the physician/patient encounter, 
striving to construct a model of decision making which is positioned between the poles 
of paternalism and informed choice.  The constant difficulty faced was the power and 
information imbalance between patient and physician summarized well by Hurley: 
The crux of the information problem is that while the health care 
provider possesses better knowledge regarding the expected 
effectiveness of health care in improving health status, the individual 
knows best how improvements in health status affect his or her well-
being (Hurley et al. 1992 cited in Charles et al. 1997, page 683) 
2.8 Sharing decisions 
In order to resolve the power imbalance and encourage a mutual style of decision 
making between doctor and patient, shared decision making (SDM) was first 
conceptualized by Charles and Gafni (Charles et al. 1997).  SDM allows the patient 
choice and information about the treatment option which they prefer and the doctor a 
role of transferring information and participation in, but not domination of, the decision 
process.  In the next section I discuss theory and practice of SDM as a model of health 
care delivery, and present the evidence for its effectiveness. 
2.9 Shared Decision Making 
2.9.1 Definition 
The precise definition of shared decision making (SDM) is subject to debate (Makoul 
and Clayman 2006), and the terminology used to describe the involvement of patients in 
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decisions about their health range from consumerism, informed decision making, 
through patient-centred care and partnership to informed consent and autonomy 
(Edwards and Elwyn 2009).  The definition of SDM is not merely semantic; a lack of 
understanding of what exactly SDM means and how it is carried out can stand in the 
way of implementing it in practice and studying its effectiveness (Mead and Bower 
2000A; Mead and Bower 2000B).  The most widely accepted conceptualization was the 
original description by Charles et al (1997) who described a decision which had 
involvement of both the patient and the doctor, a sharing of information by both parties 
to achieve a consensus and resultant agreement about which treatment to implement.  In 
simpler terms, SDM is “involving the patient in decision making to the extent that they 
desire” (Edwards and Elwyn 2006 cited in Edwards and Elwyn 2009 page 5).  In the 
original description of SDM, the steps required to adequately share a decision were 
described.  The patient’s preferences and values should be elicited so that the options 
discussed are compatible with the patient’s lifestyle and values.  Information on the 
treatment available, its risks, benefits and possible outcomes should be transferred to the 
patient in an understandable and unbiased way and the physician should recommend the 
course of action which they consider to be the best (Charles et al. 1997).  It may be 
argued that this model of SDM gained dominance as this is the most straightforward to 
train, observe and measure in clinical practice, but potentially neglects key relational 
and subjective-affective aspects of the patient’s involvement in the process, as well as a 
broader range of decision making activities and health-related behaviours (Edwards and 
Elwyn 2009).  SDM is about more than presentation of a series of options and exploring 
the patients values but a broader conceptualization that attends to how patients and 
health professionals think and feel about their relationships, rather than simply how they 
communicate health care options (Edwards and Elwyn 2009).  The most recent and 
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clear conceptualisation of decision making in healthcare is broader (Elwyn et al. 2012), 
and explains the process of patient engagement in healthcare in three steps: 
 Choice talk: this involves discussing with  the patient that a choice in fact 
exists, and emphasises the importance of recognising preference and the role of 
uncertainty in the choice 
 Option talk:  the treatment options are listed together with their respective risks 
and benefits.  This stage continues for the amount of time the patient wishes 
 Decision talk:  this involves asking the patient if they are ready to make a 
decision or receive a recommendation.  If a decision is made, the doctor must 
check that this is in line with the patient’s priorities, and if a recommendation is 
made, the doctor must confirm their own understanding of the patient’s 
preferences 
If SDM is to become routine practice, the definition and process of a shared decision 
must be broad and adaptable. A holistic view of making decisions is required, with an 
appreciation of the lived experience of ill health and the anxiety and uncertainty which 
underpins healthcare decisions (Olthuis et al. 2012).  To achieve this, clinicians require 
an understanding of the patient’s perspective of making a decision.  Rapley (2008) 
describes how much of the work of decision making for a patient takes place outwith 
the clinical consultation, distributed in time and amongst people and information 
sources.  Acknowledging this makes SDM more than informing patients about choice, 
and in doing so makes it relevant to many aspects of healthcare delivery.   
2.9.2 Effectiveness 
The culture of modern medicine demands that practice should be informed by evidence.  
The fundamental barriers to providing evidence for the effectiveness of SDM are: 
difficulty in defining what SDM is (Mead and Bower 2000A; Mead and Bower 2000B) 
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and how the ‘patient-centredness’ of a consultation is observed or measured.  Although 
attempts have been made to measure decision sharing (Elwyn et al. 2005), much 
research into the effectiveness of SDM concentrates on patient decisions aids.  Decision 
aids are information sources which can be in the form of pamphlets, videos or computer 
programs which are designed to give information about healthcare options to the patient 
and facilitate the elicitation of values and priorities for treatment from the patient.  They 
may be employed with a clinician during a consultation, but are usually used elsewhere, 
either alone, or with support.  Decision aids provide information on and help patients to 
clarify their values and preferences (IPDAS 2012).   In a recently updated Cochrane 
review of 115 randomised controlled trials the use of a decision aid was associated with 
improved patient knowledge, lower decisional conflict, a decreased proportion of 
patients who were passive in decision making and fewer patients remaining undecided.  
There was also a reported increase in patient satisfaction with the decision making 
encounter and improved perception of risk (Stacey et al. 2014).  Although this evidence 
is noteworthy, most of the improvements are more about the consultation process and 
less about clinical outcomes such as survival or quality of life.  Also, if clinicians use 
decision aids, this does not automatically mean that SDM has taken place; a decision aid 
is an adjunct to communication rather than a guarantee that a decision is shared.  Indeed 
SDM is more dependent on the interaction between doctor and patient rather than on the 
use of a specific tool (Kaner et al. 2007) 
The question of how to measure the quality of a decision is highly complex.  The latest 
update from the International Patient Decision Aids Standards Collaboration (IPDAS) 
states that in order for effectiveness of a decision to be measured, the quality of the 
decision making process and the quality of the choice that was made must be measured.  
The quality of the choice made is measured by assessing the knowledge of the patient 
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and the patient choice/preference concordance.  There are difficulties in using clinical 
outcomes in this measurement of decision quality: the outcome of the treatment may be 
poor (i.e. the patient may experience a complication), but the decision process may still 
be of good quality.  Decisions are also made in conditions of uncertainty, and patients 
may trade-off certain clinical outcomes (for example quality of life) in order to preserve 
others (for example survival) (IPDAS 2012).   
Even if clinical outcomes were to be used to assess the quality of a decision, the 
optimum outcome remains in doubt.  Quality of life is often measured via instruments 
which may narrow its conceptualisation to merely the presence or absence of disease,  
excluding the perspective of the individual patient (Bowling 2001).  The definition of 
health can be interpreted in various ways by different individuals depending on their 
values and preferences.  Any measure of quality of life should therefore incorporate 
these broader conceptualisations of health status such as quality adjusted life years 
(Thomson et al. 2005).  For example, Popay et al (2003) found that, although people 
were aware of the health risks of engaging in smoking and excessive drinking, they 
engaged in these behaviours in order to counteract the stress associated with other areas 
of life; optimization of health was not the prime determinant of their quality of life.  To 
use other clinical outcomes, such as symptom severity, can be clinician-centred: the 
quality of a decision should not be based on the severity of the symptom or outcome, 
rather the importance that the particular patient places upon it.  This means, rather than 
using clinical outcomes to determine the quality of a decision, the patient goals for 
treatment should be considered.  When the stated patient goals of treatment are 
compared with those of clinicians, there is a disparity (Sepucha et al. 2008), meaning 
that the goals used to measure decision quality must also be patient derived.  This is 
reinforced by the work of Barry et al (1995): this group found that patient reported 
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symptom severity in prostate disease did not match the treatment choice made.  The 
most important indicator of the treatment chosen was how bothered men were by their 
symptoms.  Men who were bothered by their prostatic symptoms were seven times 
more likely to opt for surgery.  In the same way, “willingness to consider replacement” 
was the best predictor of time to knee replacement in osteoarthritis patients rather than 
the patient reported pain score (Hawker et al. 2006).  Hence the choice of the most 
appropriate measure to assess the quality of a decision is fraught with difficulty.  At the 
same time, the difficulties described in assessing the quality of a decision constitute one 
of the barriers to implementation of SDM, as many clinicians feel that the time and 
effort required to change their clinical routine to incorporate SDM is not justified by the 
outcome (Coulter 2010). 
However, the argument for SDM transcends this.  Ethically, making good, 
individualised healthcare decisions which respond effectively to the needs of the patient 
is important.  It empowers patients to involve themselves in treatment decisions and 
challenges the concept that the doctor knows best (Elwyn et al. 2010).  It is seen more 
as the meeting of two experts: the clinician brings expertise and knowledge about the 
treatments, their risks and benefits and the patient brings an understanding of their 
attitudes, preferences and values. SDM allows patients, especially those with chronic 
diseases, to resist the possible ulterior motives of drug companies and other 
organisations or individuals with a conflict of interest, or those who are potentially well-
placed to gain financially from ill-health or illness avoidance (Moynihan 2011). 
If not effectively involving patients in decisions about their health, doctors are assuming 
that they know what is important to the patient (e.g. survival, effect on quality of life).  
This is not always the case, however, as if treatment priorities are compared between 
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professionals and patients there is often a disparity.  For example, in breast cancer, 
doctors thought that 71% of women would rate keeping their breast as a top priority for 
treatment, but this was only the case for 7%.  More doctors were also concerned about 
the effect of radiation on the success of reconstruction (60% vs 24%) whilst patients 
placed a greater priority on avoiding a prosthesis (30% vs 0%) (Lee et al. 2010).  
Well-informed patients  make different decisions to those who are not as well informed 
(Volandes et al. 2009), may perceive risk in a different way (Steel 2000) and adhere 
better to treatment (Joosten et al. 2008).  In a study of patients with dementia, clinic 
attenders were asked about the goals they had for treatment. Groups of patients were 
compared with and without access to a decision support tool.  The majority (86%) of 
patients with access to the tool chose comfort care and only 4% chose life prolonging 
care.  In the group without access, 64% chose comfort care and 14% life prolonging 
care.  At a follow up interview six weeks later, these choices were also found to be more 
stable in the group accessing the decision aid (Volandes et al. 2009).  In a group of 
patients who had already been consented for an elective out-patient percutaneous 
coronary intervention, 88% believed that it would decrease their risk of a heart attack.  
In contrast, only 17% of the cardiologists who had consented them shared this belief, 
which was also in direct contrast to the published literature which shows no benefit 
(Boden et al. 2007).  Around half of the patients who were consented felt that the 
physician dominated the decision process (Rothberg et al. 2010).   Generally, informed 
patients are less likely to choose surgery: for example once patients are informed about 
the risks of surgery for sexual dysfunction, 40% fewer choose it (Wagner et al. 1995).  
Prior to the use of a decision aid, 48% of women would choose surgery for abnormal 
menstrual bleeding, but this reduces to 38% after the use of a decision aid (Kennedy et 
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al. 2002) and there was a 20% relative decrease in the uptake of surgery for stable 
angina after the use of a decision support tool (Morgan et al. 2000).  
Although it can be demonstrated that SDM is popular, effective and ethically requisite, 
it is often not standard practice and implementation has been difficult (Elwyn et al. 
2010).  Although many physicians will have been trained in patient-centred 
communication, this does not always correlate well with SDM (Wensing et al. 2002).  
Indeed, despite the fact that many professionals report that they already practice SDM, 
this is not always supported (Elwyn et al. 2005).  Mulley alludes to the problem of 
“silent misdiagnosis”; clinicians are trained principally to diagnose disease in order to 
recommend effective treatment, but fail to diagnose the preference or priorities of 
patients in order to make an effective decision (Mulley et al. 2012).  Many health care 
professionals see SDM as a threat to their professionalism, almost “political correctness 
gone too far” (Carvel 1999, page 783).  Increasing SDM may increase the number of 
patients declining treatments for conditions which are not immediately affecting their 
health (e.g. hypertension), leading to an increased incidence of adverse health events 
and failure to meet treatment targets for some conditions.   
In the context of HNC, Davies et al (2010) argue that the traditional SDM model of 
decision making is ill-suited to patients facing life threatening disease.  Her 
ethnographic study was based in a United States ENT department and included 39 
patients’ clinic appointments and 22 semi-structured patient interviews.  Here, a 
‘conventional’ SDM model of decision making was followed for those with benign or 
non-urgent disease.  However, a “non-adherent” group, commonly with a diagnosis of 
HNC, relied heavily on the trust in their physician and made decisions through a series 
of conversations with physicians and relatives; many of these discussions took place 
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outside of the office setting. This non-adherent group made decisions to “do something” 
about their disease, but relied heavily on the treatment recommendation to inform their 
treatment decisions.  The authors conclude that this places the responsibility for 
decision making with the treating physician.  However, a statement of trust in the 
doctor, and a consequent reliance on the treatment recommendation should not be 
confused with an argument for paternalism in this disease.  Instead, a consideration of 
why patients rely heavily on recommendation and trust, and how their personal values, 
aims and preferences can be built into such a complex decision should be scrutinised. 
In a systematic review, Gravel et al (2006) described that the most commonly reported 
barriers to SDM were time constraints, lack of applicability of the model due to patient 
characteristics or the clinical situation, provider motivation, and perceived impact on the 
clinical process and patient outcomes.  In a systematic review, Elwyn et al (2013) found 
that indifference from health care providers was a major barrier to SDM implementation 
which originated from a lack of confidence in the content of decision support tools or a 
disruption to established patterns of work leading to organisational inaction.  
Nonetheless, Towle et al (2006) found that SDM was a well-accepted and welcome 
addition to the clinical encounter in a group of six family physicians.  In this study, the 
physicians were specifically trained in SDM and consultations were then observed.  
Although the physicians felt that they integrated the model into the consultation, this 
was not always observed by the researchers.  The values of the patient were often not 
elicited and the choices not always given.  They found that the largest barrier to 
implementation was the well-established communication methods of the physicians 
involved.  In another study of primary care consultations, Longo et al (2006) found that 
patients valued SDM less than other attributes such as a having a doctor who listens or 
who gives understandable information.  However, experience with a practitioner trained 
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in risk communication or SDM had a positive effect on the value patients placed on 
those attributes, suggesting that SDM may gain importance once patients have 
experienced it. 
2.10 Conclusion 
Through the course of this chapter I have discussed the rise of patient involvement in 
the medical consultation.  Modern medicine presents many different treatment options, 
all with risks to mortality and morbidity, and effective and safe healthcare delivery 
demands a broad conceptualisation of patient-centred healthcare.  SDM allows the 
sharing of information between the patient and the clinician: the clinician provides 
information about the risks and benefits of the treatment options; the patient provides 
information about their values and preferences.  There is a strong clinical and ethical 
argument for SDM but, despite this, it is not yet viewed as routine practice in the NHS.  
Also, the variations in care which acted as one of the catalysts for involving patients in 
decisions about their care persist today.  In order for patients to be truly central to the 
delivery of healthcare, barriers to patient involvement in decision making must be 
identified, recognised and addressed.  In order to do this, SDM needs to be flexible and 
adaptable to real-life clinical decision making and not only one-off interactions within 
the physician-patient dyad.  
Healthcare teams are increasingly used to decide upon and deliver treatment; indeed in 
cancer treatment they are the standard of care.  If patients are to be effectively involved 
in real-life clinical decisions, the delivery of patient-centred care in healthcare teams 
must be addressed.  In the next chapter I discuss the development of healthcare teams, 
the reasons for their popularity and the challenges which teams face if they are to 
effectively engage patients. 
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Chapter 3: Multidisciplinary Team Working 
Multidisciplinary team (MDT) working is seen as the modern standard of care in cancer 
treatment decision making (NICE 2004).  This means that every cancer treatment 
decision in the UK should be made using an MDT.  In this chapter, I discuss the history 
and development of the MDT as a way of working.  I present the evidence for the 
effectiveness of MDT decision making, and the effect that MDT working has on 
decision making and treatment outcomes.  I also present the attempts that have been 
made to analyse the process of decision making and patient involvement in the MDT.  
3.1 The history of MDT working 
It is generally agreed that the origin of MDT working is a report published in 1995 by 
the Chief Medical officer for England (Dr Kenneth Calman) and the Chief Medical 
Officer for Wales (Dr Deidre Hine) (Calman and Hine 1995).  Following its publication, 
similar reports were produced in Northern Ireland (Campbell 1996) and Scotland 
(SODoH 1996).  However, the “Calman-Hine report” was not the first time MDT 
working had been suggested, nor did its publication lead directly to the implementation 
of MDTs.  The report is credited with their development because its recommendations 
laid the foundation for MDT decision making in England and Wales.   
The report was written as a response to the increasing weight of evidence which 
suggested that those patients who were assessed and treated in specialist, centralised 
cancer centres, which had expertise in a disease area, had better outcomes than those 
who were not.  For example, in breast cancer the caseload of the operating surgeon had 
a significant effect on treatment outcome (Sainsbury et al. 1995) and  in paediatric 
cancer, centralisation of care improved survival (Stiller 1988).  It was also noted that 
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there was a persistent, unaddressed variation in treatment practice across England and 
Wales (Morris 1992; Harries et al. 1996) and British cancer survival statistics compared 
unfavourably with the rest of Europe (Sant et al. 2003).  Improved quality of care was 
advocated by patients themselves, with vocal pressure from increasingly influential 
patient groups such as the Radiotherapy  Action Group Exposure (Hanley and Staley 
2006). 
The Calman-Hine report was not detailed and did not provide strict plans for 
implementing its recommendations.  However, its central message tackled many of the 
problems with cancer care, and resonated with clinicians and patients at the time.    
There was a clearly stated requirement for cancer services to be “patient-centred”, but 
the key recommendations of the report were to provide centralisation of care to high-
quality, specialist care units, with early diagnosis and monitored outcomes  (Calman 
and Hine 1995).  Centralisation of care to “Cancer Units” and “Cancer Centres” across 
central and district hospitals in the UK was thus established as the future of treating 
cancer.  There was a minimum standard set for patients to be seen by cancer health care 
professionals with a subspecialist interest in the specific disease type, rather than more 
general clinicians who saw only a small number of cases per year. 
The concept of providing this service via an MDT was recommended in the Calman-
Hine report, but this was by no means the first time that it had been advocated as a way 
of organising cancer care.   The report made structural recommendations to change the 
way cancer treatment was delivered, with an emphasis on multidisciplinary working but 
making decisions in healthcare teams was already established in some cancers, 
especially breast (BBG 1994).  Despite this, the recommendations of the report faced 
significant difficulties in their implementation, as a result of various problems such as 
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manpower issues (Haward 2006).  A large part of the report’s eventual successful 
implementation was due to the fact that it triggered the preparation of disease-specific 
evidence-based guidelines for each cancer, now referred to as the Improving Outcomes 
Guidance (Haward 2006).  In each Improving Outcomes Guidance, the MDT approach 
was further reinforced as the standard of care in cancer treatment.  Specifically in HNC, 
the Improving Outcomes Guidance was published, by the National Institute for Clinical 
Excellence and clearly stated that: 
Multi-disciplinary teams (MDTs) with a wide range of specialists … 
will be responsible for assessment, treatment planning and 
management of every patient (NICE 2004, page 8) 
This established MDT working as the standard of care in HNC.  The latest audit of 
HNC treatment confirmed that 97.5% of those who had a cancer care plan created were 
discussed in an MDT (DAHNO 2011).  
3.2 Definition 
There is no one definition for an MDT and definitions vary depending on the setting and 
the disease.  Inter-professional care is seen as “a process by which professionals from 
different disciplines collaborate to provide an integrated and cohesive approach to 
patient care” (Legare et al. 2011, page 18).  MDT working is commonly linked with 
inter-professional care, but an inter-professional team is not necessarily the same as an 
MDT.  An inter-professional team involves multiple professionals in the care of the 
patient potentially at different time points: the MDT involves a single interaction or a 
series of interactions which usually take place at one time point or over a short space of 
time.  The UK Department of Health defines the MDT as: 
a group of people with different healthcare disciplines which meets 
together at a given time (whether physically in one place, or by video 
or tele-conferencing) to discuss a given patient and who are able to 
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contribute independently to the diagnostic and treatment decision 
about the patient (DoH 2004, page 3) 
Specifically in HNC, the NICE Improving Outcomes Guidance specifies that an MDT 
is: 
a comprehensive range of professionals …. These MDTs should deal 
with minimum of 100 new cases of upper aerodigestive tract cancer 
per annum, which implies a population base of over a million; most 
will be based in Tertiary Centres which have radiotherapy facilities 
(NICE 2004, page 38) 
The make-up of the HNC MDT varies between centres depending on the funding and 
expertise available.  The NICE Guidelines state that all MDTs should be attended by 
three or more dedicated surgeons, some of whom are skilled in reconstruction.  The 
team should also include clinical oncologists, restorative dentists, pathologists, 
radiologists, clinical nurse specialists, speech and language therapists, palliative care 
specialists, dieticians, an MDT secretary, team manager and coordinator (NICE 2004). 
A national audit published in 2003 highlighted that this was not being achieved: 
although over 95% of meetings were attended by an oncologist and/or a surgeon and 
80% were attended by a speech and language therapist, fewer MDTs had access to other 
specialists.  Only around half included dieticians and/or clinical nurse specialists, and 
the role of other specialists was even more variable, with teams having a mix of plastic 
surgeons, restorative dentists and palliative care physicians (Birchall et al. 2003).   The 
list of recommended attendees is by no means exhaustive, and modern HNC MDTs may 
include dental hygienists, clinical psychologists, lymphoedema nurses, anaesthetists, 
social workers, benefits advisors and psychiatrists.  The roles of the MDT are clearly 
laid out in the NICE guidelines: 
The MDT should take overall responsibility for assessment, treatment 
planning and management of all patients.  The MDT should take 
responsibility for deciding what form of treatment should be offered, 
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where the proposed treatment should be carried out, and by whom 
(NICE 2004) 
In stating this, the shared responsibility of the MDT in managing patients with HNC is 
emphasised.  Importantly, it states that treatments should be “offered”, therefore the 
outcome for an MDT discussion should be a treatment recommendation, rather than a 
treatment decision. 
3.3 Benefits of MDT working 
MDT working is popular amongst the members of staff who attend it.  In a national 
survey by the National Cancer Action Team (NCAT), 2054 members of staff who 
attend an MDT completed a comprehensive questionnaire.  Over 90% of participants 
felt that the support of fellow members was important and that working in this way was 
beneficial to the well-being of the members.  Over 80% felt that the MDT saved time 
and felt that this form of working improved job satisfaction (NCAT 2009).  Specifically 
in HNC, a qualitative study of 33 professionals in four focus groups found that the team 
provided an inclusive environment for planning care.  Staff members reported that the 
team gave support, a chance to stay up to date and an opportunity for discussing 
difficult cases (Edwards 1998).  Although interesting, this study used focus groups of 
MDT members to collect data.  MDT members were in the presence of others and 
therefore their vocal support may be a reflection of social acceptability or the awareness 
of colleagues rather than true support.  Nevertheless, MDTs are thought to increase 
recruitment to clinical trials (Twelves et al. 1998; McNair et al. 2008), improve 
adherence to care quality indicators (such as dental or nutritional assessments) (Kelly et 
al. 2013) improve patient satisfaction and shorten the time between diagnosis and 
treatment (Gabel et al. 1997).   
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MDT teams have a variety of clinicians and allied health professionals from a range of 
backgrounds.  Although some of these members have well-recognised roles within the 
team, others’ roles are more ambiguous.  Individual members of the team demonstrate 
high levels of exhaustion and members with a lesser role in the discussion, such as 
pathologists and radiologists, perceive that they have lower levels of accomplishment at 
work (Catt et al. 2005).  The proportion of UK hospital consultants with psychological 
morbidity and emotional exhaustion rose between 1996 and 2002, coinciding with the 
rise in MDT working.  This was thought to be attributable to increased stress without a 
similar increase in job satisfaction, a finding which was most pronounced in clinical and 
surgical oncologists (Taylor et al. 2005). 
Despite MDT working being uniformly viewed as the standard of care in cancer 
management, evidence for its effectiveness is sparse (Fleissig et al. 2006; Taylor et al. 
2010).  Despite this, the MDT has persisted as a way of working, which may be due in 
part to the reported benefits expressed by the majority of staff members who attend it.    
In a similar way, the implementation of the Calman-Hine report was reliant on the warm 
reception it received from clinicians.  Nevertheless, researchers and policy makers 
continue to strive to demonstrate the effectiveness of MDTs, not least because they are 
expensive and time consuming.  Best practice guidelines estimate that a radiologist will 
take two hours and a pathologist 2.4 hours to prepare for each hour of team meetings 
(Kane et al. 2007) putting the estimated cost of all UK MDT meetings at £50 million a 
year for preparation and the same amount again for attendance (Taylor et al. 2010).  In 
HNC, Mullan et al (2014) recorded the time taken for the team to discuss each patient 
over 10 meetings. They reported it varied between 15 seconds and eight minutes, with 
increased discussion times for older patients or in those with more advanced disease.  
As the majority of cancer care is delivered in large central hospitals, this represents a 
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considerable time burden for attendees.  In the age of evidence-based medicine, most 
health interventions must demonstrate effectiveness to earn their place in routine 
practice.  In the next section I discuss the evidence of effect that MDT working has on 
the decisions made and ultimately the clinical outcomes of the patient who are treated 
by them. 
3.4 Effect on decision making 
The primary problem with assessing the effectiveness of the MDT is deciding what the 
measure should be and from which viewpoint it should be measured.  In one American 
study, the treatment recommendation of the referring clinician was compared with the 
MDT recommendation in 75 breast cancer patients.  It was found that in 32 patients 
(43%), the recommendation of the MDT was different to that of the referring clinician.  
In a third of the cases where the treatment plan was changed, more clinical information 
was needed for a decision to be reached.  Importantly however, 13 patients (17%) had 
the recommendation of mastectomy (from the referring clinician) changed to breast 
conserving therapy (from the MDT).  However, it must be noted that this study was 
conducted in the United States, where the ‘referring clinician’ may not have been a 
member of the MDT; indeed the expertise and experience of the referring clinician is 
not specified (Chang et al. 2001).  In a similar study in HNC, Brunner et al (2014) 
found that in almost a third of cases, the treatment plan of the referring clinician was 
changed by the MDT.  Treatment plans were more frequently altered if the original plan 
from the referring clinician did not include surgery or if the histology was not squamous 
cell carcinoma or skin malignancy.  This study was conducted in Australia, which has a 
similar referral pathway to the United States, and hence it applicability in the UK is 
again limited.  Interestingly however, the authors included details about the expertise of 
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the referring clinician, and found that those from oncologists were more likely to be 
changed than those from surgeons.   In the UK, Kee et al attempted to ascertain if, when 
a clinician presents their patient at the MDT, the ensuing discussion changes the 
reported preference of the clinician.  In a similar proportion of cases (39%) the 
preference of the referring clinician did not match the final decision of the MDT.  
Interestingly however, they also showed that in only 26% of cases where the team and 
individual clinician disagreed did the referring clinician finally concur with the decision 
of the team and present it to the patient (Kee et al. 2004). 
Thus, although it can be said that different decisions are made by teams than are made 
by individual clinicians, it is still more complex as to whether this difference is even 
expressed to the patient.  Also, judging whether these altered decisions are ‘better’ is a 
much more difficult and complex task.  In the study by Kee et al above (ibid.), the 
authors also made an attempt to quantify the ‘quality’ of the decisions made using 
expected utility theory.  To do this, the maximum expected utility of all the available 
treatment options was compared with the expected utility of the preferred treatment of 
the referring clinician and then of the MDT in 50 cases.  The effect of the discussion on 
the net difference between the “maximum” utility score and the utility score of the 
selected treatment was found not to be significantly different from zero.  Although an 
interesting method of assessing this question, it is difficult to judge the quality of 
decisions based on this small study.   Not only this, but although the survival estimates 
were individually estimated by the physician, the utility values on which the analysis 
was based were derived from the literature, which assumes that all patients had the same 
utility for the different outcomes. 
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MDT working not only affects the treatment recommendations made, but also the 
diagnoses given.  In gastro-oesophageal cancer, there are many potential different 
methods of accurately staging patients such as CT scanning and trans-oesophageal 
ultrasound.  Davies et al (2006) found that an assessment taking into account multiple 
different methods of staging at an MDT meeting was closer to the post-resection staging 
when compared with the single staging modalities alone.  Although this resulted in 
fewer patients being under treated it could be argued that this improvement is due to the 
combination of staging technologies rather than the MDT meeting per se.  There is little 
doubt however that the MDT facilitates the discussion and combination of modalities 
such as that demonstrated here.  A systematic review of lung cancer teams found MDT 
decision making increased the number of patients being treated aggressively with 
surgical resection, chemotherapy or radiotherapy with a curative intent (Coory et al. 
2008).  Morris et al (2008) used cancer registry data for 11,919 breast cancer patients to 
compare the diagnoses and treatments given over a five year period with the degree with 
which the treating centres had implemented the recommendations from the Calman-
Hine report.  The degree of Calman-Hine implementation was estimated by the caseload 
of the operating surgeon and the make-up of the MDT.  Implementation was found to be 
variable (the study was conducted between 1995 and 2000) but it was associated with a 
reduction in the use of breast conservation surgery and an increase in the use of 
radiotherapy following breast conserving surgery.  This study provides interesting data 
which shows a change in practice over time, but it is difficult to unpick how much of 
this was due to the introduction of MDT working, how much due to the other 
recommendations of the Calman-Hine report (such as centralisation of care), or indeed 
how much was due to a change in the way patient preferences were incorporated into 
the decision.   
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The evidence presented so far suggests that since the introduction of MDT working, 
practice has changed.  It is impossible to go on to conclude how much of this change 
was due to the MDT, the other Calman-Hine recommendations or temporal trends.  The 
literature presented allows the conclusion that MDT working results in a change to the 
decisions made.  Although this demonstrates that decisions are different it is more 
difficult to define whether they are better.  It is also still not clear whether this change in 
management has any positive effects on the eventual treatment outcome.  In the next 
section I discuss the evidence assessing the effect of MDT working on clinical 
outcomes. 
3.5 Effect of MDT working on survival 
The challenges faced when assessing the impact of MDT working on survival in cancer 
was outlined by Hong et al (2010) in their systematic review on this subject.  Similar to 
the problems faced when studying the effect of SDM, the definition of MDT is applied 
variably across centres.  Benefits may reflect a selection bias of patients with a better 
prognosis, rather than a real effect, and any improvements highlighted may be due to 
other advances in screening, diagnosis or treatment which happened in the same time 
period.  Hong’s review included 21 studies which were categorised broadly into 
retrospective studies and those with cohorts before and after the introduction of an 
MDT, usually in a single centre: it was not able to demonstrate a link between MDT 
working and survival. Although the incorporated evidence suggested a survival 
advantage for the MDT, this could not be confirmed as causal due to the difficulties in 
defining the MDT and heterogeneity of study designs.    
The only UK study of the effect of MDT working on survival in HNC compared two 
retrospective cohorts of patients in the South West of England.  The first cohort of (566 
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patients) was treated in 1997 and the second (727 patients) was treated in 2000.    Over 
85% of cases were captured in each audit, but collection relied on clinicians completing 
paper-based protocols. The authors reported a number of process improvements 
between the two audits.  The proportion of patients seen in an MDT increased from 
46% to 74% between the two audits and the number having pre-treatment imaging and 
accurate staging work-up also increased.  However, perhaps as a result of this, waiting 
times also increased.  The overall survival between the two cohorts was not 
significantly different (64.1% increased to 65.1%), but analysis revealed that those 
patients were assessed in an MDT had a statistically significantly better survival than 
those who were not.  Although MDT working could have improved the ‘non-temporal’ 
standards such as pre-treatment imaging, the correlation between MDT working and 
increased survival cannot be assumed to be causative.  The authors discussed that 
survival data was probably incomplete, as the deaths reported did not match those of 
death registrations in the area. Also, temporal trends were not accounted for and 
confounding factors such as patient selection were not acknowledged (Birchall et al. 
2004).  
In Australia, MDT decision making is not mandated, and hence Friedland et al (2011) 
were able to compare the treatment and outcomes between HNC patients who had been 
referred to the MDT (395 patients) and those who had not (331 patients) over a 12 year 
period in a single hospital.  The authors found that those patients who had been seen in 
an MDT were less likely to have single modality treatment and more likely to receive a 
combination of chemotherapy and radiotherapy and/or surgery.  Also, those patients 
who had very advanced (stage IV) disease had significantly improved survival.  
However, the allocation to management within or outwith the MDT was not 
randomised, but chosen by the referring clinician; also the MDT patient group had a 
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higher age and more advanced disease.  Most importantly however, it is not made clear 
why some patients were selected to be managed by the MDT whilst others were 
managed by individual clinicians. 
There are no randomised controlled trials of MDT working and as it is now ubiquitous, 
randomisation of this complex intervention is impossible.  This means that patients 
cannot be randomised to be treated by a team or an individual.  However, during 
implementation of the findings in 1995, MDT working was introduced into one health 
board in Glasgow (the “intervention area”), but not in other health boards in the west of 
Scotland (the “non-intervention area”), allowing a comparison between two similar 
populations.  Before MDT working was introduced, breast cancer mortality was 11% 
higher in the intervention area than in the non-intervention area.  After MDT 
introduction, breast cancer mortality was 18% lower than the non-intervention area.  
There was also a reduced variation in survival between hospitals in the intervention 
area.  This study used cancer registry data on 13,722 patients, and the authors adjusted 
for temporal trends.  This large study was published after the systematic review above 
and the authors provided detail about the definition of MDT working used.  Although 
only a single study in one cancer, the size of the effect is noticeable and it provides the 
strongest evidence of a positive effect of MDT working on cancer survival to date 
(Kesson et al. 2012).  
Despite this, given the overall weight of evidence and the difficulty in accurately 
answering this question, it is not known if MDT working has an effect on cancer 
survival.  Importantly however, there is equally no convincing evidence of a negative 
effect.  Even if MDT working did improve survival, the aspect of the process which was 
responsible for such effects is not known.  This lack of effect on cancer survival 
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outcome has driven researchers to search for alternative ways to assess the effectiveness 
of the MDT.  As I discussed in the previous chapter, a treatment decision is far more 
than the clinical outcome it produces, and therefore in order to assess the MDT as a 
method of making a treatment decision further exploration is required.   
3.6 Assessment of the MDT decision making process 
Various different general quantitative measures have been developed to attempt to 
objectively record the broad ‘effectiveness’ of MDTs.  Many of these have been based 
on clear guidelines, issued by the National Cancer Action Team (NCAT) following its 
survey of MDT members entitled “The Characteristics of an Effective Multidisciplinary 
Team” (NCAT 2010).  One tool developed by Taylor et al (2012), covered many 
“observable” features of MDT working such as attendance, administration and patient-
centredness of the clinical decision making. The authors measured the patient-
centredness of the MDT decision by counting the number of cases where there was a 
mention in the discussion of patient-based information.  Patient based information in 
this study was defined as patient demographics, comorbidities, supportive needs or 
patient and family preferences.  Ten colorectal MDT meetings were video-taped and 
scored by three observers using a standardised proforma developed by the authors.  
Teams scored highly in measures of attendance, dealing with conflict and 
administration.  However eight out of the ten meetings observed scored “poor” or “very 
poor” for patient centred care.  The patient information which was included was 
frequently confined to demographics and most teams rarely considered other patient-
based factors.  Other authors have produced similar tools, usually designed to be used 
by an independent observer or by the team itself as a means of self-assessment.  Lamb 
et al (2011) developed a tool which used Likert scales to quantify 11 aspects of MDT 
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team discussion, including information about the patient, contribution of members of 
the team and the incorporation of patient views.  Five MDTs were observed discussing 
164 patients.  Teams scored highly in the amount of information given about the clinical 
history, and radiological information.  Also, the “quality” of the input from surgeons 
and oncologists was rated to be high.  The Likert scale for “patient views” ranged from 
“no provision of patient views” through “patient views from a report or account” to 
“fluent, comprehensive account of the patient views”.  MDTs were assessed by an 
observer who attended one meeting of five different MDTs and team members were 
asked to complete a similar survey individually online.  Teams were found, using this 
scale, to incorporate patient views into the discussion quite poorly.  Moreover, the self-
assessment questionnaires completed by the team members suggested that they over-
estimated the ‘patient-centredness’ of their decisions.  This may of course merely reflect 
the difficulty of defining ‘patient-centredness’, or the inadequacies of this scale.  This 
study provides an interesting insight into the content of the MDT discussion, but 
provides little information on the exact nature of patient-centred information included or 
the reasons for the difficulties in incorporating it into the discussion.  Questionnaires 
and observation frameworks such as these provide user-friendly, quantifiable measures 
which can be used by team members to assess themselves and ultimately improve their 
practice.  However, only a superficial account of the discussion is provided and many 
aspects are based on a subjective assessment of the MDT meeting alone. It cannot be 
concluded that MDTs which mention details about a patient more frequently involve 
their patient more in the treatment decisions, but both studies highlight a similar theme: 
within the team discussion, information about a patient is sparse, especially that 
regarding patient values and preferences. 
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Placing the patient at the centre of the decision is reportedly important to the members 
of the MDT.  In the NCAT Survey of MDT (2009), 95% of respondents felt that 
“Patient views should always inform the decision-making process” and  “Patient 
views/preferences should be presented to the MDT by somebody who has met the 
patient”.  At the same time, 96% of participants felt that it was not practical for patients 
to attend their own MDT meeting.  Although interesting, these data represent the views 
of the MDT members, but do not provide detail of actual practice in each MDT.  When 
the free-text responses from the NCAT survey were analysed, lack of information about 
the patient or lack of knowledge of the patient views were seen as the main reason for 
MDT decisions not being implemented (Lamb et al. 2013).  Although the authors state 
that patient presence at the meeting would “undoubtedly inhibit discussions” they 
conceded that little is known about how patients’ preferences and values should be 
represented in the MDT. 
The potential for patients to attend their own MDT meeting has been explored 
previously.  In a questionnaire survey of 135 breast cancer patient advocates  and 294 
health care professionals, only a minority (between 24% and 32%) of clinicians were 
supportive of involving women in the treatment planning meeting, compared with 93% 
of breast cancer advocates.  Advocates felt that that it would lead to information and 
empowerment for the patient, but professionals felt that it would inhibit the discussion 
and cause patient anxiety (Butow et al. 2007).  Although interesting, this study provided 
little information (other than demographic data) about who the breast cancer advocates 
were: one third had “health training” and 70% had been diagnosed with breast cancer 
within the past 10 years.    Martin et al (2011) reported almost insurmountable 
difficulties in incorporating service users onto healthcare provider teams.  In this study, 
users attended health service-development team meetings over a considerable length of 
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time.  Existing team relationships were built largely on trust, either secondary to long-
standing relationships or pre-existing hierarchies, which presented barriers to user 
integration.  Additionally, if users were successfully integrated, the distinction between 
professional team members and lay members was reduced, which acted to lessen the 
unique insight and input that users were originally intended to bring.  Nevertheless, if 
successful, user integration took place over a period of years; when applied to the MDT 
setting, there is no opportunity such relationships to develop .  A small qualitative study 
interviewing ten MDT members reported that, although meeting a patient in the MDT 
setting allowed for better information giving, one to one consultations provided superior 
communication and trust-building (Bellardita et al. 2011).  Another small qualitative 
assessment of the patient experience of attending their own MDT agrees that it 
improves information giving, but not involvement in the decision (personal 
communication, Adam Potts).  Choy et al (2007) conducted an interesting pilot study in 
which 23 breast cancer patients were invited to attend their own MDT meeting.  
Included women completed a questionnaire before and after the meeting and gave a 
short qualitative interview.  The authors used a small control group of seven patients 
who refused to attend.  It is not possible to draw any conclusions from this study owing 
to the small sample sizes but the findings were nonetheless interesting: attending the 
MDT seemed to have no effect on anxiety and improved information gathering and 
communication. The small qualitative component also highlighted some negative 
aspects of MDT attendance including the intimidating nature of the radiology and 
pathology information and the potential difficulty of hearing bad news in that setting.  
Encouragingly, professionals also gave a positive response to the intervention, despite 
feeling that the time required made it quite resource-intensive.   
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Omitting, or not incorporating, patient preference information into the treatment 
discussion potentially has an effect on decision implementation.  Rajan et al (2013) 
analysed 3230 documented breast cancer MDT discussions and found that 146 (4.5%) 
of these were discordant with the final agreed patient management plan.  Of the 
discordant decisions, 61 (41.7%) were due to ‘patient choice’: the nature of this choice 
and how it was elicited is not specified.  In a similar way, Blazeby et al (2006) analysed 
273 upper gastrointestinal cancer MDT decisions over five months and compared the 
documented MDT decision with the final treatment performed to see if treatment 
decisions made in the MDT are actually implemented.  In all there were 41 decisions 
(15%) which were changed: of these, 18 (44%) were due to comorbid disease not 
discussed, 14 (34%) were “related to patient choice” and 8 (20%) were because “new 
information” came to light.  The group undertook a similar investigation of the 
colorectal MDT at the same hospital.  In an analysis of 201 decisions, 20 (10%) were 
not implemented.  Of these nine (40%) were due to comorbidity and seven (35%) were 
due to “patient choice” (Wood et al. 2008).  These retrospective studies provide 
interesting data, but relied on review of the case notes, exposing the data to bias.  They 
also examined a case load with a very high number of patients being treated without 
curative intent.  For both of these studies, the vast majority of the changed decisions 
were to a more conservative plan, with curative treatment being changed to palliation, 
or palliation being changed to best supportive care.  It could be argued that decisions 
such as this rely even more heavily on patient values, and hence it is not surprising that 
so many decisions were changed.  Nevertheless, the studies highlight the consequences 
of not incorporating patient preference information into a treatment discussion.  They do 
not however provide the necessary detail as to how a decision change occurred, or 
indeed why.     
58 
 
This means that despite the fact that MDT members reportedly value patient 
information such as values and preferences, such patient centred information is often 
omitted from the discussion.  At the same time, MDT members feel it is not practical 
for patients to attend their own MDT meeting.  If information about the patient 
preferences and values are not included in the discussion, this leads to difficulties with 
making appropriate recommendations and decision implementation.  This presents the 
MDT with a challenge in effectively engaging their patients in the decision process. A 
large review of effectiveness of MDT working stated that “there is no consensus about 
how best to involve patients in the clinical decision making process in team meetings” 
(Taylor et al. 2010, page 744).  The issue of patient involvement in MDT decision 
making warrants further exploration. 
3.7 Patient involvement in the MDT 
Successful incorporation of the views of the patient into a discussion between 
professionals at a meeting where the patient is not present is a challenging concept.  In 
order to do this, an analysis of how the team make decisions is required, a question 
particularly suited to qualitative techniques.  Kidger et al (2009) performed an 
ethnographic study of a gynaecological MDT.  Ten meetings in one centre were 
observed and this exercise combined with 16 interviews with members of staff.  The 
results echo and build upon the problems with MDT working which have been alluded 
to with the survey and questionnaire research presented above.  The authors found that 
the consideration of patient related factors such as comorbidity information, 
psychosocial issues and patients’ wishes was unstructured when compared with the very 
structured manner in which the biomedical information was presented.  MDT members 
recognized the importance of ‘seeing’ a patient rather than an objective representation 
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through information; however information about patient preferences was only really 
presented when these were strongly held, or ran counter to the recommendation of the 
team.  This lack of information about patient preferences was at odds with the MDT 
members’ recognition of its importance.  The team exhibited uncertainty about when 
and how this kind of information should be incorporated into the discussion. 
Lancely et al (2008) performed another ethnographic assessment of a gynaecological 
MDT.  Sixteen MDT discussions in one centre were observed, and used to create 
questions for semi-structured interviews which were conducted with 12 members of the 
team.  Again, the biomedical details of the patient were at the forefront of the 
discussion, packaging patients into a semi-predictable ‘case’ which consisted mainly of 
their biomedical data.  Although information such as the ethics of treatment selection or 
the individuality of the patient was sometimes presented, the team struggled to 
incorporate this into the ‘case’ and therefore into the decision.  The authors observed 
that this often led to two strands of narrative about a single patient, which the team had 
significant difficulties combining. The authors spoke about one of the effects of this in 
the team; allied members of the team who hold the non-biomedical information (for 
example Clinical Nurse Specialists) were silenced or ignored.   
These two ethnographies suggest a dominance of the biomedical view of the patient in 
the MDT discussion despite acknowledgement from the members about the role of 
other patient information.  The biomedical dominance may however be a symptom of 
the difficulty in incorporating other sorts of information into the discussion, and when 
incorporated, the challenges in how it should be used to influence the decision or 
recommendation.  Both of these studies provide a fascinating insight, not only into the 
fact that patient preferences are not incorporated into the discussion, but also why this 
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may be the case.  However, the ethnographic studies were each based in a single centre, 
and relied solely on researcher generated notes, rather than audio or video recording of 
the interaction.  Although this methodology provides much more depth of analysis than 
survey data, the intricacies and subtleties of the team interaction which influence the 
course of the discussion and the decision made may have been lost.  Although it is not 
without its downsides, recording of the decision making conversation would provide a 
further increased level of detail (Hammersley and Atkinson 2007).  It is also unclear 
about which of the decisions were implemented and how the included cases were 
sampled.  Nevertheless, both studies act to highlight one of the major challenges facing 
the MDT at the moment: how does the MDT involve the patient in treatment decisions?  
The most striking limitation of all of the literature examining the effectiveness of the 
MDT is that it ignores the interaction of the team members with the patient.  Although 
they demonstrate a dominance of biomedical information in the MDT meeting it cannot 
be concluded that teams who have more information about a patient involve their 
patients better in decisions.  In order to reach a conclusion such as this, more data are 
needed.  The observations must extend beyond the MDT environment to include, at the 
very least, the next stage in the decision process, the clinic appointment. In omitting 
this, these studies are not an analysis of MDT decision making, rather an analysis of 
team dynamics and negotiation.  Importantly, however, if we are to truly address how 
involved patients are in MDT decisions, one of the richest sources of data would be the 
patients themselves.  It seems counter-intuitive that in all the studies so far of the 




The MDT is currently the standard of care in cancer treatment decision making, and the 
vast majority of patients who have cancer will have their case discussed in this forum.  
The MDT is popular among its members but requires the time and expertise of a wide 
range of clinicians and, as a result, has huge financial implications.  There have been 
many studies looking at the outcome of the MDT discussion, perhaps because this is 
more easily quantifiable; despite this there is very little evidence on how effective MDT 
decision making is.  It is known that when treatments are decided through an MDT, 
different decisions are often made than when they are not; it is more difficult however 
to ascertain whether the resultant decisions are in fact better.   
If patients’ values and preferences are not included effectively in MDT decisions, a 
proportion of the recommendations from the MDT may not be implemented.  The 
members of the MDT also recognise the importance of incorporating patient preferences 
into the decisions.  At the same time, the team struggles with how and when to 
incorporate individual patient information such as treatment preference into the 
discussion.  If any intervention is to be successful in improving patient engagement in 
treatment decision making in this setting, there needs to be a clear understanding of the 
process of MDT decision making.   However, in order to gain this clear understanding, 
an examination of more than just the team discussion is required. 
In order to truly explore how a patient is involved in an MDT treatment decision it is 
essential at least to observe how the team interacts with the patient.  The difficulty faced 
is that the majority of the work on involving patients in healthcare decisions has centred 
on the interaction of one clinician with one patient.  At the same time, the majority of 
the work looking at MDT decision making focuses on the clinicians and their 
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interactions with each other.  It is argued that a patient preference is not a static piece of 
information, but the result of an interaction (Epstein and Street 2011), therefore any 
research which is looking at how it is incorporated must respect this.  There is also a 
glaring lack of studies examining the patient experience of the MDT decision process, 
and there is no account of how the patient makes a decision in conjunction with the 
MDT.  An appreciation of how the patient engages with the recommendation of the 
team, as well as the team with the patient, is essential to understand how a decision is 
made and to identify opportunities for improvement.  The interaction between the two 
would provide us not only with an account of how the team make a recommendation, 




Aims and Objectives 
In Chapter One, I discussed the complexity of the treatment decisions in HNC.  Patients 
often have a low chance of survival, uncertainty about the outcome of the treatment and 
a significant functional trade-off if cure is to be achieved.  In Chapter Two I discussed 
the rise of patient involvement in the medical consultation and the drivers for this 
change in practice.  I discussed the clinical and ethical argument for SDM as a method 
of achieving patient-centred decision making, and the barriers which exist to 
implementing this into routine practice.  In Chapter Three, I discussed how, in the UK, 
HNC decisions are currently made through an MDT.  I discussed the history of the 
MDT, the scarcity of evidence for its effectiveness and outlined the difficulties that the 
MDT face when considering the values and preferences of the patient in decision 
making. 
In this thesis, I aim to examine critically patient engagement in the MDT treatment 
decision making process in HNC.  In order to achieve this aim, I have the following 
three objectives: 
Objective one: To examine critically the current function of the MDT meeting in HNC 
Objective two: to evaluate the experience and practice of decision-making by patients 
and clinicians and to elicit their views on current and preferred involvement in the 
treatment decision making process 
Objective three: To use the findings from objectives one and two to determine the 
requirements for decision support in the context of the MDT. 
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In the next chapter I discuss the methodological approach which I employed to achieve 




Chapter 4: Methodology and methods 
In this chapter I outline the theoretical and philosophical standpoint that I have adopted 
to address the question under study. I detail the assumptions which acted as the 
foundation for my methodological approach and the implications that this had for the 
data collected and its analysis.  I then discuss the methods of data collection and the 
challenges which I faced when gathering data.  I also explain the approach, recruitment 
and consent of participants and close the chapter by describing my process of data 
analysis.   
The MDT meeting and clinic is not defined by a geographical space, but rather by the 
interactions of multiple members of the team with each other, with the patient and with 
the pieces of information which are available to them.  The treatment decision is the 
result of various social processes within the MDT, between MDT members and the 
patient and between patients and their supporters.   In analysing this process, I am 
attempting to describe something which has no physical form and no parameters.  The 
process of investigation presented me with multiple, complex, variable, sometimes 
conflicting accounts of decision making in this setting (including my own).  In order to 
gain an understanding of this process, I needed an appreciation of the multiple 
viewpoints and interactions which make it up.   
4.1 Theoretical perspective 
A philosophical and theoretical basis was required which enabled me to explore the 
multiplicity of perspectives which existed during an MDT meeting, clinic and treatment 
decision.  To begin the explanation of the theoretical perspective that underpins this 
work, I will briefly discuss the ontological and epistemological foundations I adopted.   
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The setting under study and the product of this process, a decision, is a construct of an 
interaction.  In order to explore the different and sometimes divergent perspectives in 
decision making I require an acceptance that ‘truth’ or reality is something which is 
interpreted by the observer.  One ontological perspective which acknowledges this is 
termed relativism: the relativistic standpoint accepts that there are multiple realities and 
each reality constructed has equal validity (Crotty 1998).  Relativism is in direct 
opposition to realism, or the belief that an object exists in one, true, objective reality, 
waiting to be discovered.  Realism is often suitable for the study of physical but perhaps 
not social phenomena.  Kuhn argued that there is no theory-neutral observational stance 
which can be used to describe one universal truth; data will always be viewed through a 
lens consisting of the observers theoretical standpoint, and if another lens is used to look 
at the same set of data by another observer, another conclusion may be reached (Kuhn 
1970 cited in Crotty 1998).  This creates an acceptance that ‘truth’ is something which 
is interpreted by the observer, and suggests that one overarching law cannot be arrived 
at.  I acknowledge that my appreciation of the research question is relativistic; multiple 
realities may exist, guiding the behaviour of the participants, and my method of enquiry 
must respect this.  However, to adopt a purely relativistic viewpoint would also 
potentially lead to a conclusion that my analysis is merely a result of my own cultural 
influence, and no more valid a representation of reality than any other observer.  In 
order to resolve this I will draw upon Hammersley’s  description of “subtle realism” 
(Hammersley 1992).  He argues that whilst certain validity of any finding or generation 
of knowledge is impossible, this does not mean that one cannot have any confidence in 
its validity.  Hence, there is a ‘reality’ but this reality can never be known completely.  
My research aims to represent ‘reality’, but not reproduce it; indeed there will always 
potentially be other, perhaps contradictory accounts which may be equally valid. 
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However my claims should be judged by the extent to which they represent or reflect 
reality based on interpretation of plausibility and credibility.  
The constructionist epistemological viewpoint acknowledges that the production of 
knowledge (or what we can know about reality) is socially constructed, therefore an 
unimpeded or ‘raw’ view of reality is impossible.  Constructionists argue that meanings 
are constructed and objects are defined by the meaning that we assign to them; in other 
words “all objects are made and not found” (Fish 1990 cited in Crotty 1998, page 52).  
This is not to say that we create meaning as an asocial individualistic achievement; this 
would be a subjectivist viewpoint.  A constructivist viewpoint argues that meanings are 
embedded in culture and convention.  Therefore as a social group of humans, we 
generate our own collective meaning which is shaped by our culture, background and 
previous interactions (Shwandt 1994).  In accepting this, we can place the 
constructionist viewpoint between the opposite poles of objectivism and subjectivism 
(Crotty 1998).  
So, in conclusion, my ontological standpoint is one of subtle realism and my 
epistemological standpoint is constructionism.  This allows me to explore the various 
perspectives in the MDT decision process, where multiple perspectives are important, 
valid, and require investigation and analytic attention. I will now go on to describe the 
effect that this position has on my choice of methodology and the way that I will enact 
this methodology by way of my techniques of data collection.   
4.2 Symbolic Interactionism 
I adopted a scientific methodology that assumes that there is a reality which cannot be 
known about directly, as different meanings can be ascribed to objects and social 
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encounters.  Symbolic interactionism has its origins in pragmatism which developed as 
an alternative to the stimulus–response theory of action (Strauss 1993).  Pragmatism 
theorised that an organism is not passive, awaiting a stimulus before action can be 
generated, but has an on-going activity which the stimulus plays into; the response 
witnessed is the reaction between the two (Charon 1995).  Pragmatism was developed 
into progressive ‘theories of action’ by successive generations of sociologists at the 
University of Chicago.  Although it was the work of Dewey and Mead in which 
pragmatism takes it roots, it was Herbert Blumer who developed and crystallised this 
into practical theory, and first coined the term “symbolic interactionism” (Travers 
2001).  This provided the basis for symbolic interactionism to develop as a research 
perspective.   
Blumer developed symbolic interactionism as a direct contrast to “variable analysis”.  
Variable analysis is the idea that an individual can be broken down into a number of 
“variables” or complex dimensions which vary.  Blumer argued social phenomena 
cannot be described and measured in this way and variable analysis removed context 
and merely acted to simplify social life (Blumer 1956).  At the time, this quantitative 
analysis of social life, conducted through surveys, questionnaires or statistical analysis 
was popular and mainstream (Travers 2001).  Blumer contested that symbolic 
interactionism provided insight into “the real operating factors in group life, and the real 
interaction and relations between factors” (Blumer 1969 cited from Travers 2001, page 
24).  In keeping with the pragmatic viewpoint, symbolic interactionism relies on the 
subject being active; in fact interaction is the unit of study.  As humans, we are 
interacting all the time and our actions have an effect on those around us.  In turn, we 
take each other’s actions into account as we act.  Importantly, we do not only interact 
with those around us, but also within ourselves; we think and define situations then act 
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according to our assessment.  The resultant action is not pre-programmed; although we 
can predict how a certain situation is going to develop based on our past experience, we 
cannot guarantee the reactions or cooperation of others (Charon 1995): this is especially 
true in groups of people.  Joint action does not simply arise from a set of pre-given 
relationships, although these may be well known and long standing.  The situation may 
not develop as expected thus the capacity to reproduce joint action is: 
subject to pressure as well to reinforcement, to incipient 
dissatisfaction as well as to indifference; they may be challenged as 
well as affirmed allowed  to slip along without concern as well as 
subjected to new vigour…. A gratuitous acceptance of the concepts of 
the norms, values and social rules and the like should not blind the 
social scientist to the fact that any one of them is subtended by a 
process of social interaction – a process that is necessary not only for 
their change, but equally well for their retention in a fixed form.  It is 
the social process in group life that creates and upholds the rules, not 
the rules that create and uphold group life (Blumer 1969 cited from 
Cuff et al. 1998, page 115) 
Therefore action and interaction can be described, but are not defined by rules, norms 
and values; instead they are endlessly rebuilt and re-worked.  This is a necessary feature 
of social life: although rules and norms influence our behaviour they are not concrete 
and solid.  This is especially true at the level of an organisation such as a hospital where 
the rules and policies which govern behaviours are subject to frequent modifications 
and changes. 
In line with central themes of symbolic interactionism, I conducted my research using 
ethnographic methods which places importance on the observation of interaction.  
Ethnography is a method of qualitative study which places the researcher directly in the 
setting under analysis; observing and interpreting the actions of the participants.  It stays 
true to the central concept of symbolic interactionism that the contents of the mind are 




“Ethnography” was originally an anthropological methodology and would involve the 
researcher travelling and living with a foreign culture in order to produce a rich and 
detailed description of a non-western culture (Hammersley and Atkinson 2007).  It 
gained popularity and in time was used to describe Western cultures, often the villages 
or towns of Western Europe or the US (Lynd et al. 1929).  Ethnography is a central 
example of naturalistic enquiry; here, participants are studied in their natural 
environment, so the observer respects the social world or the context in which the 
actions are performed.  In the 50s and 60s the practice of ethnography was developed by 
the ‘Chicago School’ of interactionist sociologists to use as a method of studying human 
social life (Wirth 1928; Blumenthal 1932 cited in Atkinson et al. 2001).  Ethnography 
requires the researcher to participate in the daily life of the studied participants rather 
than in experimental conditions; the research takes place ‘in the field’.  Data are 
gathered from a range of sources via watching, listening and asking questions through 
formal and informal interviews.  The study is in-depth, and hence there is a 
concentration on fewer cases, and data is gathered in a relatively unstructured way.  
Analysis of data gathered via ethnographic methods is not pre-defined and focuses on 
the meanings, functions and consequences of human behaviour (Hammersley and 
Atkinson 2007).  In essence, ethnography is a development of what we already do as 
human beings to make sense of the world around us.   
In order to undertake ethnography, there is an underlying belief in cultural relativism: 
that individuals construct their own world based on their interpretation of what is 
around them (Hammersley and Atkinson 2007).  The effect that the researcher has on 
this process cannot be denied, as their cultural background and worldview will have an 
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effect on their interpretation of the data.  By using ethnographic methods, I did not  
have to rely on retrospective accounts gleaned through participant interviews which 
may provide an idealised account of events from one perspective (Strauss 1993).  My 
observations allowed me to study the participants as a group, meaning that I could begin 
to analyse the complex process of negotiation which is used to attempt to achieve a 
position of consensus in the team.  I was able to directly observe how individuals in the 
team used the information available to them and interpreted it.  The setting under study 
presented multiple examples of this and thus provided interesting and illuminating data.  
I saw how the aim of the MDT discussion varied amongst teams, and how the outcome 
of the discussion was packaged and taken to the patient in various forms by individual 
members.  I was able to observe how objects or information (e.g. scans, pathology 
reports) were interpreted and then used by various members of the team to inform and 
strengthen their argument for a particular treatment option.    
In this thesis, I aimed to examine critically the process of MDT decision making with an 
emphasis on patient engagement. Ethnographic methods have previously been 
conducted in complex settings such as medical environments (Pope 2005), by clinicians 
as well as social researchers (Zaman 2008).  By placing myself in the setting under 
study, I did not have to rely on retrospective idealised accounts provided by 
participants.  However, I have previous experience of being one of the participants 
under study, and therefore I had to ensure that my analysis reflected the data collected 
as far as possible.  Although this is not to say that I exerted no influence over the 
resultant analysis, more that the description that I produced was a construct of the data 
and my interpretation of it, rather than my pre-formed ideas or theories.  For this reason 
I chose to adopt Constructionist Grounded Theory for my data analysis and use the next 
section to describe this.  
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4.4 Constructivist Grounded Theory 
Grounded Theory provides a systematic strategy for the analysis of qualitative data and 
resulted from the work of Glaser and Strauss (Glaser 1967) during their studies of dying 
in hospitals.  In this section I describe the central tenets of Grounded Theory, the 
similarities and differences that my approach has to the original description, the reason 
for my choice of Constructionist Grounded Theory and how this reflects on the 
epistemological standpoint of the thesis. 
The original description of Grounded Theory in the book “The Discovery of Grounded 
Theory” (Glaser 1967) was novel because it challenged the dominant positivist 
epistemological viewpoint of the era, but at the same time provided practical guidelines 
for the management of qualitative data.  The central tenets of Grounded Theory are the 
coming together of data collection and analysis.  Analytic “codes” are assigned to small 
segments of data and these codes are derived from the data rather than pre-conceived.  
Emerging codes are constantly compared and the outcomes of these comparisons are 
used to guide further collection.  The categories generated are then elaborated upon and 
explored using memo writing.  Data sampling is done with the aim of developing theory 
rather than to represent populations.  In developing this methodology Glaser and Strauss 
had the aim of constructing theory from data rather than beginning with theory or 
hypothesis and using data collection and analysis to prove or disprove this.  Originally it 
was proposed that the resultant theory needed to be testable and reproducible, and used 
to create “formal generalisations” that could be, in turn, used to predict future events 
(Glaser 1967).  It was argued that this made qualitative analysis more than “soft science 
and journalism” (Blumer 1969 cited from Travers 2001, page 41) 
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If staying true to this original form of Grounded Theory, literature review should take 
place following analysis, in order for the ideas or interpretations of the researcher to 
have little or no effect on the theories emerging from the data.  Although the emergence 
of this approach provided legitimacy to qualitative analysis it has often been criticised 
for having positivistic assumptions; researchers were assumed to be neutral to the data, 
with no effect over it rather than to report it.  As a consequence of this, since its original 
description, Grounded Theory has been modified by some researchers. (Charmaz 2006, 
Bryant 2002).  The approach that I adopted was Constructivist Grounded Theory 
(Charmaz 2006) which recognises the origins and purpose of Grounded Theory in 
generating theory from data, but also recognises the effect of the researcher on the data.  
In her 2006 book, Charmaz states: 
My approach explicitly assumes that any theoretical rendering offers 
an interpretative portrayal of the studied world, not an exact picture of 
it.  Research participants’ implicit meanings, experiential views – and 
researchers finished grounded theories – are constructions of 
reality….I argue for building on the pragmatist underpinnings in 
grounded theory and advancing interpretative analysis that 
acknowledge these constructions (Charmaz 2006, page 10) 
In following these principles, the inherent effect that I had on my data was reported 
transparently, rather than denied.  This was particularly relevant in my position; I was 
observing and interpreting action in a setting in which I used to be one of the actors.  I 
was transparent about the effect that this starting point may have had on my resultant 
analysis.  This transparency was reflected in fieldnotes and memos which themselves 
formed data for analysis. This approach observes the central principle that data analysis 
takes place as the field work progresses, rather than after it, which means that generated 
ideas are tested as the data collection continues, allowing for unanticipated and new 
issues raised to be explored.   This means that it is both inductive and deductive.  It 
begins by being inductive; I was not testing a theory with the data, but building 
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theoretical concepts from it.  The data guided the emergent concepts, but was then 
tested by the further data collection.  When this was tested (either by theoretical 
sampling or data analysis) it became more deductive. Purposive sampling (discussed 
later) was used to test the concepts which were emerging from the data, seek out deviant 
cases and maximise the differences between cases.  Whilst performing the data 
collection and analysis, the division of the MDT meeting and clinic into areas where the 
patient was and was not present led to me adopting elements of dramaturgical analysis 
as a lens through which to interpret the data. 
4.5 Dramaturgical Analysis 
The MDT meeting is an area where the professional members of the team meet to 
discuss the patients, and the patient is not physically present in this space.  The MDT 
clinic is where one or more members of the team meet the patient.  Through the course 
of data collection and analysis, I found that the nature and content of the discussion 
varied according to the forum in which the interaction occurred. With this in mind, I 
drew upon the work of Goffman (1959) who detailed how people present themselves to 
others in a similar way to a theatrical performance.  We, as social beings, portray an 
image to fit with the setting we are in, so that we can influence the impression that 
others make of us.  This also applies to ‘team performances’ where a cast of various 
members are engaged in a joint performance, intended to portray a certain image to the 
audience (which in this case is the patient and their supporters).  Dramaturgical 
analysis divides social settings into areas where the performance takes place (‘front 
stage’) and areas where the actors can relax (‘back stage’). With respect to symbolic 
interactionism as described earlier, Goffman effectively identifies attempts by 
individuals and groups to manipulate interpretations of social interactions though their 
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actions in different settings.  The limits of this analysis must be made clear: it is 
contestable as to whether the MDT meeting is indeed a true ‘backstage’.  It could be 
argued that it is merely another frontstage, where the individual actor is the MDT 
member and the audience becomes the other members of the MDT, or me.  
Nevertheless, it is where the actors prepare for the performance, and ‘impression 
manage’, thus deciding how they are going to project themselves to the audience, and 
hence for the purposes of studying decision making in this setting, it is sufficient.  I 
used dramaturgical theory as a tool to analyse, conceptualise and report the data. 
4.6 Validity and Generalisability 
As I have a background in quantitative research, at the beginning of the research I 
sometimes struggled to defend my methods to a clinical audience.  Indeed, a criticism 
levelled at the qualitative methods of enquiry is that they are too subjective and cannot 
be extrapolated to apply to any other population than that which was studied (Mays and 
Pope 2000).  To address this,  I have found the description about the reliability of 
qualitative research by Seale (1999) provides a clear and accessible response.  
According to Seale, internal validity is the extent to which research conclusions are 
supported by the population or setting directly under study, and external validity is the 
likelihood that these conclusions will hold true in other settings.  Seale argues 
qualitative research provides detail or depth of analysis into the phenomena being 
described - a ‘thick description’ - and therefore potentially greater internal validity than 
a quantitative analysis.  I aim for my findings to be applicable to other settings, however 
I accept that this decision of generalisability is one for the reader to make, and not an 
assumption made by the author.  I am making no claims that the population that I am 
studying is an accurate reflection of another population seen in another MDT, but my 
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conclusions will be credible to a reader familiar with the phenomena under study, who 
can then judge whether the study results are applicable or useful in similar (but not 
identical) situations.  In other words, whilst the population may not be generalisable, the 
emergent conclusions will be. 
4.7 Data collection 
I gained ethical approval from the Newcastle and North Tyneside 2 committee 
(reference 11/NE/0200) in September 2011.  I also gained approval from the 
institutional Research and Development board for each data collection centre.  The two 
main methods of data collection were non-participant observation and interviews.  For 
clarity, I describe the methods of data collection before discussing the approach and 
recruitment of participants.  This is because the nature and timing of the observations 
presented me with ethical issues and describing the way in which data was collected 
will cast light on the reasons why the approach and consent procedure was chosen.  
4.7.1 Observation 
The collection of observational data was central to this piece of work; it allowed me to 
directly observe meaning through action rather than via retrospective accounts.   I 
performed non-participant observations in the MDT meeting and the MDT clinic in 
three HNC centres in the north east of England (see figure one).  The MDT meeting is a 
gathering of healthcare professionals involved in the care of HNC patients which lasts 
between one and two hours.   Following the meeting is the clinic (usually on the same 
day, but not in all centres) where some members of the team meet the patient.  I 
observed the MDT meetings and clinics for 30 patients in total: there were 23 males and 
seven females, aged between 38 and 87 years.  Most patients had one MDT meeting and 
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one clinic appointment, however sometimes patients had more than one: there was a 
total number of 35 MDT meetings and 37 clinic appointments over three centres (Centre 





Figure 1: study flow chart 
 
*MDT meeting between staff members:  patient is discussed, imaging and pathology reviewed but patient is not present 
+





PATIENTS: Group 1 Centre Age Tumour site 
Observation 
Int 1 Int 2 
MDT Clinic 
James Cain A 68 Pharynx 1 1 1 1 
Frances Cotton A 82 Pharynx 1 1 x x 
Philip Vase A 61 Parotid 1 1 x x 
Fred Barnes A 71 Lip 1 1 x x 
Deborah Dolphin A 54 Pharynx 1 1 1 x 
Vincent Lowry A 80 Pharynx 1 1 x x 
David Forcett A 72 Pinna 1 1 x x 
Stanley Wright A 87 Pharynx 1 1 1 x 
Daniel Carding A 64 Larynx 1 1 1 x 
John Winton A 61 Larynx 1 1 1 x 
Bobby Older A 52 Pharynx 1 1 x x 
Samuel Black A 55 Pharynx 1 1 1 1 
Keith Down A 62 Larynx 1 1 1 x 
William Runman B 73 Pharynx 3 1 1 x 
Andrew Driver B 49 Pharynx 1 1 1 x 
Donna Childs B 52 Pharynx 1 1 1 x 
David Jobling B 63 Larynx 1 1 x x 
Sophie Leicester B 49 Larynx 1 1 x x 
Edward Doman B 73 Mouth 3 1 1 x 
Eric Francais B 65 Larynx 1 1 1 x 
Gary Duck B 57 Pharynx 1 1 x x 
Jean Dixon B 63 Pharynx 1 2 1 1 
Jane Doe C 69 Pharynx 1 2 1 x 
Margaret Brigstock C 81 Mandible 1 2 x x 
Roy Dayson C 60 Pharynx 1 1 1 x 
Dana O’Malley C 67 Pharynx 1 1 x x 
Gary Nicholson C 46 Pharynx 1 2 x x 
Tracey Burnham C 38 Larynx 1 1 x x 
James Matfield C 70 Larynx 1 4 1 x 
David Dale C 84 Larynx 1 1 x x 
PATIENTS: Group 2 (interview only)      
Kevin Hair A 82 Pharynx     
David Newman A 57 Larynx     
Frank Sunnyman A 52 Pharynx     
Phil Gardener B 65 Larynx     
STAFF (interview only) Staff role     
Mr Red A ENT surgeon     
Dr Orange A Oncologist     
Mr Surton A Maxillofacial surgeon     
Miss Salt A Speech and Language Therapist     
Tessa Darling A Clinical Nurse Specialist     
Mr Halifax B Maxillofacial surgeon     
Mr Blaydon B ENT surgeon     
Mr North B ENT surgeon     
Dr Goodier C Oncologist     
   
Table one: details of included participants 
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The MDT meeting and clinic only took place for around five to eight hours per week 
and therefore I was not able to spend extended periods of time immersed in the field in 
line with previous landmark ethnographies (Wirth 1928; Whyte 1943).  At each 
meeting, I audio-recorded the entire discussion and took field notes.  Often, in a single 
MDT meeting, only one or two patients were included in my study (discussed further in 
the section on sampling).  The recording of the discussion of patients who were not 
included in this study was discarded, however I kept my reflections and field notes for 
the entire MDT meeting discussion.  Once a patient had been selected for inclusion into 
the study, I approached the clinician who was due to see the patient in clinic, and asked 
for permission to observe this encounter.  I then attended their clinic appointment, and 
audiorecorded the interaction between the member(s) of the MDT and the patient.  I 
would often then observe the rest of the clinic, without taking any further recordings but 
sometimes made some field notes. 
The main aim of the observations was to witness the real-life interaction of the team 
with one another and with the patients.  I was interested in the way in which the 
available evidence was interpreted by members of the team, the way in which this 
evidence was mobilised and used to form a treatment recommendation and the way in 
which this recommendation was delivered to the patient.  I was also interested in the 
way in which the team interacted with the patient and the role that patient had in the 
formation of a treatment decision.  The audio-recorded data for the selected patients 
were transcribed word for word and data were anonymised by changing names before 
analysis.  Before, during and after the meeting I had informal discussions with many of 
the staff members and asked questions about their thoughts or actions which I recorded 
in field notes.  These notes also contained details of the context of the observed actions 
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of team members, non-verbal actions or visual observations and reflections at the time.  
I then transcribed all field notes into a ‘reflective diary’ immediately following the 
meeting, together with my own reflections on the situation. 
4.7.2 Challenges when observing 
I have worked as a clinician in some of the research sites, sometimes alongside clinical 
staff who participated in this study, which has both positive and negative effects.  The 
main beneficial effect was that my background eased access to the setting as my key 
participant who negotiated access on my behalf required little explanation of the study.  
In his 1943 book, Whyte explains that his relationship to a key member of a studied 
group and the standing of this individual within the group was more important to the 
members of the group than the researcher themselves (Whyte 1943).  I certainly found 
this when starting my research at Centre B.  One of the MDT members wanted to ask 
some questions about the ethical process and the destination of the recordings, but 
directed these questions to one of the HNC consultants rather than me.  Although he 
contacted me for the answer, it was clear that the assurances of this consultant to his 
colleague about my credentials were a more important factor than my answers alone.  
This is in direct contrast to the advice of Goffman, who feels that this ‘top-down’ 
approach to access can lead to problems; a point that he describes as the “affiliation 
issue”.   
You can’t move down a social system.  You can only move up a 
social system.  So, if you’ve got to be with a range of people, be with 
the lowest people first.  The higher people will ‘understand’, later on, 
that you were ‘really’ just studying them.  But you can’t start at the 
top and move down because then the people at the bottom will know 
that all along you were really a fink – which is what you are (Goffman 
1989, cited from Travers 2001, page 36) 
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I did not find that problems arose from this.  Firstly I am already a member of the group 
of “people at the bottom” and so did not have trouble affiliating with them.  I am a 
surgical registrar who attended the meeting before this research began, but I was rarely 
called upon to speak, in a similar way to many other members.  Secondly I made it clear 
to all participants throughout that my role was not one of “fink”; rather it was to 
examine how they function from a critical (not criticising) perspective; part of this 
involved having a sympathetic view of the work and challenges involved.   Participants 
often knew me, which lead to minimal suspicion about my presence and often honest or 
frank insights during informal interviews.   The language used in the MDT meeting was 
also often highly complex; the meeting moved quickly and complex, detailed 
conversations took place simultaneously.  Through the course of the research I found 
that even when using technical language, the members of the team negotiated and 
manipulated with the same turn of phrase or nuance as when they used everyday 
language.  As a clinician-researcher I found that I did not need to ‘learn’ this language 
and therefore had immediate access to these discussions.  
My background also had potential drawbacks when performing observations.  The fact 
that I felt that there were challenges in effectively involving patients in decisions led me 
to asking the question which led to this thesis.  This means that I approached this work 
from the unavoidable viewpoint that there was a problem which needed to be solved. 
This concept is not unique and was termed by the anthropologist Malinowski as 
“foreshadowed problems”  
Preconceived ideas are pernicious in any scientific work, but 
foreshadowed problems are the main endowment of the scientific 




Also, the fact that I have worked previously in this setting as a clinician meant that I 
may have already constructed my own meaning for the objects that the group are 
drawing on to make a decision; it may be that I don’t see the situation through the eyes 
of the “stranger” (Schutz 1944).  This has the potential to mean that I would struggle to 
gain analytical distance from the data and hence struggle to treat the data theoretically 
(Green and Thorogood 2009).  Smaller but vital details may go unnoticed and as a result 
I strived to continually ask questions of the participants and my data.  This is mentioned 
by Whyte: 
I had to balance this familiarity with detachment….whenever life 
flowed so smoothly that it was taking it for granted, I had to try and 
get out of my participating self and struggle again to explain the things 
which seem obvious (Whyte 1943, page 357) 
I do not draw attention to these challenges to highlight deficiencies in the collected data, 
rather to demonstrate that I was aware of the challenges integral to ethnographic 
research and took steps to acknowledge or address them.  My aim was that by 
acknowledging the challenges which I faced when collecting data and attempting to 
address them, the quality of the data which I collected would improve as a result.  Thus, 
I tried to ask the obvious, ‘taken for granted’ questions, those questions which at times I 
felt I already had the answer to: “Why did you make that decision? What did you draw 
upon?”  I strived for my field notes to not only reflect my own viewpoint, but the 
viewpoint of the participants, something which has previously been covered by 
Mitchell: 
The sociological observer must exercise sufficient discipline on 
himself to ensure that it is indeed the actors meanings that are 
recorded in his notebook and not merely his own (Mitchell 1977, cited 
from Crotty 1998 page 75) 
When analysing data, I tried to make sense of the data and ground my analysis in the 
data collected rather than my own preconceived ideas (Green and Thorogood 2009), in 
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effect staying true to the data as far as possible.  I led data analysis and report sessions 
where I explained my emerging analysis to supervisors and supported my 
interpretations by reference to the data, ensuring that the analysis did not drift into 
convenient or preconceived arguments. 
4.8 Interviews 
I conducted interviews with members of the MDT and patients at all three centres.  
Hammersley and Atkinson divide interviews or oral accounts into those which are 
“solicited” and those which are “unsolicited” (Hammersley and Atkinson 2007) and this 
is a useful distinction to draw here.  Unsolicited accounts are naturally occurring 
explanations heard by the ethnographer and sometimes occur because the actual events 
are not in keeping with the normal run of events or the values of the group (Hewitt and 
Stokes 1976).   Unsolicited accounts were captured with the audio-recorded data or the 
field notes.  Solicited accounts are produced as a result of formal questions of the 
researcher to the participant however many feel that these accounts are affected too 
much by the researcher (Becker and Geer 1957 ).   These solicited accounts were 
collected ‘formally’ and ‘informally’. 
4.8.1 Informal interviews 
In the field, I regularly asked informal questions of participants to gather their views on 
a situation, or question their reasons for a certain course of action, and recorded the 
resultant data in my field notes.  Similar to previous accounts (Hammersley and 
Atkinson 2007), I found certain times and settings were suitable for gleaning these.  
Between the MDT meeting and the clinic there was often a 10-15 minute period when 
MDT members would speak informally with one another.  This was a good opportunity 
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for me to join conversations and ask informal questions.  Equally in the MDT clinic 
there is a lot of the time spent waiting for patients to come in or between patients 
(writing notes, dictating letters etc.) where staff members would debrief from 
particularly difficult decisions or prepare for the next consultation; here some very 
interesting data would be gathered.   This time spent informally interacting, was a real 
opportunity to get inside the experience of working in a team.  I was made to feel as part 
of this, and my membership sometimes allowed me some insight into the gossip around 
the table.  These data provide an invaluable, unsolicited insight into the possible 
motivations for particular courses of action.   
4.8.2 Formal interviews 
I conducted formal interviews with patients and health care professionals. These 
interviews took place in a setting removed from the MDT room and clinic and were all 
semi-structured.  A semi-structured interview is a method of interviewing which allows 
depth of investigation, but with a clear framework to guide questions.  The interviewer 
has a topic guide with the topics of discussion or specific questions on it (Green and 
Thorogood 2009).  Although the topic guide provided me with a framework to work 
around, the format of the semi-structured interview allowed the participant to talk in 
more depth on certain subjects and allowed me the opportunity to pick up on these cues 
and probe if necessary.  This means that the resultant data is comparable, but rich and in 
depth.  The development of the interview guide was iterative; as data collection 
continued, the content of the guide evolved in order to explore emerging themes.  I 
performed interviews whilst going through the process of transcribing and analysing 
observational data which allowed me to ask the participant specifically about their 
feelings on certain points, or their reasons for a particular course of action.  As the 
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research progressed I found I could also explore their accounts by highlighting 
competing accounts from other participants (anonymously) and their reasons for this.  I 
found this was a much less threatening method of probing the participants which 
yielded interesting data.  In the next section I describe the groups of participants that I 
interviewed and give some details of their characteristics.  I describe some of the 
challenges which I encountered, particularly whilst performing the patient interviews, 
how I dealt with these, and the potential effect that they had on the data gathered.  
Staff interviews 
I performed formal interviews with nine members of staff (five surgeons, two 
oncologists, one speech and language therapist and one clinical nurse specialist: see 
table one) at three centres.  Staff interviews took place with an individual staff member, 
usually in a clinical environment such as an office or a clinic room.  I was aware that the 
interview data sometimes provide “idealised/motivational accounts” (Strauss 1993) 
meaning the perspectives elicited from participants were not always directly related to 
the actions of participants in the setting under study (Hargreaves 1977).  However, the 
fact that I had observational data as well as interview data allowed me to compare the 
actions of participants in the field with the accounts given in interview.  I always 
conducted interviews after I had spent some time observing in the fields, and never the 
other way round.  I often used specific cases, conflicts or discussions as ‘anchors’ to 
talk about their feelings on a particular subject and this proved a useful way of 
exploring participants’ views.  
Patient interviews 
Patient interviews took place with the patient and sometimes a relative or carer, usually 
at the home of the patient unless they were an inpatient at the time.  This meant that the 
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atmosphere was usually more informal than the staff interviews.  The aim of the patient 
interviews was to explore their experiences of making the treatment decision.  I used the 
interviews to gain an understanding of the patients’ perspective of the process, and the 
ways in which they feel it could have been improved.  I interviewed two groups of 
patients 
Group 1, prospective group: these were patients whom I had observed in the MDT 
clinic.  I interviewed these patients at two time points: firstly between the treatment 
decision and the treatment itself, and again 6 months following the treatment.  At the 
first interview I explored participants’ views on the communication between them and 
the MDT regarding the diagnosis and treatment, and their experience of their interaction 
with the team and the decision process.  In total I interviewed 15 patients between the 
treatment decision and treatment; of these 15 patients, there were 12 men and three 
women, aged between 49 and 87.  I interviewed three of these patients between eight 
and nine months after their treatment (see table one).  I interviewed fewer follow-up 
patients as a large number either were uncontactable, or felt that they were not yet ready 
to be interviewed again.  The interview allowed me the opportunity to assess the 
patients’ attitudes towards the quality of decision making before the bias effect of 
treatment related morbidity, but still recent to the clinic appointment, ensuring richness 
of the data and minimising re-call bias (Edwards and Elwyn 2009). During the second 
interview I explored the extent to which, and in what ways, participants’ views may 
have changed following the treatment (Murray et al. 2009).  I asked them about the 
treatment related side effects, their quality of life and their function following treatment 
and the correlation of their pre-treatment expectations with these.   
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Group 2, retrospective patients:  I interviewed four patients (all male, aged 57-82) 
who had their treatment within the last 5 years.  Again in this interview I explored the 
change that patients may have experienced in their view of the MDT decision following 
the completion of their treatment.   
4.8.3 Challenges when interviewing 
Although ethnographic methods provide an interesting and rich analysis of the MDT 
decision making, patient interaction with the MDT could be minimal.  The patient often 
had little role in the consultation, and therefore there was sometimes little interaction to 
draw upon to aid analysis.  This made it more difficult to draw on the patient’s 
perspective of the process of decision making.  Although the lack of data here helps to 
illustrate the problem, it makes patient interviews challenging, as the patient has had 
very little to draw upon whilst making the treatment decision.  Not only this, but my 
dual role of clinician-researcher surfaced as a challenge time and again during 
interviews, and was something that affected me in many ways.  I first noticed it during 
my very first patient interview: 
He preferred to resort to stories or sayings when talking about the 
experience, and often gave short answers with no elaboration.  I got 
the impression this may have been because to elaborate would have 
unlocked feelings and emotions which he did not want to unlock 
before the operation.  I felt it would not be in his best interests to push 
too hard for answers – it was not something he wanted to do, and may 
have spoilt the rapport we had built up (Field Notes, 3
rd
 January 2012) 
The patients were often in a frame of mind where they were being brave before entering 
into treatment and had sometimes built a wall before entering into a very scary and 
daunting process.  I often felt that I should not dismantle this wall just for the sake of 
good quality data.  The issue of knowing how ‘deep’ to probe was also linked to my 
background as a clinician: 
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I am very used to interviewing people in a clinic setting in a short 
space of time.  The aim of that interaction however is to convert the 
stories of the patient into a scientific piece of writing, or a single piece 
of information, a diagnosis, in order to understand the story.  If I am 
unable to understand the story, or fit it into a pattern, then the story is 
of no use to me and it is discarded.  I will have picked up many bad 
habits, which must be shed.  I am used to taking copious notes in order 
to fill in records, and being limited by time.  I think it will help, in that 
I am used to talking to patients about sensitive matters, and used to 
covering difficult subjects such as cancer and death.  I must make sure 
I shed bad habits though, and encourage good ones (Field Notes, 13
th
 
October 2011)   
I sometimes felt that were I to ask too many questions and explore their decision 
making process, they may feel that, as a clinician, I was questioning whether or not it 
was the correct decision to make: 
I don’t feel that my interview technique is yet up to scratch.  I am 
trying to open up my questions, but I don’t think I am really peeling 
back the layers of the onion and finding out the true feelings of the 
patient.  This is partly because it may upset them – I don’t see my role 
as being one where I go along and upset the patient and their family; 
perhaps make them doubt that the decision that they made is a bad one 
– I think I am constantly aware that I don’t want the patient to feel that 
I think (as a doctor) that they have made a bad decision (Field Notes, 
9
th
 March 2012) 
I found that the main challenge of being a clinician-researcher was the role that the 
patient saw me as having when carrying out semi-structured interviews.  The patient 
was often confused, anxious and in need of information which in itself illuminated the 
nature of the problem under study.  As participants knew that I was a doctor, they often 
used the interview as an opportunity to ask questions and explore anxieties, which can 
lead to a consultation rather than a research interview – this is a problem which has been 
previously described (Richards and Emslie 2000).  I adopted various techniques to 
minimise the impact of this, but I was constantly aware of the effect that this behaviour 
may have on my data.  I had the choice between providing the required information, 
which would potentially compromise the nature and quality of the data I was gathering, 
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or to come back to these questions at the end.  I found that to delay things sometimes 
led to me appearing unhelpful and evasive and the discussion which ensued following 
information giving was interesting, but sometimes off the recorder.  For this reason I 
would sometimes give some information during the interview but found I had to 
carefully balance my roles of information giver and receiver. 
Without doubt, the most personally challenging aspect of my interviews was when I 
didn’t agree with the treatment decision which had been made.  This presented me with 
a direct choice: to act as a clinician or researcher: 
....the main thing was my own ethical dilemma which distracted me 
for most of the interview - "this chap is making the wrong decision" - 
this is I suppose the clash between clinician and researcher.  As a 
clinician I would have struggled to let him make that decision in the 
first place, and may have even persuaded him out of it as I think it is 
based on misinformation, but as a researcher I am there to find out 
why he made it.  I find the case interesting but also quite frustrating.  
.... he is now too far down the line to change his decision anyway.  I 
also know that my role in that situation is certainly not one of 
clinician, but I can't just drop it - I think I saw myself as having a 
‘duty’. I think that meant that I did the interview half as a clinician, 
and half as a researcher. What resulted was the worst of both though.   
As a clinician, I would have quite happily have said I don't agree with 
your decision and then taken it from there (he may of course have 
stuck with his guns), but I didn't feel I could say that here.  But his 
decision (radiotherapy) doesn't match his priorities (cure).  (Field 
Notes, 19
th
 March 2012) 
In all of these situations I primarily acted as a researcher as this was the role that I was 
taking whilst interviewing.  Most patients knew that I was a doctor; this was sometimes 
because I had been introduced as such during the clinical encounter, sometimes because 
I had used my profession to facilitate access and sometimes because it was an 
assumption by the patient.  I neither advertised nor hid my identity as a clinician, 
however I often found during interviews that it was necessary to reveal it, mainly 
because I was in a position where I could help. 
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By pointing out the multiple challenges in gathering interview data, my aim is not to 
give the picture that it is of poor quality; rather that I have strived to be aware and open 
about the challenges of interviewing as a clinician so that I tackled the problems and 
difficulties I faced, and improved the quality of the data that I gathered.  My clinical 
background did have unexpected benefits: a number of the patients included in this 
study had a very poor voice, or no voice at all as a result of the cancer or its treatment.  
This presented me with a unique methodological challenge in carrying out qualitative 
interviews which are reliant on the spoken word.  I used various methods to get around 
this.  Firstly, I am very used to working with patients in this position, so feel confident 
in talking to patients with these limitations.  I often ensured a relative or carer was 
present for the interview, to help with interpretation of what the patient was saying.  It 
was important in these situations not to let the carer take over;  I made sure that the 
patient answered my questions as well as the carer, and I constantly checked if they 
agreed with what was being said.  I used pieces of paper for the patient to write on, and 
kept these at the end of the interview.  I always transcribed these interviews myself, and 
inserted in the written notes at the appropriate points in the transcript.  Also, I 
sometimes had to guess what was being said during the interview based on lip reading 
and gesticulations of the patients.  When I was correct, I said it out loud (with the 
patient agreeing), and then transcribed it as being said by the participant. 
4.9 Recruitment and consent 
The process of recruitment and consent for the observations presented me with multiple 
challenges: I was collecting highly personal data about patients before they had met the 
clinical team, and sometimes before they had even been given their diagnosis of cancer.  
This meant that I had to exercise caution when approaching them for inclusion in the 
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study and adopted an approach which I felt was patient-centric rather than designed 
simply to meet the minimum guidelines set by the ethics committee.  In this section I 
discuss the approach, recruitment and consent of participants. 
4.9.1 Patients 
Inclusion/exclusion criteria 
Patients were excluded from the study if they did not understand written or spoken 
English, or they did not have the capacity to consent.  Patients were eligible for 
inclusion into the observation phase of the study if they had a decision to make about 
treatment for a HNC – there is more detail about this later in this section.  For the 
interview phase of the study, I concentrated on patients with laryngeal and pharyngeal 
cancer (see table one).  The reason for limiting the interview phase of the study to these 
cancers is to allow any recommendations as a result of this study to be more applicable 
to patients in these groups.  As I discussed in Chapter One, the term “head and neck 
cancer” encompasses a large range of different cancers.  There is great variability in the 
types of decisions that these different groups of patients face.  The largest proportion of 
patients in the MDT clinic have cancers of the larynx and pharynx, and face similar 
trade-offs between survival and function.  
Group 1, prospective patients 
At the end of the MDT clinic consultation, the clinician informed the patient about the 
study and provided the Participant Information Sheet.  At least 48 hours after the 
information had been given, I contacted the patient by telephone. During this telephone 
call I presented the patient with three options: 
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1) Have no further involvement in the study and have all data 
collected so far concerning them securely destroyed. 
2) Have no further involvement in the study but allow all data 
collected so far to be retained in the research project. 
3) Continue with the study and agree to an interview. 
If the patient was willing to continue in the study, I arranged to meet them at a location 
of their choice (usually their own home) where I obtained written informed consent for 
the first interview.  At the end of the first interview I asked them if they were willing to 
be contacted again regarding a second interview six months following their treatment.  
If they were in agreement, I contacted them by telephone around six months after they 
completed their treatment.  Prior to this telephone call I liaised with the clinical team to 
ensure that it was appropriate for a given patient to be re-contacted.  As with the first 
interview, I arranged an appropriate location and gained written informed consent for 
the second interview. 
Group 2, retrospective patients 
I recruited patients from the follow up MDT clinic who have had laryngeal or 
pharyngeal cancer treatment within the last five years.   Patients were identified with the 
help of the clinical team from the MDT coordinator and follow up clinic lists.  Patients 
were sent an information sheet which contained a slip which they returned if they 
agreed to take part in the research. Prior to the interview I gained written informed 
consent. 
4.9.2 MDT members 
Inclusion/exclusion criteria 




I collected data from one centre at a time, beginning at the Centre A, then Centre B, 
then Centre C.  To gain access at each centre, I approached one of the lead ENT 
consultants and told them in detail about the work.  The consultant then sent an e-mail 
(composed by me), to the members of the MDT.  Two or three weeks following this I 
attended my first MDT meeting where I collected no data, but spoke briefly about the 
project and answered any questions.  In addition to this, MDT members were provided 
with my contact details so they could ask me any questions more privately if required.  
The week following my first MDT meeting attendance, I began data collection. 
Interview 
Potential interviewees were contacted by e-mail which invited them to be included in 
the study, with a participant information leaflet attached.  Staff members registered their 
interest by e-mailing a reply.  I gained written consent before the start of the interview.  
Various different staff members attend the MDT meeting, and the following brief 
descriptions will help to contextualise the data gathered from observations and 
interviews: 
ENT surgeons:  involved in the diagnosis and investigation of the HNC.  They carry 
out many surgical resections of HNC.  
Maxillofacial (Max facs) surgeons: similarly involved in the diagnosis and 
investigation of the HNC patients.  They carry out surgical resections and surgical 
reconstruction 
Plastic surgeons: involved in surgical reconstruction following cancer removal which 
means they often have an advisory role to the surgical team. 
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Oncologists:  treat all types of HNC, and specialise in the delivery of non-surgical 
treatment; radiotherapy and chemotherapy.  Many oncologists also have an interest in 
cancers of other regions of the body 
Clinical Nurse Specialists (CNS):  usually assigned a number of patients each, and act 
as support to the patient throughout treatment and recovery.  They have a nursing 
background and specialise in the care of HNC patients.  They are the first contact for a 
patient in the community and often form close relationships with patients.   
Radiologists:  doctors who show the radiology images and discuss their report and 
opinion with the team in the MDT meeting 
Pathologists:  interpret the specimens which have been taken either during biopsy or 
resection of the cancer.  They give information about the type of the cancer, the size, 
and whether the cancer has been completely removed.   
Speech and language therapists (SALT): involved in assessing the swallowing and 
speech patients before treatment and in the rehabilitation of these functions following 
treatment 
Dietician: involved in optimising the nutritional intake of a patient in order to prepare 
for treatment and to rehabilitate successfully. 
Registrars:  A registrar is one grade below a consultant in the medical hierarchy; 
registrars from all of the medical specialities attend.  There is one ‘lead’ registrar for the 
ENT and max facs team, who usually take a principal role in providing clinical 
information about a patient at the start of the MDT meeting discussion.   
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Administrators: the administrators for each team have slightly different roles and 
backgrounds.  Administrators ensure that all patients are being seen by the correct 
consultant, and all clinical data from the clinic is entered correctly into the database 
Palliative care:  There is a Palliative care consultant at the Centre B, a physician who 
specialises in the care of the patient for whom treatment is not with curative intent 
Restorative dentists: Centre A and B included a restorative dentist who helped patients 
deal with the effect of treatment on their dentition 
Clinic staff:  Often a small number of nurses from the clinic that day will attend the 
meeting as observers 
Students:  There are medical, nursing and SALT students who attend the meeting as 
observers for educational purposes 
4.10 Sampling 
Throughout this study I have used purposive sampling to select participants for 
recruitment.  The aim of purposive sampling is to develop the concepts and themes 
which were emerging from the data (Charmaz 2006).  It was intended to build concepts 
and allowed me to continuously ask questions of the data.  When sampling I was 
interested in performing an analysis of how decisions were negotiated in this setting, 
which altered the way I sampled between and within cases.  My sampling strategy 
loosely followed a three stage procedure previously described by Strauss and Corbin 
(1990).  Firstly, a convenience sample was collected; participants were included 
opportunistically in order to begin analysis.  I took an interest in a wide range of 
decisions; treatments in early disease, advanced disease, adjuvant therapy or palliative 
decisions.  In doing this I achieved a wide spread of patients, ages, comorbidities and 
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socioeconomic classes.   As the analysis unfolded and I began to think and write 
critically about these decisions, I searched for cases which would test the concepts and 
themes which were emerging.  For example, in the early cases, I noted that palliative 
options were often not discussed or offered in the clinic, and I was keen to explore why 
this might be the case.  I often had a choice of patients to include from each clinic, and 
so I searched for a patient to include who had options for treatment, one of which was 
palliative; I then used this case as a basis for formal and informal discussions with the 
clinicians and patients about their attitudes towards palliative care and decision making. 
In his study of paediatric consultations, Strong (1979) also had to consider how to 
sample within cases – decisions needed to be made about whom to talk to, what to 
observe and what questions to ask.  This was one of my considerations: I was interested 
in the decision process, rather than the patient experience of cancer and rehabilitation or 
an in-depth view of patient experience of receiving cancer treatment.  This altered the 
way I interacted with and asked questions of the staff and patients.  In the later stages of 
the study, sampling was used to test the concepts which were emerging from the data, 
seeking out deviant cases and maximising the differences between cases. Similar to 
previous ethnographies (Skolnick 1966; Moffatt 1989)  I also sought to see how my 
concepts would hold up in other settings by visiting MDTs abroad to see if my analysis 
of decision making was generalisable to other groups. The outcome of some of these 
comparisons and observations are discussed in Chapter Nine. 
After finishing data collection in one centre I would stop fieldwork for two to three 
months in order to further my analysis, write memos about emerging themes, and 
discuss my emerging findings with supervisors.  Initially, my aim for sampling was to 
achieve theoretical saturation; this is the point at which sampling and analysing is 
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continued until nothing new is found (Charmaz 2006).  Although this may be possible 
with smaller, or more straightforward projects, the notion that this can be achieved is 
controversial and it has been suggested that it may inhibit exploration of data (Dey 
1999).  In my setting, the large range of patients, clinicians and potential treatment 
decisions made this task almost impossible; hence rather than claiming saturation, a 
more appropriate term would be theoretical sufficiency (Dey 1999) 
I did encounter challenges when sampling.  There were a large number of patients 
discussed at each MDT meeting, sometimes more than 30, meaning that many patients 
potentially could be included in the study.   Firstly, I had to be careful not to only select 
straightforward examples of radiation therapy vs. surgery.  Although these cases are 
important and provide a picture of decision making in this setting, to limit my analysis 
to these dichotomous decisions may provide a simplified picture of the challenges faced 
in this setting.  At the same time by only concentrating on more sensational, 
problematic or crisis patients I would give a view which was not representative of the 
routine work of the clinic.  More exceptional patients were included from time to time 
as their cases could also serve to cast light on the more mundane phenomena 
(Hammersley and Atkinson 2007), but I was careful that they did not form too large a 
proportion of my sample.  Secondly, my primary inclusion criterion was a patient with 
“a decision to make”.  In essence, every patient had a decision to make; to be treated or 
not, indeed to turn up to clinic or not, therefore all patients in the clinic potentially meet 
this criteria.  Nonetheless, some patients, on the face of it, did not seem to have a 
decision to make as they were provided with a single, clear treatment recommendation 
by the MDT.  However, I sometimes viewed the patient accepting the radical treatment 
as a decision, or included cases where treatment options were the subject of a long 
discussion in the MDT meeting, but not then offered to the patient in the MDT clinic.  
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Thus in the MDT clinic, it may have appeared to a patient that they did not have a 
decision to make, but the patient was included because the discussion cast light on the 
process of making a treatment recommendation and a decision in this setting.  Hence, 
my process of patient sampling aimed to provide an analysis that presented a credible 
representation of routine MDT meetings.  This required a combination of my clinical 
experience, my data and analysis so far and the discussion which was unfolding in front 
of me. 
4.11 Data Analysis 
I have described previously the theoretical and methodological foundation of my data 
analysis.  In this section, I describe the practical process I followed to perform data 
analysis. 
Stage 1, reading 
All data was collected by me, and detailed field notes were made at the time, and 
transcribed immediately afterwards.  I transcribed all MDT meeting observations, seven 
MDT clinic appointments, and all patient interviews where the patient had no voice or 
severe problems communicating.  All other observations and interviews were 
transcribed by others, but I read though and listened to each transcription on at least two 
occasions before coding.  This stage also involved some informal analysis as I recorded 
my observations and attempted to make sense of them in my field notes. 
Stage 2, open coding 
Following the reading and familiarisation, the data were coded.  The first stage of this 
was ‘open coding’.   To do this, I read the data and then assigned a ‘code’ to each line.  
At the start of data collection assigned codes were very descriptive, however as data 
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collection and analysis continued, I developed a sense of the data and was able to apply 
more analytic codes.  I aimed for the codes to be analytical rather than descriptive 
(Charmaz 2006), to say what the data was about; not just a summarising word, but a 
conceptual label (Charmaz 2006; Green and Thorogood 2009).  In practice, assigning 
analytical, conceptual codes, especially to observational data was challenging.   The 
observational transcripts contained a lot of people speaking in short, overlapping and 
sometimes unfinished sentences.  The language used was often highly technical with 
lots of interruptions which made the codes assigned quite descriptive at times.  This 
meant that coding this type of data presented me with challenges demonstrated in the 
example below: 
Observational data Assigned open codes 
MR JUNIOR:  On examination there was a 
right level 2 lymph node, which was about 
a couple of centimetres on fibreoptic 
endoscopy he had swollen retromolar area 
with a hole…. on direct questioning he 
said he had a tooth inspection recently.  He 
was found to have a large tumour which 
was filling the right piriform fossa going to 
the posterior cricoid area, right 
supraglottis, up to the right vallecula.  So 
he was brought in for panendoscopy and 
biopsies, and I think the findings were 
confirmed to be the case.  There was a 
large T3 tumour arising from the right 
piriform sinus going onto the right 
pharyngeal wall and biopsies were taken at 
the time 
Dr Slide:  They showed a moderately 
differentiated invasive keratinising 
squamous cell carcinoma and that was 
HPV negative 





Treatment so far 






DR WINDOW:  He had the scan in South 
Tyneside, here it is…. So as we are 
coming up and we are coming down, there 
are bilateral necrotic level 2 3 and 4 
lymphadenopathy, so the largest one on 
the right is 2.5 by 2.1 and the left 2.1 by 
1.6 cm.  With regards the tumour, there is 
a tumour which is there in the vallecula, 
abutting onto the epiglottis and then down 
to the right side in the right aryepiglottic 
fold involving the entire piriform fossa.  
Coming out of it laterally, but probably 
still within the confines of the….no extra 
laryngeal spread.  There’s the tumour, and 
then going posteriorly, just coming across 
the midline and then we’re going further 
down, it looks like it is involving the right 
side of the post cricoid space.  So a large, 
measuring about 3.5 by 2.4 by 5 cm.  
Piriform fossa and post cricoid and 
aryepiglottic fold involving paraglottic 
space, part of the vallecula above the 
epiglottis and tongue base, oesophagus is 
fine.  With regards the rest of him with 
regards M, he’s got… lungs are fine, no 
hepatic abnormalities, we’ve got an 
incidental adrenal adenoma and that’s it.  
Considering he’s got so much, it doesn’t 
look too bad really.  Liver’s a little 
enlarged, the spleen’s normal, so there we 
are 
MR BLONDE:  Thank you.  That’s T4 
then, N2c 
DR WINDOW:  N2c and er…. 
MR BLACK:  I scoped him and I’m sorry 
the pictures are not there, it’s on my 
desktop.  It’s a very large tumour.  There is 










Other health problems 
Using previous experience 
Cancer staging 
 
Dealing with practical difficulty 
Staging disease 
In the example above, the focus of the discussion was to build up a clinical picture of 
the patient, or a ‘case’, at the start of the MDT meeting.  In order to move beyond 
descriptive tags I tried to concentrate on the mechanisms that shape these encounters.  
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Here, the code “case building” suggests the gradual accumulation of evidence and this 
may be used to group and define the codes above.  In this sense, I have coded the 
process rather than specific topic of speech.  
Stage 3, axial coding 
After the open coding of four or five transcripts, a coding framework was drawn up.  
This is a framework which details the common, important or recurrent codes.  Codes are 
linked together if they are similar, and a group of connected and interlinked codes are 
gathered together in to a ‘theme’.  An example of this is the code “interaction” (figure 
two): 
 
As analysis went on, new codes were generated.  These were added to the framework, 
and transcripts which had already been coded were re-coded to incorporate these.  As I 
Figure 2: interaction code 
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had many different forms of data, there was a potential issue with how many coding 
frameworks there should be.  To have separate frameworks for interviews with different 
patient and staff groups, and observations from different settings would be unwieldy 
and would act to fragment the data and emergent concepts.  With this in mind, I 
attempted to code the data into as few frameworks as possible in order to emerge with a 
coherent joined-up message. 
The codes used were derived completely from the data, and were not pre-determined.  
The coding was organised using the NVivo computer package.  This package allows 
short segments of data to be logged under a particular code and kept in electronic files, 
rather than having to physically cut and paste the hard copies of the transcripts.  The 
ongoing process of coding did not take place in isolation; the framework was constantly 
adjusted and clarified according to the transcripts being coded and the new data 
collected 
Stage 4, memo writing 
Memo writing was a central part of my analysis.  A memo is a piece of writing about a 
code which detailed my interpretation of a code, and the idea or concept which it 
demonstrated (Strauss and Corbin 1990).  Memos included ideas about the data, details 
about the analysis of the data or hypotheses and theories about how the codes inter-
related and the relationships between them (Green and Thorogood 2009).  Memos were 
used to develop a deeper description of the codes and the data.  In this way, memos 
allowed the development of theory; this was used to guide further sampling and as a 
basis for the emerging data chapters.  These memos were presented to supervisors and 
colleagues and then improved upon by collecting more data. 
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Stage 5, generating testable propositions 
The process of data analysis provided a rich description of the process of treatment 
recommendation and treatment decision making, from the perspective of the MDT and 
the patient.  In describing the process of decision making I discussed the rationale for 
increasing patient involvement in treatment decision making and highlighted the 
challenges in achieving this.  I used the analysis to build an alternative model of the 
structure of decision making in the MDT.  In addition to this, and in order for the work 
to provide a solid platform for further improvement in decision making in this setting, I 
described a series of barriers to patient involvement and provided clear 
recommendations to overcome these barriers.  The findings can then be used as the 
basis for further work in this setting and hence ultimately lead to an improvement in 
care. 
4.12 Conclusion 
In this chapter I have described the epistemological and ontological foundation of the 
thesis and how this theoretical standpoint was enacted via my techniques of data 
collection.  As the MDT meeting and clinic only exists for half a day a week, I was not 
able to continuously immerse myself in the field as with some ‘classic’ ethnographies.  
However, my method of inquiry respected the principles of naturalistic enquiry by 
placing me directly in the setting under study, allowing me to observe meaning through 
action.  My position as a clinician researcher presented me with multiple expected and 
unexpected challenges; however I firmly believe that this status has awarded me with 
more benefits than problems.  Importantly, my previous status as a participant in the 
MDT allows me to conclude that the discussion and actions which unfolded were a true 
representation of the routine work of the clinic.  The methods which I have described in 
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this chapter provided me with multiple, rich sources of data.  This means that my 
analysis, by being grounded in the data, provides a detailed analysis of the real practice 
of MDT decision making rather than an idealised account.  The data shed light on the 
barriers to effective patient involvement, but importantly, allow me to explore the 
reasons why such barriers exist, and in doing this provide insight into how these barriers 
may be overcome. Thus, the thesis should provide a solid foundation for care to be 
improved in this setting.  In the next chapter I will present the first part of my analysis: 
the way in which the MDT team interact with each other and the information which is 




Chapter 5: The MDT Meeting: Laying the Foundation 
At face value, the aim of the discussion at the MDT meeting seems simple: to make 
treatment recommendations for patients with HNC.   Through the course of the next 
three results chapters I use the data that I have collected to illustrate the complexities 
and challenges in this process, and go on to demonstrate the effect that these 
complexities have on clinical decisions and patient engagement in MDT decision 
making.  Specifically in this chapter I describe the evidence that is used by the team as a 
basis of the treatment recommendation. I discuss how different pieces of evidence hold 
different levels of importance in the room and how this hierarchy is continually re-
worked through interaction among members of the team.  
Before continuing, I will explain the terminology used in this chapter.  For the purposes 
of clarity, and to reflect the prevailing viewpoint, I refer to the outcome of the MDT 
discussion as a treatment recommendation, and the outcome of the interaction of the 
team with the patient in the MDT clinic as a treatment decision. 
5.1 Information about the patient 
A treatment recommendation cannot be made without information about the patient.  In 
order to begin to understand this, it is helpful to have an understanding of the process 
through which a patient moves before reaching the MDT clinic.  Most patients attend 
the hospital with a symptom, such as a change in their voice or difficulty swallowing, 
and are then seen by a surgeon (who may or may not be an MDT member), who takes a 
history and performs an examination.  The surgeon then organises an examination under 
anaesthetic (EUA).  During this procedure, the surgeon looks closely around the mouth, 
throat and voicebox in order to assess the size and position of the cancer.  Biopsies 
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(small pieces of tissue) are taken during this procedure, and these are reviewed by the 
pathologist.  Around the time of the staging assessment the patient also has scans of the 
head, neck and chest and these are reviewed by a radiologist.  The MDT meeting is the 
culmination and amalgamation of all of this work. 
In the MDT meeting, all centres observe certain conventions as a matter of routine.  The 
meeting is chaired by one clinician and is brought to order.  The first patient’s name is 
read aloud and one of the clinical team (almost always a surgeon) gives the details of 
the clinical history, examination and the EUA.  This clinician may have been the person 
who performed these assessments, or may refer to the notes of the person who did.  The 
pathologist then reads out the results of the biopsy, confirms that this is a cancer, and 
sometimes gives information about the type of cancer or its aggressiveness.  Finally, the 
radiologist talks through their opinion on the scan, whilst showing the scan images to 
the team on a screen.  Although more evidence than this is often presented, the evidence 
detailed here is given at all meetings and appears to be viewed as the minimum dataset – 
without all of this information, the patient discussion is postponed until this information 
is available. 
Following this routine presentation of clinical data, a discussion takes place about the 
treatment recommendation.  Most of the discussion, especially at the early stage, is 
about the cancer: the precise anatomical site, size, extent and spread.  This information 
is put together to form the tumour, nodal and metastasis (TNM) stage (see Chapter 
One).  The reports that the pathologist and radiologist give are pre-prepared and often 
accepted as undisputed fact within the team, which usually leads to very little discussion 
about their source or content.  These ‘facts’ directly form the TNM status, the 
foundation of the recommendation.  The following are observational data from a case of 
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Vincent Lowry, an 80 year old male with a cancer on his soft palate.  The radiologist 
gives his report during the meeting: 
Dr McCain [radiologist]: On the right hand side, he’s just got this 
slightly increased enhancement in the tonsillar fossa, and little sort of 
cystic focus in there of fluid, just sitting there, about a centimetre in 
size.  The degree of enhancement is very mild, I’m not sure what I 
would call this, the thickening also is pretty mild. ....the soft palate 
appears normal in CT [computerised tomography], the tongue base 
appears normal on CT, and there’s nothing extending down into the 
hypopharynx; it’s very much just a localised area in there, that 
tonsillar fossa.  He’s got a couple of very tiny little retropharyngeal 
lymph nodes like that, but they’re within normal limits.  And then, 
again, the deep cervical chain nodes down here are not enlarged, so I 
think we can say that it’s N0 [referring to N stage zero], on the basis 
of this..... 




I observed that the role of the radiologist in this situation was to report the scan and, in 
doing so, describe the cancer as accurately as possible.  The radiology report leads 
members of the MDT to convert the radiological information into a TNM status, in this 
case T1N0M0.  The criteria for assigning a TNM status are well-documented (AJCC 
2010) and well-known in the team.  When the TNM status has been assigned it is 
sometimes said aloud by any member of the team.  At other times it is assumed by the 
MDT members that others will have come to the same conclusion and there is only an 
implicit conversion to a TNM stage.  The TNM status, when decided, is used as a basis 
of the treatment discussion, and I observed that this information is usually not 
questioned.  However, when looking closely at the language used, the members of the 
MDT cannot treat this information with absolute certainty: “and little sort of cystic 
focus” and “I’m not sure what we would call this”.  Although the radiologists’ 
observations are converted into a simple objective fact (T1 stage), the specific language 
used demonstrates the subjectivity underlying them.  The team use the radiographic 
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staging as a foundation for the ongoing discussion, and the uncertainty which underpins 
it is ignored in order to facilitate the negotiation.   To calculate the N (nodal) stage, the 
radiologist reports the number and size of the lymph nodes in the neck; this gives the 
team information about whether the cancer has spread.  At the end of the report, the 
radiologist clearly concludes that this is N0, something which I observed was taken 
forward by the team as fact.  However, the language used to reach that conclusion is 
again open to interpretation.  “He’s got a couple of tiny little retropharyngeal lymph 
nodes, but they are within normal limits”.  If it was absolutely certain that these small 
lymph nodes were of no significance, they would never have been mentioned.  The 
language used is not unequivocal, and the concerns about lymph nodes which are 
enlarged but “within limits” are voiced, perhaps with the intention of displaying the 
difficulty in reaching a conclusion of N0, or perhaps to absolve the radiologist of 
responsibility if the patient is under treated as a result of the report.  In most cases, the 
TNM status is decided during the pathology and radiology reports, and is used as an 
undisputable basis of the entire discussion about treatment.  At points of conflict, 
however, when one or other member of the MDT needs to reinforce a point, the 
openness of these facts to interpretation is revealed.   
Later in the MDT discussion about Vincent Lowry, I observed there was a conflict 
between MDT members about whether the treatment should be laser therapy (suitable if 
the lesion is smaller) or radiotherapy (suitable if the lesion is larger).  In the following 
observational data extract, Mr Red, an ear nose and throat (ENT) surgeon felt that 
radiotherapy was the best option and was therefore insisting that the lesion was not 
small and localised.  Mr Black is another ENT surgeon, who felt that the tumour was 
indeed small enough to be treated with laser therapy.  During their exchange they return 
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to the radiology report and reveal how the information provided within it can be 
interpreted differently by individual members of the team: 
Mr Red [ENT surgeon]: This is the level of the tonsil and soft palate, 
it’s not T1 
Dr McCain [radiologist]:  well as I say I think it’s quite difficult to see 
on the CT because 
Mr Red:  You can’t call that T1! 
Dr McCain: All we can make out is actually going on up in the 
palatine/tonsillar fossa, round here where it is more thick, and you’ve 
got that little cystic space.  So it’s quite difficult to differentiate the 
margins. 
Mr Red:  That little cystic space isn’t going to be just a little cystic 
space I wouldn’t have thought would it?  Do you think it is?  Just a 
little, innocent, little cystic space that you can just take a 5mm margin 
round? 
Mr Philips [plastic surgeon]:  But this is when the TNM classification 
is inadequate 
Mr Red:  No this is where you don’t treat an x-ray, you treat what they 
look like! 
Mr Black [ENT surgeon]:  The margins for a tonsil will be the 
superior constrictor muscle, it won’t be a smaller margin for a lateral 
oropharyngectomy procedure.  The soft palate will be superficial 
tumour, I’ll go down to muscle, and then I’ll come up [describing 
surgical removal of cancer] 
Mr Red:  I know how to do the operation, you don’t need to…. All 
I’m saying is I don’t think it’s an adequate operation, I think it’s an 
operation instead of more adequate treatment, which in my opinion 
would be radiotherapy ….  You’ve never scoped him have you?  Mr 
Black? You’re just treating the x-ray and the histology aren’t you? 
Mr Black:  And that picture 




The discussion leading up to this point had centred solely on the details of the cancer 
and the TNM status.  When directly questioned, the radiologist revealed the difficulty 
with giving the precise answer required and this uncertainty was used by Mr Red to 
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argue that this tumour was larger than had been reported.  This provides a clear example 
of the MDT members using their interpretation of the available evidence to negotiate 
and reinforce their notion of the ‘best’ treatment for the patient.  The argument between 
Mr Red and Mr Black became heated at times, which suggests both parties feel strongly 
about their perceived ‘best’ treatment, something which I recorded in my field notes: 
[Mr Black’s suggestion for laser] caused a raised eyebrow and a smile 
from Mr Red – he is sitting directly in front of Mr Black and so this is 
not seen. There was some very robust debate… Mr Black was keen to 
laser the lesion, but almost everybody else at the meeting felt that 
radiotherapy was the best treatment.  The pro-radiotherapy group was 
headed by Mr Red and some of the comments made between Mr 
Black and Mr Red were scathing. 
(Field notes, MDT meeting, Centre A, 19
th
 January 2012) 
Mr Black was facing opposition from a number of his clinical colleagues, but persisted 
with his assertions for laser, despite the weight of opinion to the contrary.  There are 
many questions raised by these data: why is there such a disparity in the recommended 
treatment options between two surgeons of the same discipline?  What it is that drives 
this and leads professionals to vehemently oppose one another?  The answers to these 
questions are multi-faceted; they lie partially in the way in which MDT members 
interpret other evidence, which is not specifically related to the patient in question and 
partially in the way in which the clinician perceives a treatment as ‘best’. I will explore 
these concepts later in this chapter and in Chapter Six. 
It can be seen from the discussion above that the characteristics of the patient in the 
MDT meeting up until this point consists solely of the details of the cancer.  None of the 
clinicians involved in the discussion have met or assessed the patient.  The discussion 
includes the soft palate, the tonsil and the neck but nothing beyond this.  The cancer 
TNM information is regarded by the team as the top of a hierarchy of evidence about a 
patient.  There are obvious downsides to this, and some of these are alluded to in the 
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MDT meeting observation data above.  For example, Mr Red argues that to confine 
assessment of a patient solely to the TNM information is substandard: “this is where 
you don’t treat an x-ray, you treat what they look like!”  Whether he alludes here to 
inspection to a visual assessment of the cancer or of the patient is uncertain, but it 
highlights the concerns of some members of the MDT in limiting the information about 
a patient to that which can be gleaned from an x-ray, histology report and clinical 
history and examination.  This sentiment is perhaps not shared by Mr Black as his 
statement “and this picture” (when referring to a projected picture of the tonsil) suggests 
that this dataset, combined with the picture, is adequate.   
It is false to suggest that the MDT relies solely on the TNM status to inform the 
treatment recommendation and the data above reinforces this.  In many ways, the 
difficulty with providing the evidence to inform the recommendation is summed up 
simply by Mr Red in his interview: 
I think people need to appreciate that the MDT is advised on the 
information that is available, and probably the most important piece of 
information isn’t available….which is the patient 
(Mr Red, ENT Surgeon, Interview, 8
th
 May 2012) 
In this short passage, Mr Red makes a simple but informative statement which outlines 
one of the fundamental challenges of MDT decision making.  The MDT is making 
recommendations based on the information and evidence which is available to them at 
the time of the meeting.  The patient is, however, absent from the MDT room and 
therefore all evidence that is incorporated into the discussion must be gathered before 
the meeting takes place. This presents the MDT with a challenge: how should the absent 
patient be represented in the room?   Different MDT meetings grapple with this problem 
in different ways.  This in itself is an indication that teams are aware that clinical TNM 
information alone is inadequate and in doing so they acknowledge the requirement for 
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more information to build their picture of the patient in the MDT meeting.    Firstly, the 
MDT members must decide the nature of the extra information required and secondly, 
they must decide how this information should be presented and then incorporated into 
the discussion.  Mr Red is not alone is his assertion that the MDT needs to treat more 
than just the TNM status and there is wide agreement from members of the MDT that 
focussing purely on information about the cancer provides an inadequate picture of a 
patient.  The following extract is taken from an interview with Sally, a speech and 
language therapist from centre A: 
You’re just making decisions based on scans and guidelines as 
opposed to an individual and having somebody ever having had the 
opportunity to explore not just their physical and psychological status, 
but their feelings about treatment.... it would be nice to have much 
more of a feel and a knowledge of the patient before it gets to that 
MDT. 
(Sally, Speech and Language Therapist, Interview, 3
rd
 July 2012) 
Her reference here to the “physical” status refers to the description I have outlined thus 
far: clinical information about the cancer and the patient’s general health.  She goes on 
to widen her definition of what a patient ‘looks like’ by extending the patient identity to 
“psychological status” and even “feelings about treatment”.  This introduces an opinion 
which is shared by many at the meeting: treatment decisions cannot be made with 
details of the cancer alone and more information is required.  Her statements reveal that 
the information provided does not give the members of the MDT a “feel” of the patient 
being discussed, or provide the team with information about the patient’s lifestyle, 
context, values and preferences.  At the same time, the task of representing the “feel” of 
a patient using pieces of information about them is difficult.  Before continuing, I will 
tackle one of the most obvious possible solutions to this problem: allowing the patient 
themselves to attend the meeting.  Direct patient presence at the meeting would provide 
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potentially incontestable evidence about the ‘feel’ of the patient, but it is an idea which 
faces strong opposition from most members of the MDTs which I have observed, and 
has been reported in the wider literature (see Chapter Three); this is the reason it is not 
current practice.  To demonstrate this clearly, I provide data from Sally again, in order 
to juxtapose her views on patient attendance with her earlier statement: 
[if the patient attended] I don’t think you could have a free and full 
discussion, particularly if you’re thinking that the prognosis might not 
be very good for a patient.  I think that it would inhibit what your 
thoughts were and so you wouldn’t be having a proper discussion then 
I don’t think.  It would have to inhibit it, because sometimes you’d 
have some quite distressing things that you might want to talk about 
and you wouldn’t discuss that with a patient in the room 




In this statement Sally is clear that she feels it is not a good idea for the patient to attend 
the MDT meeting.  It is not clear what she means by a “proper discussion” or whether 
she is protecting her patients unnecessarily, but it can be assumed that she anticipates 
her colleagues would not share all the information and opinions at their disposal, which 
would be detrimental to the treatment discussion.  These data also introduce the idea 
that the team view the meeting as a safe space, where they can share frank views with 
each other without having to concern themselves with upsetting the patient in question.  
This ‘backstage’ area is created by having a team meeting before the clinic appointment 
with the patient.  Potentially, moving the patient into this area would lead the backstage 
to be temporally and geographically relocated to a new space, further ‘back’ thus 
creating another forum and fragmenting the discussion.  This problem explains the 
resistance of the MDT to this idea, but it must be highlighted that the views of Sally 
originate from her assessment of a patient being present at a meeting in its current form.  
This does not mean that the idea of a well-supported patient attending an MDT with a 
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sympathetic team is something that would never be possible, rather that it is regarded by 
the members of the team as an unfavourable option. I will discuss further the 
‘backstage’ and ‘frontstage’ organisation of the MDT meeting and clinic, together with 
the effect this has on decision making, in Chapter Six. 
5.2 Building the ‘evidential patient’ 
I have discussed so far how MDT members agree that providing information pertaining 
only to the cancer is insufficient to inform a treatment recommendation about a patient, 
but at the same time there is strong opposition to the patients themselves attending the 
meeting.  MDTs in different centres introduce various pieces of extra information to 
solve this problem, in an attempt to construct the patient identity in the room via 
information provision: the ‘evidential patient’.  The information included in the meeting 
varies between teams: in centre A they concentrate on the medical details of the patient, 
previous health problems and comorbidities which have been obtained during the initial 
clinic appointment at first presentation.  In centre C, a clinical specialist nurse (CNS) is 
present at the appointment where the cancer diagnosis is given for every patient.  
Following the clinic appointment, the CNS sees the patient in a separate room, offers 
support and collects information about their support network and home circumstances 
which is presented at the MDT meeting later that week.  In this centre, this information 
gathering is always delegated to the CNS, rather than the consultant in charge.  By 
contrast, in centre B one of the surgeons always holds a meeting with the patient before 
the MDT in order to deliver the diagnosis.  Sometimes at this ‘diagnosis meeting’ they 
discuss with the patient the treatment options and present this, usually as a patient 
preference, at the MDT meeting. I will discuss centre B in more detail to illustrate the 
point that when this information is presented at the meeting, members of the team 
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interpret it in different ways.   This is not surprising, as it is already evident that the 
TNM status information is subject to interpretation.  These interpretations, and their 
influence on the clinical recommendation, are externalised and made visible at points of 
conflict.  
The following data segment is about a patient called Donna Childs, a 52 year old female 
who had a small cancer of the tonsil surgically removed with a laser, together with the 
removal of some lymph nodes from the neck.  She was the subject of an MDT 
discussion as the team needed to decide whether any further (adjuvant) treatment was 
needed.  It was clear from the discussion that post-operative radiotherapy was 
recommended in her case, however it was less clear as to whether chemotherapy should 
be given at the same time.  The pathologist presented the results of the examination of 
the surgically resected specimen and told the team that one of the lymph nodes had a 
small amount of extracapsular spread
2
.  As discussed in the introduction chapter, there 
is clear research evidence that patients with extracapsular spread have a five-year 
survival advantage of around 4% if post-operative chemotherapy is combined with post-
operative radiotherapy (Cooper et al. 2004).  However the addition of chemotherapy to 
radiotherapy significantly increases the side effects of treatment, particularly the effect 
on swallowing.  The data presented below are observational from the MDT meeting and 
the discussion takes place after the pathology result is known: 
Mr Ilkley [ENT surgeon]:  Er, yes.  Now pre-operative discussion 
with this lady.  She was keen to try and avoid the use of 
chemotherapy, either the primary or the adjuvant setting.  So would 
                                                 
2
 Extracapsular spread means that the cancer has spread out of a lymph node into the 
surrounding structures.   
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you consider not giving it?  Would you consider just using 
radiotherapy? 
Dr King [Oncologist]:  Just with the lymph node…. 
Mr Ilkley:  And she’s HPV positive as well [these cancers are known 
to be more responsive to radiotherapy] 
Dr King:  You know my opinions, there are some rules which I have 
to respect [giving chemotherapy to patients with extracapsular spread 
is recommended in the guidelines]. And if it is reported like this, I 
can’t do that 
Miss Dutch [ENT surgeon]:  I think the thing is, you can offer her 
chemotherapy, and I know this is how you put it, is that you offer her 
it, and tell her what the risks and the benefits are, and she makes her 
own choice.  You know people have the right to refuse these things.  I 
know Dr King won’t say….unless you have this I’m not going to treat 
you!  If she feels that strongly about it once all the evidence is…. 
Mr Halifax [Maxillofacial surgeon]:  I would view them as guidelines, 
not rules. 
Mr Ilkley:  I don’t know if you were here when we discussed her first 
time around, but her husband died, and her daughter’s partner died in 
Afghanistan, so she…. I think she’s very keen not to die. 
Shannon [Clinical Nurse Specialist]:  That’s always the case! 
Mr Ilkley:  Exactly, that’s the other side of the…. She may want to 
have that added survival benefit that chemotherapy adds, given what 
the histology shows.   
Mr Halifax:  She needs [to be given] just the full picture, and then 
make a decision.  We can’t decide that for her now 
Miss Dutch:  No 
Mr Halifax:  All we can decide is that she needs to decide 
(Donna Childs, Observation, MDT Meeting, Centre B, 1
st
 June 2012) 
In the extract above, Mr Ilkley clearly presents that the preference of the patient is to 
avoid chemotherapy, and the priority for treatment is not to die, which presents a 
potential quandary: the MDT must either make a recommendation to maximise the 
chances of survival or to avoid adding chemotherapy to her treatment.  It could be 
deduced from this that Mr Ilkley’s expressed assessment of Mrs Child’s preference does 
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not match her priority simply because of the survival advantage that chemotherapy 
offers.  It may be that Mr Ilkley is not prioritising one preference over the other, but is 
sharing this uncertainty with the team.  However, because of the statement of 
preferences, the team appear to shy away from offering a clear treatment 
recommendation of chemotherapy, and instead opt to offer the options to the patient as 
an equal treatment choice.  The disparity between treatment preference and priority is 
not explored, nor could it be in this setting.  It could effectively be argued that the 
conclusion of “all we can decide is that she needs to decide” is not necessarily correct, 
and the priority/preference disparity needs to be made clear to the patient.  Her 
preferences need to be explored, and if necessary, a treatment recommendation given 
which are in line with these.  The team react to this by taking a step back, and giving all 
the work of the decision making to the patient.  The way in which teams handle these 
positions of choice will be discussed further in Chapter Six, but the excerpt above 
demonstrates the power that expressed patient preference can hold in the meeting.  
Without this information, I observed other patients being clearly recommended 
chemotherapy by the team.  A more cynical viewpoint would be that offering choice 
allows Mr Ilkley the opportunity to control the consultation with the patient and to 
frame the discussion toward his own preference.  In a similar way to Mr Black earlier in 
the chapter, the reasons that clinicians choose to champion one particular treatment 
option over another often extend beyond the patient in question; this is something I will 
discuss later in this chapter and in Chapter Six.  There is also ambiguity in the team 
about the role of the treatment guidelines and how they should be incorporated into the 
decision.  Should they be treated as rules, with which compliance is essential, or a guide 
to strengthen the argument for a particular course of action?  Clinical guidelines are 
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usually produced with the aim of reducing clinical uncertainty, although in this situation 
the issue of how rigidly to apply them to an individual patient has the opposite effect.   
The reaction of the other members of the MDT to the information about Mrs Child’s 
treatment priority and preference is of further importance.  The following is an extract 
from my reflective diary for the day, following some informal discussions with other 
members of the team: 
I had some interesting discussions with one of the clinical nurse 
specialists (Kim).  During the meeting Donna Childs was discussed.  
It was discussed whether she should have chemotherapy or not – the 
surgeon (Mr Ilkley), during the meeting, reported that she did not 
want chemotherapy.  When I was discussing this with Kim, I repeated 
what he had said.  “Get with the program Winnie!” was her reaction 
[Winnie is my nickname]. She feels that it isn’t the patient, but the 
surgeon who doesn’t want the chemotherapy – the surgeons aren’t 
keen on the chemotherapy and therefore they gear the discussion so 
the patient doesn’t choose it.  This means that they feel that the 
opinions which are presented at the table [MDT meeting] are those of 
the clinicians, and not of the patient, and that patients are often 
presented as “not wanting it” because either the surgeon doesn’t want 
it or the patient will be persuaded out of it.  This was echoed by Dr 
Dean [Palliative Care consultant] who echoed that it is “clear” what 
the patient was going to choose because she was “talking to a 
surgeon”. 
[during the consultation the patient chose not to proceed with 
chemotherapy] 
On talking to Mr Ilkley after the patient had left the room, it was clear 
that his personal preference was not to have chemo, as it added a lot to 
morbidity for only a “small survival advantage”.  
(Field notes, MDT Clinic, Centre B, 1
st
 June 2012) 
It is not possible to conclude from these data whether the surgeon misrepresented the 
patient at the MDT meeting.  It is possible to conclude that other members of the team 
often treat information such as this with suspicion.  Although information about 
priorities and preferences may be included in the MDT discussion (as well as other 
information which is patient-centric) there is more potential room for different people to 
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interpret it in different ways around the MDT table, perhaps even discard and ignore it 
due to concerns over its source.  This not only has an effect on the unfolding discussion, 
but also the recommendations which are made by the team to the patient; the way in 
which the options are presented to the patient and ultimately, the decisions made. This 
however presents a potentially dangerous balance.  As demonstrated, a presentation of 
the perceived preferences of patients seems to hold quite a lot of ‘power’ over the 
treatment recommendation made and yet, at the same time, there is suspicion about how 
it was gathered and then presented in the meeting, and confusion about the emphasis it 
should be given during the discussion.  I have no data from the ‘diagnosis appointment’ 
between patient and surgeon; however, possession of this data would not provide the 
answer as to how this sort of information should be treated by the team and incorporated 
into the decision.  The preference information being presented by Mr Ilkley is a 
representation of an earlier interaction between him and the patient.  Through this 
interaction it seemed that Mr Ilkley tried to reach an understanding of what he thought 
the patient wanted or feared, and interpreted this in the light of what matched with his 
own clinical interpretation of best practice, finally overlaid with other personal 
preferences.  My own interpretation of this interaction (if it were available) would 
provide no ‘truer’ a representation, merely another construction of the patient’s 
preference.  This emphasises the interactional nature of a patient preference and 
reinforces that it should not therefore be treated as a fixed informational commodity 
which can be passed from person to person or presented as a fact in a meeting (Slovic 
1995; Epstein and Peters 2009) 
As I mentioned earlier in the chapter, the patient’s preference is not the only piece of 
‘non-clinical’ information which is sometimes included in the discussion.  Depending 
on the centre and the patient, members of the MDT may present information about a 
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patient’s home circumstances, support network or even character.  Although this is 
often interesting, I sometimes observed how it is difficult to incorporate into the 
decision making discussion, other than via an assumption.  To demonstrate this, the 
following is observation data from an MDT meeting at centre A.  The patient is called 
Stanley Wight, and he has a large tumour of his tonsil. 
Mr Blonde (ENT surgeon): He’s a very sort of straightforward sort of 
man, who doesn’t worry too much, but he will probably cope with [the 
diagnosis] very well.  But, he needs a lot of radiotherapy 
Dr Orange:  What age is he? 
Mr Blonde:  He’s 87, I mean he’s a very good 87 




When Mr Blonde refers to his ability to ‘cope’, he is talking about his reaction to the 
diagnosis.  In this extract there is a judgement made by Mr Blonde about the patient 
being a “very ‘good’ 87” year old.  On one level this provides more information about 
the ‘feel’ of the patient, and helps to form a more holistic picture of the person that he 
is.  On another level it is a judgement which subtly sways the team in one direction, 
towards radical management (this is what the team offered to the patient).  These 
subtleties occasionally arise when speaking about patients, their drinking or smoking 
habits, their character or their age.  They sometimes have a small but vital guiding effect 
on the tone of the discussion, which pushes the direction of the MDT decision making 
towards or away from treatment options.  This means that the subjective judgements 
which are made by the speaker and the listener when transferring information of this 
nature, potentially lead to assumptions about which treatment would be best.  
In order to continue the analysis of the discussion that takes place in the MDT meeting, 
I will turn attention to the other information that the team consider when making 
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treatment recommendations.  The MDT is a gathering of expertise, designed to create a 
pooling of experience in the same room at the same time to inform treatment 
recommendations.  I alluded earlier in the chapter to how information which is not 
directly relevant to the patient being discussed has an effect on the interaction of MDT 
members; in the next section, I will explore in more detail how the team incorporate this 
information into the treatment recommendations. 
5.3 Incorporating other information 
HNC has a paucity of good quality research evidence to guide treatment decisions and 
the research literature is of variable quality (see Chapter One).  Although this does not 
mean it is of no use, it does mean that different members of the team place different 
levels of importance on the outcomes of the research.  In order to demonstrate this, I 
shall return to the discussion reported above, which took place primarily between Mr 
Black and Mr Red, about the patient, Vincent Lowry.  The discussion had become quite 
heated, and Mr Black had quoted some research evidence to reinforce his choice of best 
treatment.  The following is the angry response from Mr Red: 
Mr Red:  Aaaah well, I don’t care what the publications say Mr Black, 
because Mr Blonde [another ENT surgeon] and I, and Mr Smithson 
[another ENT surgeon] over the years have never published anything, 
and we’ve probably done a whole load more cases than the people 
who have published things.  So whatever’s published is only a small 
proportion of the total number of cases that are done.  ….  So you 
can’t take one or two publications in isolation by people who can talk 
the talk as gospel.  And whichever the latest publication which comes 
out, that seems to be the one that we are following, and that is 
inherently wrong.  That’s the point I’m making, I think evidence 
based medicine is appropriate, but only in the full context of the whole 
of the evidence available and that includes the personal experience of 
yourself, and everybody around you, and everybody that you know, 
and everybody that you discuss with things with, not everything that is 
put on paper…. And a lot of people who put things on paper are doing 
it for their own personal reasons rather than the future of the specialty.  
And you know that, and I know that, and everybody else knows that.  
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So don’t bleat to me about publications indicating that you should 
have a certain direction for treatment, because that isn’t true.  
Mr Black:  Will you let me come back on that? 
Mr Red:  Yeah…. 
Mr Black:  So the publications I’m talking about are ones coming out 
of… a single centre.  But then I’ve seen such cases here, and the last 
paper to come out of this was a truly multicentre work across seven 
different centres in spread across the US and Germany, and the 
outcomes exceed those of T1 and T2 tonsil tumours treated by 
primary radiation.  You’re talking about 20% increase in local control, 
compared to giving primary radiotherapy alone.  And I think we need 
to give that something of consideration.  As an MDT if we believe that 
this tumour is not treated ideally by transoral resection, I abide by that, 
and we’ll offer him radiation therapy.  But we can’t not take notice of 
the excellent outcomes that have been published. 
Mr Red:  There’s no point having an MDT is there?  You might as 
well wrap up MDTs tomorrow and just forget it.  If people’s 
experience don’t matter 




The angry discussion demonstrated here may be viewed as a negative occurrence, but 
these data demonstrate the role of conflict in externalising the views of the MDT 
members and giving them opportunity to make clear what they see as important or 
express their interpretation of the hierarchy of evidence. Garrety (1997) highlighted that 
conflicts are often a window into the underlying assumptions and priorities of particular 
groups, and allow the observer to see what is 'really' at stake beyond the immediate 
issue being discussed.  The interaction is a clear example of experience and research 
competing for a position of importance in informing the discussion of which treatment 
would be ‘best’.  In this situation, radiotherapy is an established treatment for cancer of 
this size and laser is a new treatment which, although it may improve some patient 
outcomes, has not got a large weight of evidence to support it.  There is some research 
evidence from the other cancer centres that it can produce good clinical outcomes but, 
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as it is new, many clinicians have little experience with it.  This means that to choose 
radiotherapy in this situation would be to follow a conventional treatment pathway for 
cancers such as these.  To choose laser therapy would be to believe and trust the 
preliminary data from other centres and have a goal to move forward the treatment of 
cancer.  Either way, the persistence for laser or radiotherapy depends in part on the way 
in which the members of the team interact with the wider research literature and 
combine it with their own experience and practice.   Some of the comments by Mr Red 
were raised when I interviewed him two weeks prior to this meeting.   
 I certainly don’t think that some of the decisions made [in the MDT] 
are necessarily the right ones, because I think sometimes personality 
and persistence outweigh pragmatism, common sense and 
experience…. I think, it seems that the people who are persistent are 
often those who have least experience, but have probably done the 
most recent reading.  I think some of them might have a hidden 
agenda because they want to be trying out new things.  And they 
might be right because that’s how you make progress….  I remember 
when I first started I was a lot more aggressive than I am now because 
I’ve seen what happens to people.  You go to national meetings and 
people will always present their fantastic results, and their fantastic 
new operation and their fantastic new operation will disappear 5 years 
down the line.  ….I think some people [are] doing it for an ego thing.  
And you’ve heard it all in there; you hear the egos, people quoting 
papers.  And the other point is of course that people who work in units 
like ours ….they don’t publish papers about all the cases because they 
don’t have time, so all those papers that are published by definition 
are done by people who have the time to do that which makes you 
question whether or not they’ve actually done the cases in the first 
place, or they’re just collating somebody else’s.  We haven’t got the 
time or the inclination to. So all the evidence that you read in the 
journals probably comprise, I don’t know, fewer than 1 or 2 percent of 
the number of cases that have ever been done. 
(Mr Red, ENT Surgeon, Interview, 8
th
 May 2012) 
These data highlight a multitude of issues concerning the interpretation of research data.  
They demonstrate the way in which members of the team may doubt the validity of the 
research or question the motives of the authors of the research.  Additionally, even if the 
data are to be accepted as valid and applicable, the way in which new research data 
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should be amalgamated with the considerable existing experience of the surgeons and 
other MDT members, and hence incorporated into the recommendation, is not clear.  
Not only this, but the actual act of presenting research data in the meeting can be 
interpreted in a negative light, linked to self-aggrandisement and a “hidden agenda” .  
Mr Red even suggests that the underlying principle of medical research, to “make 
progress”, leads to fashionable new surgical procedures waxing and waning in 
popularity, something which he has had the benefit of witnessing due to many years in 
practice.    
Together these data highlight some of the considerable complexities of applying 
research data to individual patients.  From the viewpoint of Mr Red, this suspicion 
immediately devalues research evidence as a tool to make decisions.  He quite clearly 
states that research evidence should come within the hierarchy of evidence, but most 
certainly not at the top.  It is also evident that he disagrees with the idea that this 
information should be given priority over the experience of the team.  His views are not 
shared by all members of the team and the presentation of this data is not intended to 
suggest that this is the case.  Instead, the data provides insight into the ways in which 
the research literature may be interpreted.  His comment “And you know that, and I 
know that, and everybody else knows that” was not supported by other data, and 
highlights a common misconception expressed by many different members of the team: 
that everybody else in the team sees things from the same viewpoint.  It is often stated 
during dialogue or interview that viewpoints are widely held or agreed with when this is 
not the case, mainly because the differences in the viewpoints and the reasons for them 
have never been explored.   The data also demonstrates the other factors which drive a 
clinician’s conviction for a particular course of action, other than the current clinical 
situation.  Although the discussion above centres on Mr Lowry, the outcome of the 
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discussion (and the final recommendation made) will have implications for future 
patients with a similar cancer.  Thus, the MDT discussion for an individual patient 
provides a platform for wider debate and how the knowledge which informs the 
discussion is formed and how the different sources and types of knowledge are 
aggregated is a complex process. 
The experience of the individual members of the team has a large number of effects on 
treatment decisions across the centres.  On one level, the experience of the members of 
the team effects the clinical opinion that they provide, and I shall explore the effect of 
this next.  The clinical opinion and knowledge of the members of the MDT is a valued 
commodity.  To demonstrate this I will present observational data from Centre A.  The 
discussion is about the patient, Bobby Older, who had been recently treated with 
chemotherapy and radiotherapy for a cancer at the base of his tongue.  Following the 
treatment he had a PET CT (positron emission tomography computed tomograph) scan: 
this is a relatively modern type of scan which highlights groups of cancer cells by 
changing their colour on the scan.  Confidence in the use of this scan is growing as it is 
used more frequently.  The patient had a residual lymph node in his neck, shown on a 
conventional CT scan, after completing his treatment.  Before the advent of PET CT, 
the lymph node would have been removed as the likelihood of it being residual cancer is 
high.  The PET CT scan had been performed however, and it had not changed colour; 
the scan suggested that it was not cancer.  To believe and proceed on the basis of it 
would have been to trust the results of the PET CT scan implicitly.  These data are from 
the discussion where the team are deciding whether or not they should proceed with 
removal of the lymph node: the operation to remove it is called a neck dissection: 
Mr Black [ENT surgeon]:  This is a point for discussion around the 
group.  In this man’s case clearly, Mr Surton, what do you think, this 
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man, as a group we need to discuss this, this man has a neck node on 
the left hand side, very metabolically active pre-treatment [on the PET 
CT scan]. Post-treatment, it’s not active at all…. 
 Mr Surton [maxillofacial surgeon]:  You’re thinking of doing a neck 
dissection? 
Mr Black:  We have a series of 20 or so far, we haven’t found viable 
tumour in any.  The last guy we did was Bob Tressey, quite a chunky, 
4 cm node, again non-viable tumour cells, so as a group, are we 
actually ready to decide that….? 
Mr Surton:  ….we’re not going to dissect on the basis that…. 
Mr Black:  ….sit on it and not do anything. 
Dr Winter [radiologist]:  Well, I think it, I mean every case is different 
isn’t it.  There is a case, the residual node is solid and it’s not necrotic 
[necrosis in a node is a sign of cancer]…. and there wasn’t any 
activity, but the problem we have is, we have some patients where we 
have not done a PET CT, it’s a necrotic node and my worry is you 
might have a bit of tumour in a necrotic node…. a lot of evidence 
shows that you can, you know, sit on these, a lot of papers can come 
up 
Mr Surton:  ….if we’ve made a decision we’re not going to do it, 
obviously, a little bit at the back of the mind says, are we not going to 
miss a chance to do something earlier on?  But if we do an ultrasound 
now, as a baseline, and then an ultrasound at three months, and then 
maybe another PET CT scan…that will give us an idea of whether 
there are any further change 
Mr Blonde [ENT surgeon]:  Yeah, I think that is the question, about 
how we should decide to follow these up if we’re not going to operate 
on them.  And does that sound reasonable, if we had an ultrasound, at 
the time of deciding not to operate? 
Dr Winter: It would be nice to know what the ultrasound would look 
like, as Mr Surton said, what it looks like now, then in three months, 
you say well I know what it looked like…. 
Mr Surton: So if the decision is not to operate, and a baseline 
ultrasound within a week to ten days and another at three months. 
Mr Blonde:  Yeah, OK 
Mr Black: OK 






The extract shows the team actively adapting their care as they discuss.  It is a drastic 
new change to their management plan, and a very different potential treatment course 
for the patient.  Trusting the negative PET CT results means that the team would 
recommend that the patient should not proceed to neck dissection.  This means that he 
avoids the risk of the operation, but takes on the small risk of persistent cancer which 
was missed by the scan.  The patient was primarily under Mr Black, but his use of the 
MDT was evident when he said “This is a point for discussion around the group”, “as a 
group we need to discuss this” and “so as a group, are we actually ready to decide 
that?”.   This repeated referral to the decision as one which is made by the group shows 
Mr Black sharing responsibility and spreading the decision across the team.  As the 
discussion continues, the team can be seen gradually shifting from ‘what should we do’ 
to ‘this is what we should do’ as the various members voice their support for the 
conservative management plan. At the same time, an important question is raised by the 
data, which I will answer in the coming chapters.  Where does the patient come into 
this?  Following a conservative management plan avoids the risk of the neck dissection, 
but accepts the risk of a missed cancer.  It could be argued that whether or not to 
proceed is in fact a value judgement based on attitude to risk, and this judgement should 
be made by a patient, not a professional team
3
. 
These data demonstrate one of the main benefits of working in the team, a shared 
responsibility or ‘safety in numbers’.  Mr Black is not reporting his decision to the 
MDT team, but clearly asking for advice.  The extract shows treatments being adapted 
in real-time, and provides an example of research evidence being actioned in practice.  
                                                 
3




It also shows how new technologies move within the hierarchy of evidence and become 
incorporated into the discussion.  Here, the PET CT scan (a relatively new 
advancement) has little high quality evidence to guide decision making and it is jostling 
for position in the hierarchy through the interaction of the members with each other.  A 
long journey lies ahead until the technology gradually becomes ‘trusted’ by the team, 
but through this journey, the findings of the scan become less of a discussion point and 
more of a ‘fact’.  As a result the scan results slowly move up or down the hierarchy of 
evidence over time. 
The data I have presented shows that the clinical opinion of the MDT members as a 
resource on which to base decisions is not as open to interpretation as the use of 
research evidence.  As a result of this, the team sometimes find it easier to incorporate 
their own opinions into the decision discussion. In the data above, research evidence is 
used loosely to inform the discussion, but the clear driver for the change in management 
plan is the opinion of the individuals in the team.  Team experience in the form of 
clinical opinion shapes the behaviour of a team and provides the individual members 
with support in following management plans, especially those which are alternative to 
standard care.  However team experience has effects which extend beyond the opinion 
of the clinicians.  When visiting the different centres, I noticed that there seemed to be a 
considerable variation in care between centres across one, quite small geographical 
region, which did not seem to be explained by the patient population.  Patients who 
would probably have been treated radically in one centre, were treated palliatively in 
another.  I found that, when watching patients being counselled, I sometimes formed my 
own clinical opinion as to how they should be treated; when the opinion of the team 
members was very different to mine it sometimes shocked or surprised me.  As a result 
of this, the reasons for this perceived variation in care therefore became one of the 
130 
 
focuses of my investigation.  In centres A and B the vast majority of patients were 
treated with curative intent, with extended courses of chemotherapy and radiotherapy, 
or large operations and surgical reconstructions.  Two and sometimes even three of 
these therapies (surgery, radiotherapy and chemotherapy) were combined and patients 
suffered debilitating side effects as a result, impinging upon many aspects of their 
quality of life.  In HNC treatment it is well-documented (DAHNO 2011) that around a 
third of patients die within two years of developing their cancer despite the hardships 
endured during radical treatment. 
When I visited centre C, a greater proportion of patients seemed to be treated with 
palliative intent that in the other centres.  The team were happy to give a treatment 
recommendation of “best supportive care”, and when they recommended radical 
management they usually included “..or best supportive care” as an alternative treatment 
recommendation.  In centre A and B, the option of “best supportive care” would often 
not be mentioned or discussed, even in patients with advanced disease.  During his 
interview, Dr Goodier, an oncologist in centre C, gave some insight into the reasons for 
this: 
There is a school of thought that if you want to get control of head and 
neck cancer you have to bold, aggressive.  And I don’t disagree with 
that… and I came into head and neck cancer very much, I think with 
those views.  It didn’t take long to learn that that isn’t an appropriate 
approach for everybody I’m afraid.  Partly because some of the 
patients just can’t withstand too much intervention.  …  And if it goes 
wrong, you know if you push patients in for aggressive treatments 
who really can’t stand it, my gosh.  If you’re a human being at all you 
do regret that.  I mean there will be some patients at the margin where 
we do all agree, “Let’s go for aggressive treatment.”  But it turns out 
half way through treatment or whatever that actually, that was not a 
very clever decision. …. death from advancing cancer in patients 
who’ve had multimodality of treatments is probably even worse…. the 
only blowouts from carotid arteries I’ve seen in head and neck cancer 
are patients who’ve had high dose radiation to the neck.  And you 
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know that patient may not have had a carotid blowout if they’d not 
had the intervention in the first place. 
(Dr Goodier, Oncologist, Interview, 18
th
 January 2013) 
A “carotid blowout” is a hole quickly developing in the main artery of the neck, the 
carotid.  It is almost universally fatal, as the resultant haemorrhage bleeds the patient’s 
entire blood volume in under a minute.  It can occur as a result of HNC or its treatment 
and is an extremely unpleasant mode of death to experience or witness.  In this data 
extract, Dr Goodier describes the experiences he has had when treating patients with 
advanced cancer and not succeeded in curing them.  In his statement “my gosh.  If 
you’re a human being at all you do regret that” his language changes from the rather 
clinical, factual tone which characterises the rest of the interview to one which is quite 
emotional.  The language and tone in this part of the interview gives insight into the 
emotions which he has experienced which drive his practice.   This shows the lasting 
effect that the interaction between patient and clinician can have on clinicians, and 
hence on future patients, and the human, emotional response which clinicians have to 
experiences which fundamentally shape their practice. Importantly however, Dr 
Goodier is referring to quality of death rather than to quality of life, and he makes a 
judgement that dying after treatment is ‘worse’ than dying without treatment.  Besides 
the fact that this is value judgement, one can perhaps sympathise with this viewpoint 
when he talks about mode of death.  Given the dramatic nature of a carotid blowout, it 
could be understood that if Dr Goodier, rightly or wrongly, felt responsible, that would 
be a highly unpleasant experience and therefore highly likely to affect his future 
practice. This highlights an interesting concept, as when speaking of SDM, clinicians 
often refer to the anxiety that decision responsibility may invoke in patients.  However 
here is an example of the weight of decision responsibility on the clinician.  Rather than 
invoking anxiety, this may invoke an equally powerful emotion, regret.  To demonstrate 
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this further, I will juxtapose words of Dr Goodier with those of Mr Halifax, a surgeon 
from centre B: 
We can technically always do an operation…. Statistically you ain’t 
going to do very well because you’re T4 with a big tumour, but it 
doesn’t mean to say that some of them haven’t done okay. …I mean 
we will say to them “Prognosis is 25%,” but they’d rather have 25% 
of something than - essentially palliation means, “I’m dead.” They’re 
going to make it as comfortable as possible for him, but “I’m dead”. 
Why not?  See the other thing as well is, it’s bloody horrible, it’s a 
horrible death. So however mutilating and horrible the surgery is, it’s 
often better than the death. I mean I have seen a few who have had 
nothing, it’s grim. Absolutely grim.  Well you just get a big hole in 
your head. You can’t eat, all your food comes through it, all your 
saliva comes through it, it stinks. It’s nasty to care for. ….and yet it 
doesn’t kill you instantly, ….you don’t blow out until you catch your 
carotids which is often …a long time away.. So not having – having 
half your head removed is bloody horrible, but it doesn’t smell as 
much and it’s generally not as bad. Trouble is in your heart of hearts, 
as a clinician you know that, so you tend to push a bit on the treatment 
side because you know, by God, if I don’t, it’s bloody horrible. You 
know, and they bloody live with you, the ones you don’t treat you 
know, oh my God. 
(Mr Halifax, Maxillofacial surgeon, Interview, 5
th
 October 2012) 
In this passage, Mr Halifax talks about the times he has not treated radically and the 
effect this has had on him.  Again, Mr Halifax, in a similar manner to Dr Goodier, uses 
quite emotional language to describe the lasting effect that these decisions have, and the 
language is out of character with the rest of the interview. Again, he refers to the quality 
of the death, and expresses how he sees death after treatment, as a “better” death than 
one without treatment.  To illustrate his point he gives distressing details of the nature 
of a cancer death without treatment, but provides us with no similar information about 
one with treatment.    Interestingly, whilst illustrating this point, he emphasises the 
process of dying as opposed to Dr Goodier, who spoke more about the mode (“carotid 
blowout”), but it is clear which of the deaths Mr Halifax feels is preferable. He also 
goes on to provide an indication of the sort of effect that this has on his practice “so you 
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tend to push a bit on the treatment side because you know, by God, if I don’t, it’s 
bloody horrible”: his more radical approach is supported by my observations. 
These two pieces of data are shown to demonstrate that a concept which is shared 
between centres, the experience of watching patients die, can have completely opposing 
effects on the delivery of care in different settings.  In one centre, the talk of regret and 
quality of death drives the team to palliate more, in another, to treat more radically.  The 
previous two pieces of data have some remarkable similarities: an emotional response to 
death, but coupled with a feeling of responsibility for the nature of these deaths.  Both 
express feelings of “regret” or patients that “live with you” and, with this in mind, it is 
not surprising that the clinicians allow this to affect their practice.  Both also refer to the 
quality of death, either the process of dying, or the mode of death, and the effect that 
this, coupled with the feeling of responsibility, has on the clinician.  It exposes the 
practice of medicine as an emotional process; the resultant emotions have a powerful 
effect on future actions.   
The data presented in this chapter demonstrate the variable effects that the previous 
experience of members of the MDT team has on the recommendations made.  On a 
superficial level, prior clinical experience forms clinical opinion which can be used as a 
source of information for other members of the team to draw upon.  This kind of 
experiential knowledge, although largely anecdotal, stands high on the hierarchy of 
evidence informing treatment recommendations. However, the effect of the prior 
experience of team members extends beyond this: it shapes the way the members of the 
team interpret research evidence and clinical guidelines, and incorporate them into 
treatment decisions.  Additionally, on a more fundamental level, the human reaction of 
clinicians to clinical experiences guide their practice over time, and feelings of 
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responsibility or regret for past decisions have a major influence on the nature of the 
care delivered in a particular centre.  If I return to my question earlier in the chapter, 
“What is it that drives a clinician’s conviction for a particular treatment plan?”, previous 
experience, would certainly seem to provide part of the answer.  
So far in this chapter, I have highlighted how the team use the evidence available to 
them to inform their discussion about making a treatment recommendation.  Some of 
the information is related to the patient, and some is related to experience of the team or 
the wider HNC community.  I have discussed the way in which this evidence is viewed 
by the team and interpreted, and have given some examples of the effect of this on the 
recommendations made.  This process of evidence ‘mobilisation’ is complex but, as I 
have outlined, the team interaction is governed by more than just the patient in question.  
In the final section of this chapter I will go on to demonstrate how the environment or 
atmosphere in which the MDT discussion takes place exerts further, over-arching 
effects on the behaviour of the team and the decisions made. 
5.4 Team behaviour 
When I visited each MDT, there were similarities between them and conventions 
observed by each team.  The MDT was always chaired by a surgeon, and the clinicians 
always dominated the discussion.  The order of the discussion was always the clinical 
details of the patient, followed by radiological and pathological information to form the 
TNM status, and then further discussion to form a treatment recommendation.  
However, I also observed that there were subtle differences between teams which 
altered the behaviour of the members.  Each team which I visited had a different 
atmosphere and this had an effect on the discussion: not only its content, but also its 
length, the degree of conflict and the ‘position’ of the patient in relation to the team 
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recommendation (I will discuss the patient ‘position’ further in Chapter Six and Seven).  
I observed the team atmosphere to be affected by many different factors; this was 
always most evident to me when joining a team, as after repeated attendances the 
atmosphere became less obvious, as it had done for the MDT members over time.  To 
demonstrate how the atmosphere of a team was generated, I present the following 
extract from my reflective diary after my first attendance at Centre B: 
The room is much quieter than it was at the Centre A.  There were 
fewer people present – everybody in the room had more of a role.  
There were few people who said absolutely nothing at all.  There were 
many less phones ringing – there are no dect phones in Centre B [a 
dect phone is a mobile phone which is carried in the hospital.  In 
centre A these rang frequently and often people spoke quietly on them 
during the meeting], and people are contactable by pager.  This means 
that they not only have to leave the room to answer this but also that 
the conversation takes place away from the room.  It has the added 
benefit that people are not as likely to contact people in the MDT for 
more trivial matters.  The room is quite small, and the tables are 
arranged in a square.  …. There is coffee and juice available in the 
corner, which everybody makes use of.  The nurses… seemed to be in 
the central ‘gang’ of the team, and were very pally with each other.  
At the end of the meeting there was a ‘round the table’ where 
everybody was invited to speak, even if it was just to say that they had 
no issues.  …It was obviously something that [the nurses] were 
waiting for and they told the team about issues with patients or news.  
This exercise took almost as long as the meeting itself.  …  It helped 
to generate more of a team atmosphere. 
(Field notes, MDT Meeting, Centre B, 18
th
 May 2012) 
These data document my initial impressions of the MDT at centre B, but also outline 
many of the factors which generated the atmosphere.  As mentioned previously, 
although there are many aspects of the discussion which were the same, small 
differences in the set-up of the room, the facilities available and the attitude of the 
members generated an atmosphere which I observed as being more inclusive to the 
allied health professionals.   In contrast to this, Centre A provided an occasionally 
combative, sometimes quite threatening atmosphere.  Most of the observational MDT 
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meeting data in Centre A included discussions between consultant clinicians, but there 
were a large number of other people present in the room, sometimes as many as 40.  
This means that speakers were greatly out-numbered by non-speakers and at times the 
MDT meeting turned into an ‘observed conversation’ rather than a group discussion.  
To demonstrate some of the reasons for this, as well as the effect that it had, I will 
present interview data from Tessa, a CNS in centre A: 
But as soon as that one person walks in the room it all clams up …. 
Which is … quite worrying. I think some of the conflict can be very, 
very uncomfortable at times…. embarrassingly uncomfortable.  I 
don’t think that an MD meeting is the place to be like that.  It should 
be a comfortable atmosphere where everybody feels comfortable to 
speak…..the atmosphere I think needs to be very relaxed.  I don’t 
think the pressure that we’re under …helps.  I think we’re all under so 
much pressure.  Even things like …. we don’t even get a cup of coffee 
now.  I think part of it is that we have very complex patients and I do 
feel the complexity of the patients has increased…. you’re pulled in so 
many different directions.  I just don’t feel that I’m doing a 
particularly good job because I just can’t do it all.   I can hopefully 
speak out for the patient if I know the patient well enough.  But then I 
think sometimes that, that becomes hard …. because of the workload I 
don’t think we have as much insight as we’d like to have. 
(Tessa, Clinical Nurse Specialist, Interview, 23
rd
 October 2012) 
In these data, Tessa describes the atmosphere of the room in a negative way, but goes on 
to outline the reasons for this.  On an individual level, high workload means that she 
doesn’t know her patients as well as she feels she should, which leads to a poor 
perception of her own ability to perform her role and “speak out” for the patient.  At a 
group level the workload means that the atmosphere that she feels would help to form 
an inclusive discussion is not achieved.  The people present in the room additionally 
affect the atmosphere, sometimes in a negative way, presumably due to strained 
relations with the rest of the group. These data demonstrate that the MDT meeting is not 
a ‘socially neutral’ space, but subject to the same requirement for understanding, 
inclusiveness and acceptance as another social situation.  Stripping back these social 
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niceties (even to the extent of failing to provide coffee), whether due to workload 
pressures or other reasons, affects the atmosphere and decreases the quality of service 
provision in the eyes of the members as a result.  The resultant atmosphere, at least in 
centre A, provides a challenging environment in which to make treatment 
recommendations which, as I have discussed so far, are already complex.  Importantly, 
many of the factors which generate this atmosphere, such as the attitude of members, 
set-up of the room or facilities available are modifiable.  The provision of coffee, team 
exercises such as ‘round the table’ at the end of the meeting and the exclusion of phones 
are simple additions to the MDT meeting.  Other factors such as personal differences 
and historical interactions between individual members are more difficult, but certainly 
not impossible, to address. The workload of the MDT and allied health professionals is 
also a more significant challenge to rectify, merely because of the investment and 
personnel which is required to achieve this.  
The data above allow us to begin to see the perspective of the members of the MDT 
who speak less regularly and provide evidence of the effect that the atmosphere may 
have on the team decision making.  In centre A, other allied health professionals (such 
as speech and language therapists) echoed the sentiment that the atmosphere is not 
conducive to their input.  In order to demonstrate this, I present data from Sally, a 
speech and language therapist in centre A: 
I don’t think it is always a full and frank discussion.  Because when it 
becomes threatening like that….for some people in the room anyway, 
it just results in silence doesn’t it?  [You just] keep your mouth shut 
because you’re going to say the wrong thing. I know from my own 
perspective, I would be much less likely to talk some weeks than 
others.  But that’s because I’ve had my hands burned and I’ve 
contributed sometimes and said the wrong thing and been in the line 
of fire, and I’m not prepared to do that….Even if the patient were my 
relative and it was for the best outcome for them, I wouldn’t put 
myself through that now. 
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(Sally, Speech and Language Therapist, Interview, 3
rd
 July 2012) 
These data provide a stark demonstration of the effect of the atmosphere on the 
contribution of the allied health professionals.  Speech and language therapists provide 
specific expertise about the pre-treatment function of patients with regards to their voice 
and swallow, and have an intimate knowledge of the functional outcomes in the months 
and years after treatment.  Here Sally states that, although the atmosphere varies, an 
atmosphere which is not conducive to her input results in her not adding anything to the 
discussion; by silencing her, vital details about the patient may be omitted.  The grave 
negative effect that the atmosphere has on her input is clear from her words when she 
states that she would not add to the discussion “Even if the patient were my relative and 
it was for the best outcome for them”.  These data provide insight into the detrimental 
effect that the atmosphere of a room has on the input of the allied health care 
professionals.  It is not only an effect on their feelings; they are present to provide 
expertise, often of a different nature to the evidence presented by the doctors.  An 
atmosphere which is not conducive to including these allied health professionals in the 
discussion will have consequences on the evidence available to inform the 
recommendation.   
The data presented in this section outline two important concepts about the atmosphere 
of the team.  Firstly it is modifiable, and secondly, it has a significant effect on the input 
of the allied health care professionals.  If the modifiable factors which encourage 
inclusion in the team are ignored, this potentially limits the input of allied health 
professionals and hence the nature of the discussion and potentially the 
recommendations made.  It is not possible to conclude that treatment recommendations 
would be different if the atmosphere were different.  However, my observations support 
the account above that the atmosphere of each centre I visited changed the way in which 
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MDT members interacted and hence the nature of the discussion.  This means that 
implementing changes to facilitate the input of these members would help to provide a 
more inclusive atmosphere, which would in turn increase the contribution of the allied 
members, and with it the information that they bring.   
5.5 Conclusion 
Through the course of this chapter I have discussed the initial stage of the work of the 
MDT team.  The aim of the MDT meeting is to produce a treatment recommendation 
and, in order to do this, the members need information and evidence on which to base 
this decision.  There are two main sources of information: firstly, information about the 
patient being discussed and, secondly, information gleaned from elsewhere, such as the 
research literature or the previous experience of the team. These discussions do not take 
place in contextual isolation; they are framed by the atmosphere, history and culture of 
the team.  All discussions take place with a backdrop generated by the people present, 
their history together, their previous discussions and the pressures which they are 
facing, both individually and as a group. 
Different pieces of evidence hold a different importance in the room to the various 
members.  This is not a pre-defined list or rank ordering, it is a hierarchy which is 
continually defined and re-defined depending on the patient and the negotiation that the 
team is having.  There are pieces of information which are less contestable, but certainly 
not immune to discussion, such as the size and extent of the cancer, and the clinical 
opinion of the team.  The other evidence varies in importance, depending on the patient, 
the disease and the proposed treatment.  The importance of these pieces of evidence also 
varies over time, as new technology is introduced and new research performed.  Much 
of the research evidence available to the MDT members in HNC is of limited quality 
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which allows members to sometimes alter their interpretation to reinforce their 
argument. 
The experience of the team has a substantial effect, which governs not only the 
individual decisions made, but also the behaviour of the team over time.  The members 
of the team appear to value the ‘safety in numbers’ that team experience brings but, at 
the same time, previous experiences, especially those which are negative, shape the 
pattern of the discussion and the treatment recommendations made.  Thus experience 
has positive and negative effects on the discussion, but potentially creates a clinician–
driven variation of care between teams. 
In this chapter I have shown that before the point is reached where the ‘decision talk’ 
can even take place, the evidence underpinning the decision needs to be made available 
and mobilised.   In order to do this, the team attempt to construct the ‘evidential patient’ 
out of a number of pieces of information about the patient.  This ‘evidential patient’ is 
designed to reproduce the patient in the room via information.  There is disagreement, 
not only about which evidence should be used, but also how it should be drawn upon.  
Even in teams where there is less conflict, and the evidence used to construct the patient 
is more stable, one wonders whether it is possible to produce a patient identity in the 
room by providing information.  The “feel” of a patient is not a fact which can be 
presented, but rather is a product of an interaction. This means that any attempt to 
represent it, other than via interaction with the patient, is potentially doomed to fail.   
The data presented in this chapter represent an extra layer of complexity in the process 
of decision making in teams.  In a clinical encounter between one doctor and one 
patient, the evidence and information used and its hierarchy is clearer.  This is partly 
because the work involved is performed by one individual (the clinician) rather than a 
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group.  The patient is also well-represented; they may not always be called upon, but the 
information required to get the “feel” of the patient is available to the clinician via 
interaction with them rather than via the ‘evidential patient’.  Hence, I have outlined an 
additional complexity of team decision making; a step before treatment 
recommendation, where the foundation blocks for the decision are put in place.  Whilst 
presenting the data so far, I have not given details about how the recommendation is 
made, how this is communicated to the patient and ultimately how a decision is reached.  




Chapter 6: Delivering the Treatment Recommendation 
In Chapter Five I described how the evidence which is used as the basis for a treatment 
recommendation is mobilised and negotiated within the MDT.  In this chapter I move 
the focus to the next phase of the decision making process: delivering the treatment 
recommendation to the patient.  I discuss the motivations of the team to arrive at a 
treatment recommendation, the challenges that the team face in order to acknowledge 
and then offer treatment choice and the effect that these challenges have on the 
treatment decisions made. 
6.1 Assessing ‘best’ 
The basis of the MDT discussion is to come to a recommendation of which treatment is 
‘best’ for the patient and when I observed the MDT meeting and clinic, the mention of 
‘best’ was commonplace.  In the following extract Mr Halifax describes his view of the 
aim of the MDT discussion: 
[The team] need to leave the MDT [meeting] with the treatment 
options ….prioritised. So a rank order of [the] best treatment clinically 
– slightly irrespective of the patient’s wishes. From a clinical point of 
view to try and get best outcome, this would be our first, this would be 
our second, this would be third and fourth and fifth. Then you discuss 
it with the patient and say, “This is what we think.” 
(Mr Halifax, Maxillofacial Surgeon, Interview, 5
th
 October 2012) 
In this data extract, Mr Halifax clearly states his view that the aim of the MDT 
discussion is to decide the “clinically” best treatment for the patient and even goes as far 
to say that this could be “irrespective” of the patient’s wishes.  It could be argued that in 
restricting his view of best to ‘clinically best’ he is accepting the limitations of making 
recommendations in the MDT setting and adapting his clinical practice to suit.  
However, Mr Halifax’s reference to “best treatment clinically” is open to interpretation.  
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In the MDT meeting the patient is not physically present, but this does not mean the 
patient is not present in any form.  I discussed previously how the team build the 
‘evidential patient’ in the MDT meeting; in this way the patient is present through case-
related information, much of which is non-clinical.  The patient is also present as a 
manifestation of collective past patients, hence more ‘patient-related’ factors become an 
integral component of this ‘clinical’ assessment.   This means the distinction between an 
assessment which is ‘clinically best’ and that which is more ‘patient related’ is unclear.  
Even if ‘clinically best’ were to exist, individual clinicians, in varying situations, have 
differing  views on what they would consider it to be; it is certainly not an objective 
entity which exists as one, incontestable truth.   Hence, although Mr Halifax may have 
his own clearly held view, this may not be shared by other members of the team.  In this 
quote Mr Halifax does not refer to how this assessment of best interests should be made, 
what its basis should be and who should perform the assessment.  He also does not 
acknowledge the difference of opinion which may exist when assessing what is 
clinically best, perhaps because he does not recognise it. 
As I mentioned, many clinicians have a view of what they feel is best in certain clinical 
situations which is formed through a combination of clinical opinion, experience and 
research.  This view of what is best is often quite strongly held: 
In general head and neck there often isn’t an option; you’ve got the 
best treatment that there’s an evidence base for that… once you’ve 
decided on that option it’s not that I’m deciding on it as a non-surgical 
oncologist or a surgical oncologist deciding on it; that is the truth as 
far as we know it…that is at present universally thought to be the best 
treatment for the patient.  So once that decision has been made that’s 
it…… the patient’s decision….may not be I want radiotherapy, I want 
surgery, it’s do you want the best treatment we know of or not. 
(Dr Orange, Oncologist, Interview, 18
th
 January 2013) 
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In this extract, Dr Orange clearly states that one treatment option is often “best” and 
thus, from his perspective, the only choice which exists for the patient is whether or not 
to accept this.  He refers to this assessment of the best as being something which is 
“universally thought”.  My observations support his assertion that MDT members often 
see their own assessment of the ‘best’ as incontestable, indeed this is one of the reasons 
why conflict arises.  At the same time the MDT often decides that two options could, 
equally, be considered as the ‘best’.  However, in a similar way to Mr Halifax, Dr 
Orange does not acknowledge the difference in opinion which may exist or indeed the 
difficulty in defining the ‘best’ treatment.  What does ‘best’ mean?  Who should decide 
this?  Which part of the treatment is being referred to?  Is it a value judgement?  Unlike 
many others, Mr Blaydon, an ENT surgeon, discussed some of these difficulties in the 
assessment of ‘best’: 
Mr Blaydon: I don’t think you can have one definition [of best]… I 
think clearly there are different potential definitions.  One definition 
would be that you actually look at what statistically their best survival 
outcome might be. And you could quite legitimately say, “That’s in 
their best interests.” But that is only their best interests if survival is 
their key objective. If their key objective is lifestyle and function then 
it may not be that that’s in their best interests.  So it very much 
depends upon what the patient’s wishes are, and actually getting that 
information out of them is actually quite difficult. In some people they 
are very clear, but in the majority of people my own experience is that 
it’s actually quite difficult to get them to actually impart that 
information. And we probably aren’t that good at asking the question 
directly, “What’s most important to you? Is it survival at all costs or is 
the quality of your life more important than your absolute survival?”  
(Mr Blaydon, ENT Surgeon, Interview, 25
th
 October 2012) 
Here, Mr Blaydon refers to what is commonly accepted as the ‘best’ treatment by many 
members of the MDT: “what statistically their best survival outcome might be”.  
However, he goes on to discuss other aspects of treatment outcome which may be 
considered to alter an assessment of best, such as lifestyle or function.  Most 
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interestingly however, he gives insight into the difficulties he faces in extending the 
conceptualisation of best outside of the optimum chance of survival.  In order to extend 
the concept of what is best for a particular patient, information is required about what 
the patient’s wishes are, what is important to them, and what their aim is for treatment.  
He gives the reasons why integrating this information into an MDT discussion is 
difficult: the MDT “aren’t that good at asking” but also even when asked, “it’s actually 
quite difficult to get them to actually impart that information”.  It is difficult to ascertain 
whether he thinks this is a result of the patient group and their characteristics, the 
complex nature of the disease, the format and structure of the MDT meeting or a 
combination of these factors.  Also, even when information of this nature is 
forthcoming, the task of trading off one outcome (e.g. survival) for another (e.g. quality 
of life) is not straightforward, and varies between patients (Jalukar et al. 1998; Hamilton 
et al. 2012; Laccourreye et al. 2012).  Nevertheless, the data highlight the difficulties 
that the MDT members face when deciding what is ‘best’ for a particular patient and 
thus the challenges that exist in using this as a basis for a treatment recommendation.  
However, this treatment recommendation, or consensus view, is the culmination of the 
MDT discussion. 
6.2 The treatment recommendation 
At the end of the MDT discussion, the team come to a ‘consensus’ view, or treatment 
recommendation.  The recommendation is sometimes deliberately repeated or 
emphasised by the chairman or other member of the MDT, but sometimes it appears 
that the recommendation is assumed to be known in the team and therefore not 
articulated.    Importantly, this does not mean that everyone agrees with this 
recommendation, rather that this is the message to be delivered to the patient in clinic.  
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In keeping with Goffman’s original description, the MDT meeting room is in this sense 
a ‘backstage’ area for the actors (MDT members) to prepare for the performance on the 
‘frontstage’ (the MDT clinic).   The ‘line’ that the team are going to take during the 
performance is agreed and a unanimous ‘front’ is therefore presented.  After the 
treatment recommendation is stated, the performance is set, and dissent from the 
members is no longer allowed, even if there is still disagreement.  Here, to illustrate the 
‘setting’ of the performance, I again use the case of Vincent Lowry: in the previous 
chapter I included the MDT discussion of this patient.  Mr Black felt very strongly that 
laser treatment was ‘best’ for the patient, however Mr Red felt equally strongly that the 
‘best’ would be radiotherapy.  The discussion between the clinicians was protracted and 
at times heated.  The following data are from the end of the meeting; Mr Blonde is the 
chairman of the MDT: 
Mr Black (ENT surgeon):  [Laser is] amazing…. I can pull the patient 
data, I have a database of the [laser resections] I have done, I’ve done 
about 12 so far, tonsil and soft palate tumours, and it’s just….it’s 
something we need to take notice of 
Mr Blonde (ENT surgeon):  Yeah, I think we’ll need to, we’ll have to 
discuss it another time or we’ll take up the whole morning on one 
case.  But, I think there are arguments for and against... 
Dr Orange (oncologist):  I would suggest he has radiotherapy, because 
he will have a slightly better functional outcome, and he’s 80 and 
…because of his age, and because of the possibly better function…. 
But you know we have had these patients and we’ve given them 
radiotherapy and the radiotherapy has failed….Soft palate seems to be 
more radio resistant.  But the tonsil, I think radiotherapy would be 
much better.  But then, I’m a radiotherapist.  But I think the guy 
should have radiotherapy without chemotherapy.  ….would you Dr 
Yellow? 
Dr Yellow (oncologist):  Yes 
Mr Blonde:  I think there is a consensus view of the MDT, would be 
for radiotherapy 
MR Black:  OK 
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There was clearly uncertainty and disagreement about which of the treatments would be 
‘best’ and Dr Orange alludes to this when he is summing up the role of radiotherapy.  
However, the data demonstrate clearly the chairman of the MDT (Mr Blonde) bringing 
the discussion to a close and plainly stating that the treatment recommendation (here 
described as the “consensus view”) should be radiotherapy.  In stating this, the 
performance is set; the ‘front’ is decided and a unanimous team performance promoting 
the certainty and expertise can be provided for the audience in the MDT clinic. These 
data show how the MDT meeting is treated by the MDT members as a ‘backstage’ area.  
It is where the performance to the audience is “painstakingly fabricated, illusions and 
impressions are openly constructed” (Goffman 1959, page 114).   The data show how, 
in this case, all members of the MDT ‘agreed’ that one option was the ‘best’ and once 
this agreement was in place, dissent was not longer allowed.  When this is the case, this 
treatment option is delivered to the patient as a clear, single treatment recommendation.  
In the majority of cases this treatment is accepted by the patient.   
The first step between a treatment recommendation and a treatment decision is the 
delivery of the recommendation to the patient.  The process of delivery varies slightly 
between centres.  In centre A and B, an individual member of the MDT, the ‘lead’, is 
usually chosen to deliver this message to the patient.  Sometimes it is decided that the 
patient should see two leads, usually an oncologist and a surgeon, either separately or at 
the same time.  The decision about who should be the lead depends on various factors: 
whom the patient is under, who is available in the clinic and the nature of the 
treatment(s) being recommended.  In centre C, the majority of the patients are seen in 
the ‘combined clinic’.  The combined clinic takes place on a different day to the MDT 
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meeting, and is staffed by at least one surgeon and one oncologist.   In all included 
centres, at the MDT/combined clinic, many of the allied health care team such as the 
dietician, SALT or CNS are either present at the consultation or available to be called 
upon.  The role of the allied health professionals is variable from week to week and 
depends on how many staff and patients are present at the clinic.  Sometimes they are 
present for the entire clinic consultation, sometimes they move between consulting 
rooms.  This usually means that the clinic is quite busy and it is not unusual for staff to 
be entering and leaving rooms as a consultation is ongoing 
The MDT does not always make a recommendation for one treatment alone.  At other 
times, the MDT concludes that there is more than one option which could be considered 
as ‘best’ for the patient.  Two treatment options may have similar or equal survival but 
differing side effects and functional deficits associated with them.  One option might be 
seen as ‘better’ with regard to clinical outcomes such as survival, voice or swallow but a 
second option with a different pattern of outcomes and side effects may be regarded as 
being good enough to offer as a second option.   In these situations, the expression of 
treatment recommendation at the end of the MDT discussion is sometimes accompanied 
by a description of how it should be presented (or performed) to the patient in clinic.  
The following data come from the end of the MDT meeting discussion about James 
Cain, who has a large tumour of the voice box: 
Dr Orange:  One question here is, if we give him chemoradiotherapy 
and we can rid of this tumour, which I doubt, am I going to leave him 
with a functional larynx [voice box]? 
MR BLONDE:  And swallowing yes,  
MR BLACK:  His larynx is compromised as it is 
MR BLONDE:  It actually…. If you’re going to have a chance of 




Dr Orange:  If he’s agreeable to that, if he’s not agreeable to that, I 
would regard this as palliation 
MR BLONDE:  Yeah, so I think it’s really from his point of view, if 
he wants…. The advice to him would be the best is to have a very big 
operation, but it’s… 
Dr Orange:  I think if he were to have the operation he needs 
radiotherapy [after the operation] 
MR BLACK:  OK? 
MR BLONDE:  Yep, OK 
Dr Orange:  And if he turns down the operation we can give him 
chemoradiotherapy 
MR BLONDE:  Yep, OK, thank you 




These data show how the MDT decides not only on their performance, but on the role of 
the audience; the rules of how the actors and the audience should interact are clearly 
stated.  The recommendation which would be offered in this case was surgery with post-
operative radiotherapy, and the patient would be given the power of veto over this.  If 
this veto were used, chemoradiotherapy would be offered as a second option.  Although 
the members of the MDT voice the uncertainty associated with the outcome of Mr 
Cain’s swallowing after the treatment, by planning to make clear recommendations they 
potentially obscure this uncertainty in order to deliver a convincing performance to the 
audience
4
.  These data show how the MDT sometimes reacts when there are two 
treatment options which could be recommended, however this is not the only way in 
which the MDT handles this situation.  MDT members may acknowledge that there are 
two options available which could equally be regarded as the best, or perhaps that the 
                                                 
4
 Total laryngopharyngectomy (removal of the voice box and part of the throat) was 
offered to, and accepted by, Mr Cain 
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assessment of which of them is best cannot be made in the backstage area (and hence 
without the patient).  In this position, the MDT has a situation of treatment choice and 
in the following sections, I will discuss how the team manages this. 
6.3 Treatment choice 
The challenges in the assessment of ‘best’ and the difficulties of how to effectively 
involve patients in treatment decisions are most pronounced when there is treatment 
choice.  Clearly treatment choice always exists: patients may choose not to attend clinic, 
or they may refuse the clear recommendation of the team.  When I refer to choice here, I 
refer to treatment choice being offered by the MDT to the patient.  However, in order to 
offer choice, its existence must be acknowledged.  
6.3.1 Acknowledging choice 
If choice is not acknowledged by the MDT it can never be offered to the patient.  The 
MDT acknowledges choice by recognising that two or more options are indeed 
available for a particular patient.  Stanley Wright is an 87 year old gentleman with a 
large tumour of his tonsil.  During the MDT meeting the team decided to give a clear 
recommendation of radical radiotherapy: 
Dr Orange:  Right, so it stops at the soft palate 
Mr Reggie:  T4a…. 
Dr Orange:  Why doesn’t he have any nodes with a tumour this size?... 
What symptoms did he have? 
Mr Blonde:  Just a sore throat, and some difficulty swallowing.   
Miss Salt:  He has had some weight loss, and what have you, so it 
sounds like he’s already losing weight, got swallowing troubles. 
Dr Orange:  Obviously he needs radiotherapy then.  If you actually put 
him in a slot, whoever’s finished first will see him  
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Mr Blonde:  Well it’s T4 N0 M0, as far as we can tell, yeah.  Erm, 
thank you 




In this extract, it can be seen that the team has come to a clear recommendation of 
radiotherapy.  To Dr Orange, this is ‘obvious’ as clearly radiotherapy is the ‘best’ 
treatment to cure this particular grade of tumour in this anatomical location.  However, 
of interest in this extract is the data which is missing.  Radiotherapy can only be 
regarded as the ‘best’ treatment in this case if the aim is to cure the disease.  In order to 
achieve cure the patient has to withstand the risks and morbidity (and potential 
mortality) associated with treatment: radiotherapy will have a profound effect on his 
swallowing and nutrition, and probably lead to a requirement for a feeding tube.  The 
trade-off needed to achieve treatment cure, the risk of treatment effects being 
overwhelming or cure not being achieved may not be acceptable to Mr Wright.  Indeed 
the chance of achieving cure in T4 oropharyngeal cancer in an elderly patient is low.  In 
this way, by not discussing the palliative option, treatment choice is not acknowledged 
by the members of the MDT.  When choice is not acknowledged, it can never be 
offered.  I spoke informally to Mr Blonde after the meeting about why this was the case: 
They discussed an 87 year old with large disease of the oropharynx.  
They decided that he should be treated with radical radiotherapy, 
however looking at the disease, I was doubtful whether this was going 
to be curative, and again I wondered if he should be offered a 
palliative option.  I asked Mr Blonde … he said that the prognosis is 
often so poorly known (as in the data isn’t available), that it is difficult 
to tell what his chances are and therefore whether to give him the 
palliative option 
(Field notes, MDT meeting, Centre A, 2
nd
 February 2012) 
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These data suggest that the reason the prognosis associated with treatment was not 
discussed was because this information was not available 
5
.  There is well accepted 
evidence that one in three HNC patients will die of the disease (DAHNO 2011); the 
difficulty that faces many clinicians is predicting which of any three patients has the 
poor prognosis.  Mr Blonde reacted to this lack of information by treating the patient 
radically; this reaction to the lack of prognostic data is commonplace: 
The best chance of curing someone’s the first chance.  We don’t know 
which third is going to be…. so how do you choose that third [of 
patients who will die of their disease]?.  In the future we may have 
better tumour markers, we may have better co-morbidity marks and 
just basically genetic markers showing how well a patient is going to 
live….  Really, we do not have the prognostic markers on head and 
neck 
(Dr Orange, Oncologist, Interview, 18
th
 May 2012) 
A prognostic marker is a clinical indicator used to estimate the likelihood of success of 
a treatment or the reaction of the patient or the tumour to certain treatments.  These data 
clearly show that Dr Orange feels that the lack of prognostic markers leads him to treat 
more radically.  If he is presented with three patients with HNC, he is therefore unable 
to estimate which of these patients has a poor prognosis.  This, coupled with the belief 
that the best chance of cure is the first time that a patient is treated, drives him to treat 
all three with radical therapy in order to provide the best chance of cure.  However, a 
‘trial by treatment’ approach advocated here means that a lot of patients are treated for 
disease when they are very unlikely to survive the disease or the treatment.  I was able 
to put Dr Orange’s opinion directly to the oncologist at centre C, Dr Goodier, and the 
following was his response: 
                                                 
5
 In the MDT clinic, it was decided to proceed with radical radiotherapy.  Palliative 
management was not discussed 
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Ha ha!  But if you look at the decades of reporting……and compare 
that with the sort of shall we say, the more softer approach, the overall 
five year survivals are not that different.  And in my own experience 
…we can recognise which patients are going to tolerate treatment and 
which are not and our predictions are usually right…if you treat 
aggressively you can see the damage you’re doing and they don’t 
recover.  There still will be one or two patients who we’ve made the 
wrong decision.  We’ve gone for an aggressive, you know potentially 
a curative approach and we’ve regretted it. 
(Dr Goodier, Oncologist, Interview, 18
th
 January 2013) 
Dr Goodier’s views are in direct contrast to Dr Orange, who strives for more concrete, 
perhaps ‘scientific’, markers of prognosis on which he can base decisions. Dr Goodier 
referred again to the emotional effect of pushing patients through radical treatment 
which has a further effect on his treatment recommendations.  These data demonstrate 
how the lack of availability of prognostic information can be interpreted in a completely 
different way by two individuals; this interpretation has a fundamental effects on the 
treatments recommended to patients. 
The data presented so far in this section demonstrate how a lack of prognostic data can 
lead to treatment choice (in particular palliative options) not being acknowledged.  This 
lack of prognostic data is interpreted in different ways by different clinicians, but 
nonetheless if clinicians and patients are not aware of the prognosis of treatment, this 
potentially acts as a barrier to offering choice.  However, this is not the only barrier to 
offering choice: even when choice is acknowledged by the MDT as a group, it is not 
automatically offered to the patient.  In the group setting the disagreement of which 
option is ‘best’ (and hence which option should be recommended) can lead to a unique 
situation where the group acknowledge that treatment choice exists, but there is no one 
individual in the meeting who feel that two (or more) options could be viewed equally 
as the ‘best’.  Mr Vase had a rare tumour of the parotid gland which had been removed 
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surgically. Below, the MDT are trying to decide whether or not it would be ‘best’ to 
give him radiotherapy post-operatively: 
Dr Orange (oncologist):  He’s had quite a lot of tumour manipulation 
as well; I’d give him radiotherapy but…. 
Mr Surton (maxillofacial surgeon):  There was no sense that we 
actually breached the tumour or saw the tumour, it was always 
encapsulated…. 
Dr Orange (oncologist):  Would you keep him under observation 
then? 
Dr Yellow (oncologist): [nods] 
Dr Orange: I think you would cause not really very much morbidity 
[with radiotherapy], it’s so peripheral and so lateral.  So Mr Surton, if 
you want him treated, send him to me, if you want him under 
observation, send him to Dr Yellow 




Here, Mr Surton  asks for advice from Dr Orange and Dr Yellow, the oncologists who 
have attended the MDT meeting that day.  There is a clear difference of opinion 
between the two: Dr Orange feels Mr Vase should be offered radiotherapy, and Dr 
Yellow feels that he should not.  Here, the MDT acknowledges that choice exists: the 
group feel that two options are available.  However, both the individual oncologists feel 
that one option is ‘better’ than the other.  In such a situation, the selected lead may stick 
rigidly to the performance and recommendation decided by the team, and dutifully 
deliver the balanced view of the MDT, or he / she may deliver a recommendation based 
on their own view of ‘best’.  At the time of selecting the lead, it is impossible to say 
how rigidly they will stick to the ‘party line’.  This makes the group’s choice of lead to 
deliver the recommendation to the patient a proxy for the recommendation which will 
be delivered.   
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When choice is acknowledged by the MDT, the choice of lead is not the only problem; 
there is further disagreement as to whether choice should be offered at all  Samuel 
Belton was a 55 year old male with a moderately sized (T2) cancer of the tonsil which 
had not spread to any lymph nodes in the neck.  The MDT discussed the available 
treatment options, and different members felt that two different treatment options would 
potentially be the ‘best’ for him.  Mr Surton (maxillofacial surgeon) felt that the lesion 
could be removed surgically and then reconstructed using tissue from the patient’s 
forearm.  Dr Orange (oncologist) felt that the patient should be treated with radical 
chemotherapy and radiotherapy (‘chemoradiotherapy’).  We join the discussion at the 
point when the two treatment options have been verbalised by the respective 
consultants: 
Mr Surton [Maxillofacial surgeon]:  So shall we see him together 
(Silence 10 s) 
Mr Blonde [ENT surgeon]:  Depends how you put it to the patient 
isn’t it, you know! 
Mr West [Plastic surgeon]:  It’s one of these things, we’ve done this 
before, and you see the patient, and you have two people there, and 
you confuse the patient even more.  I think…. 
Tessa [Clinical Nurse Specialist]:  It’s horrendous, I think it is the 
worst thing you can do for a patient 
Mr West:  I agree.  I think it’s a terrible thing 
Tessa:  Patients just don’t know, they just don’t know what to do 
Mr Surton: But are we not supposed to give the patient choice? 
Mr West:  And if we can’t decide, I think it’s really unfair, I know 
we’ve been here before and we’ve spoken about it, but this is… 
Tessa:  Hey I’ve seen…., you know it’s picking up the pieces 
afterwards, because they’re really cannot make that decision 






This is the start of a lengthy argument in the MDT meeting about whether this treatment 
choice should be offered to Mr Belton and if so, how.  The majority of the conflict 
involves how (or whether) to offer the choice to the patient, rather than specifically 
which modality should be chosen.  The situation is a stark representation of the 
difficulties that the MDT encounters once choice has been acknowledged: the group feel 
that there are two options available, but each individual has a clear view of which of 
these two options is best.  So how should the team proceed?  It is easy to initially judge 
the viewpoints expressed as being paternalistic or over-protective, but in order to 
understand them, they need to be explored further.  The following data extract is taken 
from later in the discussion:  
MDT coordinator:  So you want to see him separately?  See him first, 
and then oncology or…. 
Tessa:  This is where it becomes difficult for the patient 
Mr West:  Yeah, I don’t think we’re doing the patient any favours to 
be honest.   
Tessa:  It traumatises them, they don’t know what to do 
Mr West:  I’ve been in these discussion before, and I don’t agree with 
them, … I don’t think we’re helping the patient… I think we should 
decide what we think the best option for the patient is, we mention a 
different option for treatment, and we say as an MDT, with all of our 
experience we feel this is the best way to go 
Mr Blonde:  …I think with most of these things, your first chance is 
your best, and I think he stands a better chance of getting away with 
less treatment from primary radiotherapy, with consideration of 
chemo.  That’s what I would say.  Tessa, you’re dispassionate if you 
like, in terms of the modality of treatment? 
Tessa:  I’m just…. I’m not bothered about necessarily the modality of 
the treatment, I just don’t think we should be going in there and saying 
you need to decide…. 
Mr Blonde:  No, no, no, I didn’t mean that, I mean if he’s your family 





Mr Blonde:  I think that is right.  I think in this day and age, I don’t 
think you can say to the patient you should have this, and not to allow 
the patient to ask the question is there an alternative 




In this extract, the evidence has been mobilised and assessed by each member of the 
team, and different members of the team have come to different conclusions about how 
to proceed. One is vocalised by Mr Surton “You have a duty to tell the patient what the 
treatment options are” and the other is vocalised by Tessa “I just don’t think we should 
be going in there and saying you need to decide”.  When I interviewed Mr Surton, his 
feelings on the aim of the MDT and the relationship of the MDT with the patient were 
clear: 
I truly believe in our role being one of providing information and 
supporting people in their decision making process...  I think you just 
have to be sensitive to the individual, …The MDT as a concept cannot 
be aware of the subtle things to do with what makes a patient tick, 
what makes a patient happy, what makes a patient feel comfortable.  
We present, really a history, an x-ray, a biopsy and therefore a 
diagnosis and we are offering treatment based upon that, but that 
really isn’t enough to make these important decisions, otherwise we 
could just be using an algorithm 
(Mr Surton, Maxillofacial Surgeon, Interview, 28
th
 May 2012) 
At the beginning of this data extract Mr Surton states his view of the aim of the MDT 
meeting.   He goes on to detail his reasons for these assertions; that the MDT is not 
aware of the more subtle patient factors which affect decision making.  The information 
which is available (mainly clinical information about the cancer) is not enough to make 
a decision in the room on behalf of the patient.  With this in mind, he is stating that 
when choice is acknowledged by the MDT it should then be offered to the patient.  
However, in order to explore the opposite viewpoint, I will present data from Tessa, the 
clinical nurse specialist: 
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I just think the patient is looking to us all the time.  And of course then 
everybody is sort of saying, “Well, it’s not really for us to make that 
decision, it’s for you.  All I can do is give you the information that 
we’ve got.”  And I just think that’s very, very difficult… I always 
worry that if that treatment that they decide then turns out to be 
potentially the wrong decision they could potentially blame 
themselves.  And that’s what worries me, I just think that, that would 
be awful.   
I definitely think we should have an idea as to what treatment we 
offer.  So, I don’t think whether the patient should be told, “We can 
offer radiotherapy or surgery and then the outcomes is potentially 
going to be the same.  But if one doesn’t work then we’ll go on and do 
other.”  That’s terrible and I really don’t agree with that 




Tessa clearly feels that the patient is dealing with the diagnosis and impending 
treatment and should not be laboured with all the work of decision making in addition to 
this.  In the interview, it was difficult to unpick whether this viewpoint stemmed from a 
belief that decisions should not be shared with patients or previous experiences of 
witnessing it being done poorly.  In saying this, she is recognising the anxious situation 
in which the patient is in, faced with multiple experts and with limited time.  The view 
point which she holds is widespread, both by MDT members and patients.  When 
speaking to the patient in question, Samuel Belton, about the situation, he said the 
following: 
From the patient’s point of view having two sets of professionals who 
disagree on something wouldn’t make me feel very good…. it might 
make me say well look can we have another opinion….you know if I 
was put into that situation I would want the medical people to make 
the best decision for me because they would know that 
(Samuel Belton, Patient, Interview, 6
th
 March 2012) 
Here, Mr Belton holds a common stance with Tessa and feels that the members of the 
MDT should make the decision for him.  I will discuss the patient experience of 
decision making in the next chapter, but present this data here to show that the view of 
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Tessa, although it could be interpreted as being paternalistic or over-protective, is 
widely held, even amongst patients included in this research.  Indeed, it is difficult to 
disagree with the argument that patients are in need of support and guidance during the 
time of their cancer diagnosis. The data presented in this section demonstrate that when 
choice is acknowledged by the team, there is disagreement as to whether it should then 
be offered to the patient.  This disagreement centres on whether, by presenting two or 
more options without a recommendation for one, the team are offering choice or 
presenting uncertainty.  In order to explore this further, I will focus on the end of the 
MDT discussion about Samuel Belton.  Of particular interest is the way in which the 
chairman of the meeting, Mr Blonde, achieves consensus within the team, allowing the 
resolution of the discussion:    
Mr Blonde:  I think with patient communication, what you’re doing is 
you should make the patient feel that they can trust you to do what’s 
in their best interests.  And in this situation, you say that the surgery’s 
going to be big, and you’ll have difficulties with it and we, as a team, 
will do our best to look after you through all that.  You could have a 
big operation, but it is a big operation with quite a lot of healing up, 
and it is possible that you could need some radiotherapy after it.  
There is the alternative to have radiotherapy and chemotherapy, but 
it’s unlikely that you’ll get away without significant difficulties with 
your swallowing, and I think it would be unfair not to add that last bit.  
But I think if you put it in that way so the patient feels that they can 
trust the team 
Tessa:  Yeah 
Mr Blonde:  I think when they fall apart is if we say we can’t decide, 
and we don’t know what we’re doing 
Tessa:  Yes, and that’s when it becomes difficult 
Sally [Speech and language therapist]:  That we’re arguing yeah…. 
Mr Surton:  No, I agree entirely with what you say 






In this extract, Mr Blonde emphasises that they should allow the patient to feel that they 
can “trust the team”.   This reframes the problem from one about whether or not to 
present uncertainty to one about instilling confidence and is the linchpin that the whole 
team feel comfortable signing up to.  By advocating that the MDT should instil “trust”, 
Mr Blonde does not address how this uncertainty should be presented in the frontstage, 
but rather how it should be hidden.  Nevertheless, the mention of “trust” gives the MDT 
a common purpose to move forward with.  Importantly he makes it clear that they 
should not present the patient with uncertainty: this is the point which brings wide 
agreement from the team.  It is clear that uncertainty exists: none of the information 
which underpins the decision could be viewed as certain and there are very few, if any, 
‘facts’ which can be seen as undisputed.  It is widely accepted amongst the MDT 
members that patients should not be exposed to uncertainty and equally wide agreement 
that the patient should be given choice, but the two concepts are closely interlinked
6
.   
The data presented provides valuable insight into the backstage behaviour of the actors.  
The conflict presented above about Samuel Belton centres on how the performance 
should be delivered with uncertainty viewed as ‘destructive information’.  Goffman 
(1959) refers to destructive information as  “facts which, if attention is drawn to them 
during the performance, would discredit, disrupt, or make useless the impression that 
the performance fosters” (ibid, page 141).  This leads to uncertainty being kept from the 
audience in order for the performance to be convincing.   In order to explore why 
uncertainty is viewed in this way, I will turn to Mr Halifax, the maxillofacial surgeon.  
                                                 
6
 In the MDT clinic the patient was offered chemoradiotherapy.  Surgical resection was 




I think they need to know there is uncertainty, I don’t think that’s 
unfair. You can say, “Well it isn’t clear cut in your case, x or y or z, 
but we think this, this or this.” I think you have to have the bollocks to 
rank them in order.  I really do not believe it’s fair to say to the 
patient, “We’re quite uncertain, we don’t know what to do, these are 
the options, what do you want?” I mean that is just shit because you’re 
the bloody expert, that’s what they’re paying you for, “What would 
you do?” and you have to be able to say, “I would – if this was my 
mum, that’s what I’d do.” I think they should leave with a degree of 
certainty about their treatment…. that is beneficial psychologically to 
them. And they have to walk away with that.  They can’t walk away 
thinking, “Christ, even the experts don’t know what to do.” That’s 
desperately wrong.  How you’d bring [a patient into the MDT 
meeting]  more, productively – saying, “Here we are, come to the 
MDT, we’ll all bloody – we all shout at each other over the table, 
you’re completely involved from square one.” How’s that going to 
help them? They’re just going to see uncertainty and general larking 
about, which isn’t great.   But out of [the MDT meeting] comes, you’d 
hope, some reasonably….clear decisions and that’s the aim of it I 
think…. What comes out at the end of it is a fairly useful decision 
making order of priorities for the patient that they can then go away 
with. 
(Mr Halifax, Maxillofacial Surgeon, Interview, 5
th
 October 2012) 
In this extract, Mr Halifax links the provision of certainty to his status as a professional 
or expert.  Uncertainty, on the other hand, is seen as not knowing what to do, and is 
viewed by him as something which should be avoided.  At the same time, Mr Halifax 
does not think that it should be a ‘secret’: he clearly says that the patient should know 
there is uncertainty.  This apparent paradox is in part resolved by the effect of 
presenting the patient with a professional recommendation in the face of uncertainty.  
This makes the ‘art’ of the professional to be delivering a reasonable and justified 
recommendation frontstage despite the challenge of uncertainty. This viewpoint is 
widely held, and presents the MDT with a challenge.  The team frequently face 
situations where two options are available, with only the conviction of the various 
individuals around the table separating them.  There is no way of saying, with the 
evidence and expertise available, which of them is ‘best’, partly because of the 
difficulty in defining ‘best’ that I have already discussed.   Whether the team perceives 
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this as a position of uncertainty, or a position of choice is central to how they deliver the 
message to the patient. 
6.3.2 Offering choice 
So far in this chapter I have discussed the challenges that the MDT face when 
acknowledging that choice exists for a particular patient.  However, even when choice is 
acknowledged, it is not always offered to the patient.  Nevertheless, situations do arise 
where the team acknowledge that choice exists and agree that it should be then offered 
to the patient.  In this section I discuss the complexities that the MDT members face in 
offering choice effectively.  As already noted at the end of the MDT discussion, the 
team select a lead to deliver the treatment recommendation to the patient.  The lead has 
ultimate control over how the performance plays out to the audience and thus how the 
recommendation of the MDT is delivered.  Leads usually have a clear individual view 
of which treatment they think is best and this view may be different to the 
recommendation of the MDT.  If the MDT has acknowledged choice and agreed that it 
should be offered, the lead may still feel that one treatment option is ‘better’ than the 
other. Their own views/opinions may shape how rigidly they stick to the MDT 
recommendation, and means that when delivering the recommendation for two or more 
treatment options, the description of the treatments are ‘framed’.   
Framing is when the emphasis of the treatment recommendation is presented in such a 
way so as to provide bias, or at least make it very difficult for the patient to do anything 
other than comply with the lead’s assessment of best.  To demonstrate this, I present 
two extracts, both involving a consultant oncologist talking to a patient about 
radiotherapy.  In the first extract the patient (David Dale) had advanced disease 
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involving the lymph glands of the neck and had a choice between surgery and 
radiotherapy.  The following is Dr Green’s description of the treatment to the patient:   
Dr Green: The first thing that would happen …they would make you a 
plastic mask ….because it’s a very accurate treatment.. …. And then 
when you start the treatment you’re just lying down like as if you’re 
having a scan, wearing that plastic mask. They shine the radiotherapy 
at you. You don’t feel anything. You just lie there and then you go 
home again. …But, the radiotherapy does cause some side effects and 
they can be quite nasty, the side effects. Obviously the aim of the 
radiotherapy is to try and get rid of this cancer and to do that we have 
to give quite big doses of the radiotherapy. And the way it works is, 
it’s a little dose each day and it builds up.  So your skin on the outside 
will start getting red like it’s had a sun burn-type reaction and on the 
inside it starts getting red and inflamed as well. And that means that 
you’ll start having problems like a sore throat and some problems with 
your swallowing… And that means that you’ll need lots of support as 
you go through the treatment. So, you’ll be put on special mouth 
washes and you’ll need to be on pain killers and things to help you 
with that. …. You’ll feel more poorly if you’re not keeping your 
strength up so we would arrange [a gastrostomy] before you started 
the treatment….It’s just a little tube that’s put in your tummy. It goes 
under your clothes and you’d be taught how to use it and you can 
put… They give you special food and you can put medicines and 
things down it as well…. I can’t pretend that it’s anything other than a 
hard treatment because it is a hard treatment….But the aim, obviously, 
is to get you through and out the other side. 
(David Dale, Observation, MDT Clinic, Centre C, 21
st
 February 2013) 
Here Dr Green’s emphasis on the positive aspects of the treatment can be seen 
throughout.  The simplicity of the radiotherapy treatment process is emphasised and 
comparisons are made to previous experiences which are undoubtedly unpleasant and 
difficult, but certainly not overpowering such as “sunburn”, “sore throat” or “feeling 
poorly”.  The rest of the description given also seems positive and non-threatening: the 
verb used for delivering the radiotherapy is “shine”, the treatment is “accurate” the food 
given is “special”.  In addition, each time a side effect is mentioned, the efficacy of the 
treatment, or the support that will be provided to overcome it is emphasised.  Also, the 
statement “… get you through and out the other side” implies that there will be a period 
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of unpleasantness followed by normality on the ‘other side’.  This seems to suggest that 
despite the hardship the patient will encounter, help will be provided, and he will 
probably be cured of his cancer as a result. From the description above, it is clear why a 
patient may agree to proceed with this suggested therapy and this was indeed what the 
Mr Dale did.   
In the second piece of data the consultant oncologist is Dr Goodier, and the patient Gary 
Nicholson, who had a large (T4) cancer of the soft palate but no sign of spread.  He had 
a history of alcohol abuse but was quite young (46 years old) in comparison to most 
patients with HNC.  In the MDT they acknowledged that the recommendation should be 
an offered choice between radiotherapy and best supportive care.  The following is Dr 
Goodier’s (oncologist) explanation of radiotherapy: 
Dr Goodier: To do that, we need to spread it out over six weeks of 
daily treatment. That means you coming up from home, Monday to 
Friday, every day for six weeks with just gaps at the weekend. You’d 
be with us for half an hour or so each day. We would lie you on a 
couch on your back, wide awake and this machine would rotate 
around you and deliver radiation – a dose of radiation – every day to 
exactly the same area for a few minutes. Then you get off the couch 
and off you go, home and you’d come back every day ‘til you’ve had 
30 treatments.  As the treatment goes through, your body starts 
reacting to the radiation that we’re giving it.  We don’t like radiation. 
Our bodies don’t like it. Everything becomes inflamed and sore. The 
outside of your skin and the inside of your throat will all become quite 
red and hot and sore and that’s why swallowing will become very, 
very difficult – probably impossible. Even swallowing your own 
saliva will be impossible by the time you get to the end of that six 
weeks.  And during that time, also, you’re made very tired, 
increasingly tired as you go through the treatment. …. 
The risk is, you know, we could start off with treatment, you coming 
every day. The first couple of weeks you’d probably be okay but as 
this soreness – we’ll call it that – develops, it saps your energy. Even 
the strongest guys struggle, believe me and by the time they get to six 
weeks, life is very difficult; made worse if you’re used to drinking 
alcohol and used to smoking. You have relied on alcohol for your 
nutrition for a long time and to reverse that and then to have the 
protein that you need to heal up… because what happens is, you lose 
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the lining of your throat. All the protection that we have from bugs 
disappears, so infection gets into your throat no problem and you’re 
overwhelmed and that’s what usually happens with guys like you who 
just haven’t got that reserve. And we cause it. We end up putting 
people through this harm because we want to treat to you. We want to 
try and get this better, but sometimes we’ve just got to be sensible I 
think; sit back and say “Actually, is this really going to work and is 
this in your best interests?” 




Here, the striking contrast between the descriptions of exactly the same treatment can be 
seen.  Some of the emphases that are given are quite subtle: the treatment is “spread 
out” and “every day”, a description which sounds more laborious and less simple than 
that provided by Dr Green.  When describing the side effects, the emphasis becomes 
less subtle.  Where Dr Green describes a “sore throat”, Dr Goodier describes 
“swallowing will become very, very difficult – probably impossible. Even swallowing 
your own saliva will be impossible”.  Dr Green describes “poorly”, Dr Goodier 
describes “overwhelmed”.   Also Dr Goodier makes several references to Mr 
Nicholson’s dependence on alcohol which may have shaped his bias away from 
recommending curative radiotherapy
7
.  The comparison of these data extracts 
demonstrates how the description of a treatment can have a fundamental effect over the 
treatment choice made by the patient.  A doctor can offer choice, without ever really 
offering choice at all.  It would be understandable for the patient to choose Dr Green’s 
description, and turn down Dr Goodier’s, and yet both are the same.  Both descriptions 
are also correct – some patients have the experience which Dr Green described, and 
some have the experience which Dr Goodier described.  The main difference between 
the two scenarios is that Dr Green’s description is to a patient whom the clinician wants 
                                                 
7
 Mr Nicholson was managed palliatively 
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to accept the radiotherapy treatment, and Dr Goodier’s is to a patient whom the clinician 
wants to turn it down.  Importantly though, neither doctor is lying, both are informing 
their patients; indeed both doctors may feel that they are giving their patient choice.  
The data illuminate how offering choice consists of far more than describing two 
options and explaining them verbally.  
During my fieldwork I observed many different motivations for framing a treatment 
description.  The lead may be adhering to the agreed performance of the MDT, or may 
be manipulating the performance in order to guide the patient into agreeing with their 
individual assessment of best.  Sometimes they are describing to the patient the 
‘mechanism’ for the MDT recommendation and using framing to explain why an option 
is viewed by the MDT as being unfavourable.  In this way they are describing the 
treatment in order to paint it in a dim light, and hence justify the team’s decision to not 
recommend it.  Sometimes it is done unintentionally or subconsciously, when 
attempting to present treatment options equally, and sometimes it is done to frame the 
treatment in a positive light and hence protect the patient and engender hope. 
Nevertheless, the use of treatment framing is a barrier to offering choice to patients.  
Framing a treatment description does not always lead to a patient agreeing with the 
clinician but the existence and effect of framing must be explicitly acknowledged before 
choice can effectively be offered in the MDT clinic.  The effect of framing is most 
pronounced when discussing palliative or non-curative treatment options as I discuss in 
more detail below. 
Discussing palliation 
I have discussed the influences on the rate of palliation between different clinicians 
previously.  Here, I examine how the way palliation is described is sometimes a major 
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barrier to pursuing non-curative treatment options. The extract below relates to David 
Forcett, a 72 year old patient who had a recurrent cancer which was invading one of the 
muscles of the neck.  Palliative management was briefly mentioned and hence 
acknowledged in the MDT meeting, and the following extract is from the end of the 
clinic appointment, and takes place between Mr Phillips (plastic surgeon) and the 
patient: 
Mr Phillips (Plastic surgeon):  What kind of pastimes do you enjoy? 
Pt: Oh I go fishing 
Mr Phillips:  Fishing, well hopefully many years of fishing to enjoy 
hopefully…so our aim will be to cure you 
Pt:  Right.  Thank you 
Mr Phillips:  And, so as long as you don’t want to give up, we’re not 
going to give up 




Here, the language used to express the prognosis, the expectations of the success of the 
treatment, and palliation is of particular interest.  It can be seen that Mr Phillips 
expresses the prognosis of the treatment in broad terms: “hopefully” and “aim”.  These 
are very general words which do not give the patient any clear indication of their actual 
likelihood of survival.  The use of words such as ‘hope’ and ‘aim’ is widespread in the 
MDT clinic, indeed it is difficult to find examples of where prognosis is discussed in 
any other terms.  The use of these words may be as a result of a paucity of prognostic 
data, but also, both ‘hope’ and ‘aim’ are quite positive words, which are likely to give a 
message that survival is something which should be expected.  Of particular interest 
with regard to offering choice is the way in which Mr Phillips implies that the palliative 
option is to “give up”: this description is beyond framing of the treatment options and 
the words are close to offering no choice at all.  To “give up” implies that if the 
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palliative option is selected, then the patient may be abandoned, with no actual care 
offered.  However, the language used to describe palliation is more complex than this; 
the context in which a discussion takes place is central to whether palliative 
management plans are selected by patients, as I now explore.   
Edward Doman was a 74 year old patient with two synchronous cancers in the 
oropharynx and the mouth.  The operation being proposed to remove the cancer was 
extensive, and likely to require post-operative radiotherapy to achieve cure.  The cancer 
was also invading the bone of the jaw which meant that radiotherapy was not going to 
offer a curative treatment.  Mr Doman attended clinic on three successive occasions; on 
the first two occasions further scans and opinions were required to assess his suitability 
for surgery.  During the third MDT meeting, the team recommended that palliation 
should be offered to him as a first line therapy.  It is important to note that up until this 
point, over successive clinic appointments the focus of discussions between Mr Halifax 
and Mr Doman had been to provide cure.  The following extract is from when this was 
discussed with him in clinic: 
Mr Halifax: My concern as I mentioned to you last time is surgery 
would be very extensive and would still lead on to radiotherapy. 
Radiotherapy…wouldn’t be a walk in the park …and the disadvantage 
of radiotherapy is that we know there’s some bone involvement there 
so they would increase the dose on where the bone is, it would 
probably kill the bone to some degree but surgery would actually 
completely remove it…And we obviously need your opinion as well... 
Any form or treatment to try and completely cure this is going to be 
extremely extensive, do you see what I mean? And I think, as I say 
we’ve discussed this at some length and there may be some merit in 
going for the radiotherapy first to try and control what’s there. That 
was in essence the upshot of the discussion.  
Patient: Could that cure it, my disease?  
Mr Halifax:  Certainly the idea it would certainly delay it. I don’t 
think we could sit here and offer you a cure with any form of 
treatment. That just isn’t...  
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Patient: With any form of treatment? Even the surgery wouldn’t?  
Mr Halifax: I couldn’t sit here and guarantee you a cure with 
anything. That’s just a fact. I would be an idiot to do so. ….And the 
first thought is whether we can try and contain that with radiotherapy 
and see where we are at that point. 
(Edward Doman, Observation, MDT Clinic, Centre B, 15
th
 June 2012) 
In this passage Mr Halifax is offering choice: the first is complete removal of the 
cancer, reconstruction and post-operative radiotherapy.  This is extensive treatment, and 
would have a significant impact on the Mr Doman’s quality of life; indeed the MDT 
doubted whether he would survive this.  However, the surgical option is the only way 
Mr Doman could achieve a cure.  Radiotherapy would not provide cure and would also 
cause side effects, although not as severe as those he would experience during surgery.  
The mismatch between this presumed aim of achieving cure and the treatment of 
radiotherapy means that the consultation was long, drawn out and confusing and Mr 
Doman struggled to accept radiotherapy as a treatment option.  Importantly, Mr Halifax 
was not dismissive of the palliative option at any point but despite this, the patient had 
difficulty in accepting it.  At the conclusion of the consultation, Mr Halifax felt that Mr 
Doman should speak to the oncologist, as he felt that the source of the confusion was 
the details of the treatment itself.  However, during this meeting, the same confusion 
arose again: 
Pt:  I did get the impression that Mr Halifax thought that radiotherapy 
would be the best way to go 
Perdy (Clinical Nurse Specialist):  But the radiotherapy would not 
cure you of the cancer 
Pt:  So what would it do, the radiotherapy, would it just delay it? 
Dr Strong: It may slow the progression of the cancer 
Pt: But it couldn’t cure it? 
Dr Strong: No 
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Perdy: No, it won’t cure it.  The cancer’s gone into the bone, and 
radiotherapy doesn’t work very well when the cancer’s in the bone 
Pt: It is in the bone is it, the cancer? 
Perdy: Yeah.  
Pt: Then the only chance I’ve got is to go through the operation isn’t 
it….It’s the only chance I’ve got? 
(Edward Doman, Observation, MDT Clinic, Centre B, 15
th
 June 2012) 
In this passage the focus of the discussion between the MDT members and the patient is 
on curing the cancer.  Mr Doman is not aware that the key difference between the two 
options is that surgery provides some (albeit small) chance of cure, whereas the 
radiotherapy provides none.  If the aim of the discussion and treatment was more 
explicit, this would provide the clinician and patient with a foundation for palliative 
decision making.  However, because the aim of the treatment has not been made explicit 
or discussed, Mr Doman presumes both treatments are with the aim of cure.  Dr Strong 
realised that the patient’s aim of treatment did not match the treatment which was being 
offered, and so Mr Halifax was invited into the room to resolve this: 
Mr Halifax:  So we are trying to preserve as much as what you have 
already got for as long as possible, given the extent of the cancer that 
you’ve got.  And that’s why, on balance, it’s not a question of “Can 
we do an operation”.  Yes you can do an operation; you can always do 
an operation, but is that going to be of any great benefit to you? 
Pt:  That’s what I’m worried about 
Mr Halifax:  And that’s what I’m worried about, because I’m not sure 
it is….So as I say, you are going to send an inordinate amount of time 
in hospital recovering from your surgery and going through 
radiotherapy.  Whereas the design of the radiotherapy that is proposed 
which is essentially to shrink the tumour and keep it at bay for as long 
as possible, will keep you doing as you’re doing for as long as 
possible…. It’s not going to cure you, but neither am I.  But given the 
fact that neither of us are saying that we can cure you, we are then in 
the situation where we need to try and keep you going doing whatever 
you are doing for as long as possible. 
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Pt: So the radiotherapy from now on will be the best bet, really, 
that’s what you’re saying? 
Mr Halifax:  So therefore it’s: do you have a big operation and spend a 
lot of time in hospital, potentially, if we looked at the next 6 months or 
a year or however long, how much percentage of that time are you 
going to spend in hospital, with an operation and radiotherapy to 
follow, it’s going to be a heck of a lot of it.  With radiotherapy which 
is basically designed to shrink the tumour and keep on top of the 
symptoms, you’re going to weather that a lot better and spend an 
awful lot more time doing whatever you’re doing at the moment.   
(Edward Doman, Observation, MDT Clinic, Centre B, 15
th
 June 2012) 
These data demonstrate Mr Doman shifting towards an acceptance of palliative 
management once the aim of the treatment is made clear.  With the statement “to try and 
keep you going doing whatever you are doing for as long as possible” Mr Halifax is 
shifting the aim of treatment from cure to preservation of quality of life.  At the start of 
the clinic discussion, the assumption of Mr Doman was that cure was the aim of 
treatment: in that case, palliation will always be seen as failure.  These data highlight 
that the aim of the treatment must be absolutely explicit for effective decision making, 
especially when discussing palliative options.  Not only this, but when the aim of the 
treatment is clear, the care that is available to the patient in order to carry out the 
palliation can be openly discussed.  This converts palliation from a passive process of 
‘not treating radically’ to an active process of caring for a patient with non-curative 
interventions.  Making the aim of treatment clear is not only to inform discussion of 
palliative management plans but also to help inform assessments of which treatment is 
considered ‘best’.   It is difficult to conclude from this data why the aim of the 
discussion was not clear: it may reflect an unwillingness or reluctance to discuss 
palliation.  Nevertheless, if the aim of the treatment is always assumed to be cure, even 
if the words used to describe palliation are positive, the non-curative option will always 




The purpose of the MDT discussion is to come to a recommendation of which treatment 
is ‘best’.  This assessment is difficult to make as many aspects of treatment outcome 
may be considered to alter an assessment of best such as survival, lifestyle or function.  
In order to decide what is best for a patient, information is required about what the 
patient’s wishes are, what is important to them and what their aim is for treatment.  The 
MDT faces difficulty in incorporating information of this nature into the backstage 
MDT discussion.  Not only this, but even when this information is available in the 
backstage (as I discussed in Chapter Five), the MDT members have difficulty 
incorporating it, meaning the resultant recommendation cannot adequately take it into 
account.  In order to involve patients the aim of the MDT discussion and the 
unavoidable limitations of the MDT recommendation must be clear to MDT members 
and patients.  Although this only strengthens the argument for a central role for the 
patient in HNC decision making, how this should be enacted in practice remains a 
challenge.  I will continue this analysis by describing how the treatment 
recommendation is used by the patients and clinicians to make a treatment decision in 
the next chapter.   
Once a recommendation has been made, the nature of the interaction between patient 
and MDT member, and the effect that this interaction has on the final decision reached 
must be understood.  Framing is commonplace, and acts as a barrier to patients being 
allowed real opportunity to build in their own values and preferences into a decision.  
Also, the aim of the proposed treatment is not always clear, leading to an inhibition of 
the decision discussion, especially with respect to palliative decisions.  Thus, in order to 
present choice effectively, more than a mere verbal description of two treatment options 
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is required. The aims of the proposed treatment and the effect that this has on the 
decision made must be recognised.  The MDT must understand how to effectively 
engage patients in this interaction in order to conduct a fair discussion of the options 
available.   
The challenges in the assessment of ‘best’ and the difficulties of how to effectively 
involve patients in treatment decisions are most pronounced when there is treatment 
choice.  If choice is to be offered in the MDT setting, the complexities of 
acknowledging and offering choice must be explicit and understood.  To offer choice is 
sometimes to expose the uncertainty underpinning a recommendation to a patient.  
Although uncertainty is often seen as ‘destructive information’ which should be kept in 
the backstage, it could equally be used as an opportunity to acknowledge and 
incorporate the preferences and values of a patient.   In this way, the presence of 
uncertainty could provide a basis on which patients build in their own opinions and 
views to a treatment recommendation in order to form a treatment decision which takes 
them into account. 
If the MDT is to involve patients in decisions the limitations of the recommendation, the 
effect of the interaction with the patient and the uncertainty associated with treatment 
choice must be recognised.  However, even if patients are offered choice effectively, 
this does not mean that they are involved in decisions about their care in the MDT.  In 
order to further understand how we can involve patients we must gain an understanding 
of the perspective of the patient and the way in which a patient makes a treatment 
decision.  Only by understanding this can the team facilitate the process of patient 
engagement and then support choice, after it has been offered.  In the next chapter I 
shift the emphasis of the analysis away from the team and towards the patient.  I explore 
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further the way in which choice is seen and dealt with by the patient, and highlight 
further the challenges that the healthcare team and the patient face together in making 




Chapter 7: Enabling Patient Involvement 
The analysis in previous chapters has concentrated on how the MDT negotiates and 
delivers a treatment recommendation. In this chapter I move the focus of my analysis to 
consider how a patient makes a decision within the current MDT care pathway.  To 
conclude the chapter I outline how MDT decision making could change, so that the 
perspective of the patient becomes an integral part of the structure of the clinic. 
A diagnosis of HNC presents patients with treatment options which will have a 
fundamental effect on their appearance, swallow, voice and survival.  The available 
treatment options are often complicated with complex changes to the anatomy of 
breathing or eating, or grafting of tissue from one part of the body to reconstruct 
another.  The complexity of the decisions being made often leads patients to turn to the 
members of the MDT for support and guidance.  The following data is from Eric 
Francais a 65 year old patient with a cancer at the top of his larynx: 
Pt: You know, they’re the doctors, they’re the professional people. 
And I’m just Joe Bloggs off the street. Well, let’s face it, they’re the 
people…who know.  I mean, for a lot of years, I was a steel erector.  I 
wouldn’t expect you as a doctor coming along and doing what I could 
do. Do I?  I mean, you’re the people that know how to do the job and 
what to do. 
DWH: You feel a decision should be the doctor’s decision? 
Mr Francais: Oh, definitely, without a doubt. It’s got to be the 
doctor’s decision. How could I make a decision like that? 
(Eric Francais, Interview, 29
th
 June 2012) 
In this extract Mr Francais acknowledges that his own area of expertise is far removed 
from the world of medicine and therefore he cannot have responsibility for the treatment 
decision.  In this situation this has led to him delegating the decision to the MDT as to 
him, decision making is an expert process.  Although this does not mean that Mr 
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Francais is disengaged from the decision making process, it means he is allowing the 
assessment of ‘best’ performed by the MDT to act as the basis for his treatment 
decision.  The view expressed by Mr Francais is widely held by patients included in this 
study, which endorses and perpetuates a sometimes paternalistic viewpoint which is 
expressed by MDT members: 
I think one of the questions is, is shared decision making the right 
model for head and neck cancer?  And it may not be…..I think it’s not 
the right model for head and neck cancer.  I suppose what we’re doing 
is informed benign paternalism.  Paternalism again has got negative 
connotations and it doesn’t necessarily always need to have, in that 
you know a real father will look after a three year old child and stop 
them running into the road and stop them sticking their hand in the 
fire….that is paternalism but it’s not necessarily  bad  I think.  [The 
MDT] is good for reaching a decision for what’s the best treatment for 
a patient and then it’s up to the patient to either accept that or turn it 
down. 
(Dr Orange, Oncologist, Interview, 18
th
 May 2012) 
Dr Orange uses the concept of shared decision making to talk about patient involvement 
in the broader sense.   He not only states that he feels shared decision making is not 
happening in the MDT decision process at the moment, but makes the assessment that 
shared decision making is something which should not happen in this disease and 
setting.  Through the course of his argument he highlights that paternalistic decision 
making, in some form or another, is a viable alternative.  The scenario he provides, of a 
father protecting a 3 year old child, presents an irrefutably ‘good’ application of 
paternalism.  However, it also implies a similarity of relationship between doctor/patient 
and parent/child which reinforces the opinion of ‘doctor knows best’.  Nevertheless, the 
acceptance of the complexities of the disease and decision making in this setting, could 
justifiably lead any observer to the same conclusion, as the following entry from my 
reflective diary highlights.  This entry was made after I observed a maxillofacial 
surgeon attempting to involve the patient in a decision about how to treat a small cancer 
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on his lip.  The surgeon had offered treatment options of surgery or radiotherapy to the 
patient, but had offered no support to help him to make the decision.  Also, he had used 
various verbal and non-verbal cues to bias the patient in favour of surgery.  The patient 
and his wife left the clinic room far more anxious than when they entered it: 
There was an imposition of the SDM [shared decision making] model 
on the paternalistic model, ending in the worst features of both.  I left 
[the observation] with the distinct feeling that [the surgeon] should 
either share the decision properly, or not at all – to do it poorly is more 
destructive to the patient than taking a paternalistic approach.  To take 
a paternalistic approach is not necessarily ‘wrong’.  When reading the 
transcripts, researchers in healthcare are not able to understand some 
of the nuances of the decision, so how should a patient be expected to?  
Is it right …. to dumb down the decision, or make the options more 
simple and straightforward (and therefore perhaps falsify them) in 
order just to ‘tick the box’ that you have shared the decision?  It 
should not be assumed that SDM is what ‘should’ happen in this 
setting …. perhaps SDM is not the way to go forward. 
(Field notes, MDT clinic, Centre A, 8
th
 December 2011) 
This is my reaction to observations of MDT members attempting to involve patients in 
decisions.  I worried that involving patients in these complex decisions was potentially 
an impossible task, and concluded that paternalism was the safest way of making 
decisions.  I would emphasise this is not the view which persisted throughout the course 
of this work, but present the data to demonstrate how taking part in, or observing the 
MDT decision process in this disease can and does sometimes feasibly result in this 
conclusion.  To agree that this is the way to proceed with decision making in the MDT, 
is to accept that the recommendation made as a result of the MDT discussion should be 
accepted by the patient, and hence converted directly into a treatment decision. This 





In this simple model of decision making, the recommendation comes directly from the 
assessment of ‘best’ from the team, based on expertise and current evidence.  In this 
model, the patient accepts that the MDT’s assessment of best is accurate and thus the 
recommendation is representative of their aims for treatment.  Arguably, this model of 
decision making is well suited to the MDT structure of working.  The paternalistic 
model accepts that there are parts of the decision making process which are less 
accessible to patients: in the MDT meeting the clinical information is mobilised 
backstage, negotiated and combined with other evidence to decide which treatment 
options are available.  The patient can have little role in this step unless they have 
expertise in HNC.  However, the paternalistic model has limitations in its utility in 
MDT decision making.  I have discussed previously how to accept the recommendation 
of the MDT without question is to accept that the assessment of ‘best’ can be made in 
the backstage.  In previous chapters I have discussed the significant problems with this: 
the backstage recommendation is based on the ‘evidential patient’ and the various MDT 
members’ interpretations of the relevant research and experience available to them.  
MDT members have difficulty in incorporating information other than the clinical 
details of the cancer into the ‘evidential patient’ and thus into the recommendation: the 
resultant ‘clinically best’ recommendation cannot adequately incorporate the values, 
preferences and opinions of the patient.  The MDT recommendation is sometimes based 
on considerable uncertainty, and the presence of treatment options may not have been 




acknowledged or offered by the team.  This model also awards no role to the patient 
apart from the Parsonian ‘sick role’ (Parsons 1951): accepting the recommendation of 
the doctor.  In order to better understand the role of the patient in the MDT decision 
process, and to further explore the limitations of the paternalistic model of MDT 
decision making, I shall begin to describe the process through which a patient makes a 
treatment decision.  Jean Dixon is a patient who had a cancer of the base of the tongue: 
Husband: It’s lack of experience.  I mean really, we don’t really know 
what cancer is any road  
Pt: Well I do, as my mam died of cancer. 
Husband: Yeah, but we’re not people that have had it….We don’t 
really understand it.  It would be better…  from our point of view if 
we didn’t have the choice…Everything’s brand new so we can’t 
really, you can only judge things from experience and we don’t have 
the experience… 
Pt: Yeah, it was [hard to make the decision].  I mean I still keep 
thinking “Have I done the right thing?”. … He said I didn’t have to 
[make the decision] straight away, I could think about it.  But if I had 
come home I still wouldn’t have known 
(Jean Dixon, Interview, 2
nd
 July 2012) 
Mr and Mrs Dixon have had family members with cancer, however they recognise that 
this experience is not applicable to their current decision.  In recognising this they were 
left with nothing to draw upon, and hence they were struggling to have any active role 
in the decision.  Their reaction to this was to search for a recommendation from the 
surgeon and even to wish that no choice had been offered.  During the decision 
consultation, this delegation of the responsibility for the decision could easily be 
interpreted by the clinician as an endorsement of the paternalistic model.  These data 
reveal how their delegation of the responsibility for decision making was a reaction to 
the disempowered situation in which they found themselves, with nothing to draw upon 
to help them to take part in the decision making process..  Although patients may 
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justifiably actively delegate some or all of the responsibility for the decision to the 
MDT members, at the same time, the MDT have a duty to ensure that this is not due to 
disempowerment as demonstrated here.  However, patients do not always discard their 
existing knowledge, experience and opinion in the MDT clinic.  John Winton was a 61 
year old patient with a large cancer of his larynx; when the MDT examined the CT scan, 
it appeared that the laryngeal cartilage was being invaded by the cancer, which 
identified the cancer as T4.  As the tumour was so invasive, the MDT decided that a 
single recommendation of total laryngectomy should be delivered to the patient in 
clinic.  The following is data from this appointment: 
Mr Black (ENT surgeon): This tumour in your throat is a fairly big 
tumour, and it’s spread to the neck as well.  And we had a to and fro 
discussion at the multidisciplinary team meeting.  We believe that 
there are two possible ways that we can manage this.  At some parts of 
the scan, there is evidence that the tumour may have gone into the 
Adam’s apple cartilage.  It’s not entirely certain, but it looks like it.  If 
that is the case, surgery would be the only option to get rid of the 
tumour.  But surgery would involve you losing your voicebox, losing 
part of the swallowing passage, you would need a big neck operation.  
We’ll take some tissue from your forearm, and use it to reconstruct 
your throat.  Once we do the surgery, your speech will be different, 
you won’t be speaking the same.  You will have a hole in the centre of 
your neck, a tracheostomy 
Pt:  Nah, nah [shakes head] 
Mr Black:  You wouldn’t fancy that? 
Pt: No 
Mr Black:  That’s the surgical option.  On the other side is the option 
of radiation therapy 
Pt:  I would rather take a chance with that 
Mr Black: The only concern with the radiation we have was, where I 
mentioned on the scan, where the Adam’s apple is slightly…. 
Pt:  Aye 
Mr Black: With the tumour, if you have radiation, radiation doesn’t 
nicely tackle when there is tumour inside the cartilage.  So when that 
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happens, your tumour may not completely go away.  You will be left 
behind with a bit of tumour, and you may still need surgery after that 
Pt:  I’ll take a chance with the radiotherapy and progress from there  




At the start of the extract, Mr Black mentions that there are two options for treatment, 
despite the recommendation of the MDT being that only total laryngectomy should be 
offered.  As I discussed in Chapter Six, presenting two options and then outlining why 
one was recommended rather than the other was a common method of delivering the 
treatment recommendation to patients.  In the extract above Mr Winton took control of 
the consultation by clearly stating that he did not want surgery and he would rather 
“take his chances” with radiotherapy.  In doing this, he made a decision to reject the 
recommendation of the MDT.  Mr Winton was adamant that he did not want a total 
laryngectomy throughout the consultation, and eventually the treatment decision was 
made to instead treat the cancer with radiotherapy.  In the paternalistic model of 
decision making, if a firm treatment recommendation is given to the patient they usually 
accept this recommendation.  However, a problem arises for this model when the patient 
becomes an active participant in the decision process rather than a passive receiver of 
the recommendation.  Few would disagree that patients should be allowed to participate 
in their decision in this way; indeed, it is not possible to perform a treatment on a 
patient if they refuse it.    When I interviewed Mr Winton, we discussed the rationale for 
his decision:  
Pt: Well you see my mother died of cancer… my father died of 
cancer, and I’ve seen the way cancer works.  I’m not being cheeky, 
and I’m not being horrible once they cut you open, it’s like your 
letting fresh air into a bulb, it then just spreads, and they stitch you 
back up again and “We’ve cured it”, right, for how long?  And then it 
comes back again… 
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DWH:  And what’s important to you when you’re making that 
decision?   
Pt:  Surviving as long as I can…, I mean if you get the year, 18 
months it’s better than getting two weeks isn’t it? 
(John Winton, Interview, 5
th
 March 2012) 
These data provide insight into some of the thought processes which guided the decision 
processes for Mr Winton: his work of decision making.  In the case of Mr Winton, the 
basis of this work was his experiences of relatives’ cancer.  At the time of the clinic 
appointment this was the only information which he had available to draw upon to make 
his decision.   Although this information is personally relevant, it is not clinically 
relevant to the situation in which he finds himself; as a result of this his aim of treatment 
(cure) potentially did not match his treatment decision (radiotherapy).  If patients are to 
become active participants in the MDT clinic, this work of decision making needs to be 
acknowledged in the decision process.  If this work is not acknowledged, this does not 
mean that it does not take place; instead, patients perform the work based on limited 
experiential information.  Alternatively, as demonstrated in the next data extract, they 
perform it after the decision has been made.  Keith Down was a 62 year old with a 
recurrent cancer of his larynx.  In his MDT clinic appointment a recommendation for 
partial laryngectomy (removal of part of the voice box) was made and accepted by the 
patient.  The following week, the patient returned to clinic with his sister as his family 
had doubts about whether it was the best decision for him: 
Pt: And my daughter didn’t agree with that about having the thing in 
your throat [surgery] and I said, as I said to you on Friday, if that’s 
better, the more chance and everything… and she says “Oh we don’t 
want this”.  And they got talking to each other and everything and…. 
It’s just what they’re thinking, and they’re talking to different people 
and everything 
Sister: Will he get his voice back? 
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Mr Black: Yes, he’ll have voice, he’ll have a serviceable voice, but his 
voice will be something like this [whispers].  It’ll be a strain initially.  
Patients tend to do differently; we have one or two who are doing 
fairly well 
Sister: Will it stay like that?  Or will it get any better? 
Mr Black: It will stay like that, yes. 
Sister: And does he have to ... have a tube in for a long time? 
Mr Black: He’ll have a tube to feed for about six weeks I reckon.  
That’s the average among these patients. 
(Keith Down, Observation, MDT Clinic, 15
th
 March 2012) 
Mr Down attended the previous clinic appointment alone.  On returning home he had 
discussed his decision with his sister and two daughters who raised concerns about the 
decision and ordered Mr Down to return to clinic.  In clinic, the surgeon was able to 
address the family’s questions, and eventually the same treatment decision was made as 
the week previously.  These data demonstrate that this work of decision making still 
takes place, even if the MDT structure does not make provision for it.  The opportunity 
to report the results of their work to the MDT clinic was something which was 
beneficial for his family: 
Sister: Well he went himself, and his daughter rang me and she said 
“Well I’m not very happy about this”, and I thought here we go 
again… I had… got myself wound up, and I was crying, and I felt as 
if …. I didn’t understand, and I said to Keith, I don’t understand, can I 
come with you?  Do you really know what you’re doing?.... I thought 
that maybe …he had closed up a little bit and he was just going for the 
operation because it was easier….but no, I heard what the doctor said, 
…. I’m happier now, and I can go back, and I can tell the daughters…. 
I phoned them up and I said, no, I says he’s going for the best option 
DWH: And what are his daughters like now? 
Sister: Alright, she said as long as we know that there was somebody 
there, and you’ve heard clearly what they’re saying you know.  And I 




other family as well, he’s got a brother and sister who live in 
Thailand, and it’s just been so hard. 
(Keith Down, Interview, 22
nd
 March 2012) 
Here, Mr Down’s sister describes how the patient reported the decision to his family 
and they had expressed concern about whether the choice of treatment was ‘best’ for 
him. It demonstrates a picture of ‘relational autonomy’: a view that humans are not self-
sufficient and independent and instead generate autonomy through interaction with 
others (Keller 1997).  Hence Mr Down and his close family discussed and negotiated 
what was ‘best’ for him amongst themselves.  Rapley (2008) described how patients 
enact relational autonomy by distributing their decision across people, encounters, 
situations and technologies.  Hence decision making is not a one off episode, but a 
process in which patients make decisions over a range of encounters, rather than just 
one.  In this way, Mr Down does not complete the work alone; he involves those around 
him.  They had little to base this discussion on and this led to anxiety about whether he 
had made the ‘right’ choice, and unanswered questions about alternatives.  In this case, 
a concerned family requested a further appointment to report back the results of this 
work, and clarify the decision.  However this would not always be the case; in some 
cases this patient work of decision making may come to a conclusion which agrees with 
the decision made, in others the work may change the decision and in others again it 
may lead to doubt and anxiety for the patient and their supporters.  Nevertheless, the 
MDT decision process cannot ignore this work: it is required for the patient to construct 
treatment preferences and hence is an essential part of involving patients in treatment 






By building the patient work of decision making into the MDT decision process, this 
model includes a step in MDT decision making that a patient can have a central role in  
As I have demonstrated, this work is often based on prior experience or knowledge and 
can have a significant effect on the treatment decision made.  Thus the model introduces 
two processes which contribute to the formation of a treatment decision; that of the 
MDT and that of the patient.  Importantly, acknowledgement of patient work is only the 
first step toward inclusion, and is not in itself sufficient for patient involvement.   The 
patient process needs to be incorporated into the MDT pathway, rather than just 
acknowledged.  In this section, I will show data to demonstrate how the MDT can 
ensure that this work is worthwhile, relevant to the decision being made and 
coordinated with the MDT process.   
To facilitate the patient work, we need an understanding of how, where, when and by 
whom it is performed and an acceptance that this may vary between individuals and 
Figure 4: building the patient work of decision making into the clinic structure 
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over time.  To begin, I will turn to James Matfield who, despite the constraints of MDT 
decision making, was given the opportunity to become involved in the decision.  Mr 
Matfield was a 70 year old patient with a large cancer of the voice box who had been 
offered a choice of radiotherapy or total laryngectomy. Radiotherapy would affect his 
swallow function and may mean that he needs tube feeding in the short or long term.  It 
would also involve six weeks of daily travel to the hospital for treatment, but would 
allow him to retain his voice box and therefore his voice (although his voice would be 
hoarse as a result).  Total laryngectomy would involve a two week stay in hospital; the 
effect on his swallow would be potentially less, however he would breathe through a 
stoma in the neck and his speech would be affected as a result.  In addition to this, 
having surgery involves being admitted as an inpatient, but radiotherapy is usually 
performed as an outpatient.  He attended the clinic appointment with Mr Cove (ENT 
surgeon) and Dr Green (oncologist) to discuss the decision.  Mr Matfield had the choice 
of two options, and Mr Cove and Dr Green had not made a firm recommendation for 
either.  At the time of the appointment, Mr Matfield was very keen to make the decision 
on the day of the clinic appointment: 
Pt:  I like to make my decision straight away. 
Dr Green (oncologist): Yeah, but it’s a big… It’s a life-changing 
decision and you don’t want to just make a snap decision and then 
regret it either. 
Mr Cove (ENT surgeon): I think it might be beneficial to come back 
next week. 
Pt:  You see, my wife …  I’m going into hospital for a fortnight, 
leaving her alone in the place, like  
Wife: Either way, you’re… you know. 
Pt: I know, but I’ll be coming back on the night-time, like. 
Wife: I know you will. 
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Mr Cove: There’s a lot going…. 
Pt: The chances are I can keep my voice? 
Mr Cove: I think you’ve got a lot going on in your head. Okay? I 
really think this is such a big decision that you should go away and 
have a week … and think about it. 




Mr Matfield was very keen to make the decision in the clinic room, but, as 
demonstrated, Mr Cove and Dr Green felt that he needed more time to weigh up the 
options.  Despite the protestations of Mr Matfield, the clinicians strongly discouraged 
him from making the decision that day.  They arranged for him to have a separate 
discussion with the clinical nurse specialist, during which she reiterated the decision to 
be made and made clear what his role should be.  She also provided further information 
for him, and arranged to ring him during the week to ask if he had any questions.  They 
arranged for him to be seen again in clinic, in a week’s time, and organised the 
ambulance transport for him and his wife to travel to this appointment.  In this way, the 
team almost forced Mr Matfield to take time, talk to others, find out more then make his 
decision; this is something he later told me he appreciated: 
Pt:  And then when he says to give yourself a week to make the 
decision, which was a good thing because I was going to make it there 
and then…. and to come back and really think about it and read…. 
everything about it again. It gave us time to think. And I decided, if I 
can save me voice box rather than have the stud thing in your neck, 
I’d rather have it, try the radiotherapy first. 
DWH: So you found that week valuable? 
Pt: Yeah, yes I did, really. And very, I thought the doctors were great 
and all, very good. 
DWH:  What did you do during that week? 
Wife: Well you read through the book didn’t you? 
Pt: Aye, I read through the books yeah. 
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Wife: And we talked about it. 
Pt: Yeah, and I had a good talk with you. 
Wife: Asked the family. 
Pt: Asked the whole family what they thought.   And they said it came 
down to my decision. But our [daughter] said, “Dad, if you can save 
your voice box and that, you know, to try and save it.” And hopefully 
they can. That’s all I’m hoping for now.  
(James Matfield, Interview, 4
th
 March 2013) 
In this situation the MDT had acknowledged that there were treatment options for Mr 
Matfield and agreed that these options should be offered in the clinic by Dr Green and 
Mr Cove.  Mr Cove and Dr Green felt that he should be offered more support.  Hence 
the extra time and support that Mr Matfield was afforded was not due to a particular 
MDT or treatment decision, but rather the specific clinicians that he happened be 
seeing.  The clinicians acknowledged that the patient work of decision making needed 
to take place and facilitated this work by giving him information, support from the CNS 
to ask questions, a geographical area outside of the clinic room to consult with family 
and time in which to perform the work of decision making. The data reveal more detail 
about how this work is done and reinforce that for the patient, much of the work of 
decision making may not be done in the clinic room, but rather it is done outside of it: 
[Mr Cove] says, “No, no, this is my advice, you away and think about 
it.” And that was good advice he give us because when I come back 
home and I read everything again and that, I said “I’m pleased Mr 
Cove said to go away”.   I read [the information] again [and] I made 
my decision then within about two days. I’d made my decision after I 
spoke to the family and everything. So yeah, that was good. 
(James Matfield, Interview, 4
th
 March 2013) 
It could be argued that Mr Cove behaved in a paternalistic manner by strongly 
instructing Mr Matfield to engage with the decision in this way; nevertheless Mr 
Matfield was “pleased” to be afforded this opportunity.  Importantly, the structure of the 
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decision making process in Mr Matfield’s case meant that when performing the work, 
the decision was still his to make.  Hence he had the opportunity to use this work to 
contribute to the final decision, rather than justify a decision already made.  He 
discussed the decision with other people, and valued the opportunity to consult with his 
wife and other members of the family.  The information was interpreted by the patient 
in the light of his own values and preferences; in doing so he sought to gain an 
understanding of the effect of the treatment options on his daily life and his relationship 
with others: 
And the, the worry I had is, if I was going to get admitted to hospital 
me family were going to have to travel to get there …. And I might 
not see anybody, ‘cause [my wife] doesn’t drive. So she would have to 
rely on our children coming up here to get her, to get her and fetch her 
down to hospital, probably. That was the other worry to me than most 
things.  But then, with her being on her own… but obviously it’s not 
going to be that way ‘cause I’ll be brought back every night and 
whatever for the chemotherapy. And that was one of the other 
decisions why I had my other decision too because I was going to be 
admitted to hospital. 
… 
Except, of course, me voice is never going to be the same, and it’s that 
me voice will never get back to normal.  I mean, I know it’s nice to 
have your voice you’ve had all your life, but it had to change, it’s just, 
at least I’m not, the main thing is I’m not going to die. 
… 
The longer I live the better because I love life and I love to be, like, 
this morning walking through the fields seeing the deer and things, 
that’s the sort of thing I like. And I like nature and that, I love fishing. 
I like me fly fishing, you know. I just hope I can continue with that.  
(James Matfield, Interview, 4
th
 March 2013) 
These data are taken from different points in the interview, but show that Mr Matfield 
had different pieces of information available to him, and placed a different importance 
on each of these.  Mr Matfield weighed up the trade-offs he had to make, but at the 
same time incorporated them into his own way of life.  In the clinic room, the common 
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considerations are survival, swallowing and the presence or absence of the voice box.  
The data show that Mr Matfield’s quality of life was not necessarily linked to his voice, 
but instead to his ability to be there for his wife, walk in the countryside or fish, all 
pursuits which arguably are not reliant on the presence of a voice box.  He lived in the 
countryside and therefore the practicalities of the actual treatment were important such 
as the availability of transport to the hospital or the working arrangements of his 
daughter. Thus the preference of whether or not to keep the voice box was included in a 
hierarchy of other considerations.  In the clinic room, some statements included in the 
above data extract could be interpreted by the clinician as meaning that Mr Matfield was 
willing to lose his voice box to achieve cure.  However, through the course of 
performing this work, other considerations (such as caring for his wife) were 
considered, by him, to be more important.   Nevertheless, in the clinic appointment, the 
decision was reported as one being dependent on the presence or absence of the voice 
box: 
Mr Cove: And, so, we, we left you with some difficult thoughts. 
Pt:  Yes you did. 
Mr Cove:  Are you glad you had the week to go..? 
Pt:  Yes I did in a way ’cause I read through them both again and then 
I decided to take the radiotherapy. 
Dr Green: Okay. 
Pt: If it saves me trying to save some of my gear up here like - like, 
you know? 
Mr Cove: Yes…You could, you could do either, but you’re right. If 
you want to have a chance to save your voice box- 
Pt: Yes I do, yes. 
Mr Cove: We’ll not take it out. 
Pt: It’s worth taking the chance. 
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Mr Cove:  Yes, exactly. So, I think that’s, I think that’s entirely 
reasonable. That’s very good 




These data demonstrate a brief confirmation of Mr Matfield’s treatment decision as well 
as reassurance from Mr Cove.  The rest of the clinic appointment was a discussion of 
the practicalities and risks of the treatment which lay ahead.  These data extracts 
provide valuable information about the work of decision making for patients, and how 
they incorporate facets of the decision into their own worldview and circumstances.  
This data is not intended to show how much importance Mr Matfield placed on his 
voice box, rather that by being given the opportunity to perform the patient work, he 
was able to place it in a hierarchy of other considerations.  They also present a new 
backstage area: the patient’s backstage. The actors in this backstage are the patient and 
their family or supporters and the setting is outside of the clinic room, in multiple areas 
including the patient’s home.  The actors use the information available to them, and 
negotiate its importance amongst themselves.  At the clinic consultation, Mr Matfield 
and his wife present a team performance with the clinicians as the audience members; it 
was a short confirmation that he had made his decision rather than a protracted 
discussion again of the options.  Mr Matfield appeared to have become more confident 
during the week away from clinic and as such was able to be an active participant in the 
decision making discussion on his return.  Thus, in this case, the work of Mr Matfield 
was acknowledged and then successfully incorporated into the decision process.  If the 
support that the MDT provides is to be incorporated into the model of decision making, 





In order to discuss further the challenges in enacting a model such as this in practice, I 
will firstly discuss how the MDT can support the work of decision making for the 
patient and secondly discuss the role of the treatment recommendation in this process.   
7.1 Supporting the work of decision making 
To support his work, Mr Matfield was offered information, time to understand and 
discuss the information, an  area outside of the hospital to perform the work, support 
from the CNS to interpret the information and a route back to clinic to report back his 
work and ask further questions if required.  The MDT already recognise that 
information provision is an important part of supporting patients thought their treatment 
process and hence a large amount of information is already provided for patients about 
the disease process and outcome; but most of this is provided after the treatment 
decision has been made. Stanley Wright was an 87 year old patient with a large cancer 
of the tonsil who attended the MDT clinic where the decision was made to treat the 
Figure 5: an engaged model of MDT decision making 
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cancer with radical radiotherapy.  Mr Wright received large amounts of verbal 
information about the process of treatment and large booklets of information to return 
home with.  At the time of his interview, I asked him about his expectation of the 
treatment: 
Interviewer: Do you have any vision of where you will be in [a couple 
of months]? 
Pt:  Well I hope to be on top of the bill...... [coughs]…I hope to be 
back to normal…..I do sincerely hope to be back to normal. 
Interviewer:  Back to where you were in say October last year [before 
the illness]? 
Pt: Well, exactly, yes..  I mean I had everything to live for and I used 
to go to the shop and I used to say “I’ll have that, I’ll have that”  you 
know….I hope [the gastrostomy is] a temporary measure.  I hope 
within the next month or so, that I’ve got a resemblance of weight 
back. 
(Stanley Wright, Interview, 21
st
 February 2012) 
Here, Mr Wright is expressing a lot of hope for the treatment which lies ahead:  he 
expects to survive the treatment, and for his function to return to pre-treatment levels.  
Mr Wright was a cheerful and positive patient, and so it was difficult to determine 
whether these words were the result of hope or expectation.  However, at the time of 
interviewing him, his responses concerned me, as I knew that his expectations were also 
very unrealistic.  He was an elderly patient with advanced disease: he had a low chance 
of survival, and if he did survive the effect of the radiotherapy on his quality of life was 
likely to be significant.  When trying to follow him up six months later I was saddened 
to hear that he had died of his disease.  These data provide a striking example of a 
patient’s expectations being far removed from the clinical course which lay ahead.  It 
could be argued that the fact that his outlook for treatment was far more positive than it 
turned out to be is not detrimental and allowed him to enter into treatment with a 
positive frame of mind.  At the same time, it perhaps denied him the opportunity to 
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come to terms with his own mortality, make preparations for the difficulties which lay 
ahead or even make the necessary arrangements and say good bye to members of the 
family.   
Nevertheless, it is important to explore why his expectations were so unrealistic.  At no 
point during the clinic appointment or information giving session was Mr Wright given 
any real indication of the small chance of short or long term survival.  I have discussed 
the effect of this lack of prognostic data on decision making in previous chapters.  
However immediately following his clinic appointment Mr Wright attended another 
appointment with a CNS, speech and language therapist and dietician.  At this 
appointment, a large amount of written and verbal information about the process and 
outcome of his cancer was given: 
Tessa:  Now we are going to give you this booklet it’s called 
understanding head and neck cancers, okay? And there is a section in 
here about radiotherapy okay, and I have written on their five 
appointments prior to starting treatment okay?  And it goes through 
the side effects that may occur okay? We warn you about all of them, 
because obviously we don’t know which ones are going to affect you 
and the worst scenario for us, is that you might require …. some 
morphine based medication towards the end of treatment alright? 
Pt: I hate morphine 
Tessa: You might not like it, but you will like it if you need it 




The pathway of treatment and rehabilitation facing Mr Wright would have a severe 
detrimental effect on his quality of life, however the Tessa was unable to describe how 
severe his individual reaction to treatment would be.  This is because it is difficult, if 
not impossible to predict the severity of the side effects that a patient may experience 
from HNC. Undoubtedly if more prognostic information were available it would 
facilitate information giving in this setting. However even if this were to happen, it must 
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be acknowledged that true individualisation of information is an impossible task.  This 
does not mean that the MDT should not attempt to risk stratify their patients; more that 
if this is done, it should be combined with an acceptance of the limitations of this.  Thus 
instead of attempting to provide a patient with a picture of certainty, the MDT should 
instead address and present the uncertainty associated with survival and outcome (I 
discuss further how this may be achieved in Chapter Eight).   
Additionally in the data above, it can also be seen that the effect of the side effects of 
treatment on Mr Wright’s life was not clear.  Tessa states that “the worst scenario for us 
is that you might require some morphine”: it is not clear in this statement why the 
morphine may be needed.  The pain from treatment may be so severe that Mr Wright 
would be unable to swallow effectively, perhaps leading to him not being able to take 
any food or liquid by mouth.  Although morphine may be given to help with this 
symptom, the real “worst scenario” is arguably his inability to swallow, rather than the 
provision of morphine.  It is understandable for the MDT members to concentrate on the 
methods which will be used to alleviate symptoms, rather than the symptoms 
themselves.  However, in doing this, they sometimes present a barrier to the patient 
developing an understanding of the real effect that the treatment may have on them.  
The outcome of this was that although Mr Wright was provided with a large amount of 
information, he was not provided with an insight into the ‘experience’ of treatment.   
In HNC, the MDT often strive to provide information about the ‘experience’ of cancer 
by encouraging new patients to meet other patients who have already gone through 




Well I’m not really bothered about [meeting a patient].  Because 
everybody’s different. … If I was to meet somebody and, and they 
said “Oh it was great” …I would think “Oh well, I should be all 
right.”.  And I might not be.  So I’m not really bothered about meeting 
anybody, because I think my experience is gonna be different.  
Everybody’s different. 
(Jean Dixon, Interview, 2
nd
 July, 2012) 
Here, Mrs Dixon recognises that the experience of the patient she meets may be 
different to hers, and therefore she discards it as a method of information gathering.  If 
she is told by the patient that treatment will be straightforward, and she then experiences 
side effects, then this may lead to more anxiety.  Indeed she may be frightened to meet a 
patient in person and hence come face to face with her own possible future.  
Importantly, this does not mean that information or experiences of this nature are of no 
use to new patients, more that if they are to be used, a range of patients or experiences 
may provide new patients with a broader range of outcomes and information. 
The data presented reveal information giving as a far greater challenge than merely 
presenting a patient and their supporters with verbal and written information, or indeed 
meeting a single patient. Instead, information needs to be provided with opportunity, 
encouragement and support to interpret, engage with and understand this information.  
Although at first this seems straightforward, in this disease and setting, further 
challenges emerge.  Sometimes when patients are given treatment related information, 
they are also given the contact details for the Clinical Nurse Specialist (CNS).  This 
allows the patient opportunity to ask questions and potentially helps them interpret the 
information available to them.  On the face of it, the provision of contact details for the 
CNS appears to be a simple and effective intervention to support patients in performing 
the work of decision making, however there are some hidden challenges.  Mrs Brigstock 
was an 82 year old lady with a large tumour of her jaw bone.  The cancer of the jaw 
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bone is resectable, and hence potentially curable, but this would have a significant effect 
on her function and quality of life post-op.  Additionally, the MDT felt that she may not 
survive the general anaesthetic and the immediate post-operative period and therefore 
the option of best supportive care was also discussed.  The following data extract shows 
Mr Siddell (maxillofacial surgeon) discussing the available treatment options and 
explaining to the patient what her role in the decision is: 
Mr Siddell: Have you got any thoughts yourself about those two 
routes? In other words, trying to help control the symptoms without 
doing anything big or doing something big with the hope of trying to 
get rid of it? ….So those are the good sides and the bad sides, and it’s 
not really for me to sort of say one way or the other if you see what I 
mean. I can see both sides of that and obviously because we’ve been – 
I’ve been here a lot with other patients, I know the good parts and the 
bad parts for each of those routes. I can’t predict what’s allotted to 
you; I don’t know if you go down one route is it going to be much 
better than the other route because I’ve given the balance.  
…. There isn’t a right answer, there isn’t a wrong answer, but if all of 
a sudden you turn round to me and say, “Well I do not want a big 
operation,” then that’s easily done, or you might turn round to me now 
and say, “Actually I want you to do absolutely everything possible to 
try and get rid of this, no matter what the risk,” then that’s fine.   




Mr Siddell clearly avoids making a treatment recommendation and presents both 
options as being completely viable to the patient.  In this extract  and in the discussion 
during the rest of the appointment, there was no framing of the treatment description; 
the risks and benefits of both treatment options were patiently discussed without 
emphasis or bias, and in doing so, Mr Siddell awarded  nearly all the control for the 
decision to Mrs Brigstock. Mr Siddell told the patient that she should go away and 
discuss with the family, and that Jane, the CNS, would contact her in the next week to 
answer any questions and help her through the decision process.  On the face of it, this 
seemed like he was providing a supportive and inclusive environment for the patient to 
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perform the work of decision making.  However, the following is taken from my 
reflective diary after the patient had left the room: 
Once the patient [and her son in law] left, the message changed.  After 
saying to the patient that she had equal choice and a chance of 
surviving the operation, he said afterwards her chances of surviving it 
were basically zero.  It was obvious that he thought she should go for 
best supportive care, however did not make this recommendation to 
her during the consultation.  The patient’s son in law said [during the 
consultation] that they would go for the option which meant she could 
“live as long as possible” but [after both had left the room] Mr Siddell 
said to the nurse, “but I think….” And the nurse said “yes I know” – it 
wasn’t explicitly said, but it was clear that both [Jane and Mr Siddell] 
thought that best supportive care was the way forward and I can’t see 
her making any other decision.  It was almost as if the choice was a 
charade -  a process through which they should go.  It was done very 
well….but if that was the way he felt, why did he not tell the patient 
that?  Why make them equal? 
(Field Notes, MDT Clinic, Centre C, 17
th
 January 2013) 
During the clinic appointment, the statement from the son in law of “live as long as 
possible” was interpreted by Mr Siddell and Jane as meaning that he would prefer to 
pursue radical treatment.  When Mr Siddell said “but I think….” he did not finish his 
sentence, but it was clear that he disagreed with this, and felt that Mrs Brigstock should 
be treated palliatively.  Thus, in this case, the patient was given support but its aim was 
to ensure that she chose the option that the Mr Siddell and Jane felt was best.  I have no 
access to the discussion which took place between the Jane and the patient (this was 
mainly on the telephone), but the decision for best supportive care was indeed what was 
decided  in clinic the following week; her return appointment was a very brief 
confirmation that she had complied with the Mr Siddell’s ideas of the ‘best’ treatment.  
In this case, Mr Siddell thought that the recommendation should be best supportive care, 
however instead of explicitly stating this to the patient (and hence allowing a full 
discussion about the options with this information available), the provision of ‘support’ 
was used as an additional method of persuading the patient via framing.  Although Mr 
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Siddell is correct to provide a treatment recommendation, if this is to be done, the 
provision of support should not be viewed as an opportunity to frame the decision or 
manipulate the patient into complying with the clinician.  Rather the recommendation 
should be explicitly communicated and discussed with the patient and their supporters.  
These data highlight the significant implications of the nature of the support provided 
for the decisions made.  Close consideration should be given to which members of the 
MDT support the patient, how the patient accesses them and the specific role and 
training that the supporting MDT member has.   
The nature of MDT decision making and HNC presents barriers to the provision of time 
in which patients can perform the work of decision making.  Mr Blaydon is an ENT 
surgeon: 
I suppose the ideal is … that you probably shouldn’t delay decision 
making too long otherwise you may undermine the patient’s 
prognosis, that it would be nice to come up with a decision sooner 
rather than later. … It’s prognostic things, but it’s also logistic things 
as well in that you may have a situation whereby there may be a clock 
ticking in terms of the cancer waiting…. times timeline. You may also 
have a situation whereby for logistical reasons there may not be a 
clinic the following week with an oncologist there. I think there’s a 
general principle to – to arrive at a decision sooner rather than later 
would be good, but it’s not unreasonable to – for example if the 
patient needs more time, to actually give them that time to maybe talk 
it over with their family, if necessary meet other patients who have 
had similar treatments or whatever to help them come to a decision. 
(Mr Blaydon, ENT Surgeon, Interview, 25
th
 October 2012) 
Mr Blaydon agrees with the concept of providing patients with time, but outlines some 
of the prognostic and logistical barriers to this.  The disease being treated is unrelenting 
hence the commencement of treatment is time sensitive.  The make-up of the MDT 
changes from week to week, so the patient may have a discussion with a clinician who 
is not available the following week, or indeed there may be no MDT clinic.  Also, 
patients are often referred to the clinic as part of the cancer waiting times national 
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strategy, which dictates that treatment must be started with 62 days of their first 
presentation, a target which is often referred to as a “clock ticking”.  Thus, although he 
agrees that although providing time is beneficial, the barriers to this, particularly those 
which are organisational, need to be acknowledged in order for time provision to be 
routine practice.  In addition to this, if the engaged model of MDT decision making is to 
be enacted in practice, the role of the treatment recommendation also needs to be clear.   
7.2 The role of the treatment recommendation 
The case of Vincent Lowry has provided insight into the backstage actions of the MDT 
members throughout the preceding data chapters.  In Chapter Five, I discussed how 
there was disagreement about whether laser or radiotherapy was ‘best’ to treat his 
tonsillar tumour.  In Chapter Six I discussed the conclusion of the MDT discussion, 
where they decided to offer him radiotherapy as a single treatment option.  Here, 
frontstage data from the clinic appointment reveals how the recommendation was 
delivered to the patient: 
Mr Black:  After a lot of discussion, the consensus…. would be to 
give you radiation therapy…. that was what we jointly decided.  And 
we think with that treatment there is a very good chance of controlling 
your disease completely.  I’ll stop here and you can ask me more 
questions if you and the family want to ask any further questions.   
Pt:  Well, I’ll do as you say 
Daughter:  So there’s no other operation, it would just be 
radiotherapy? 
Mr Black:  We discussed this at length at the meeting, and in fact 
there was a significant discussion, and the majority of people in the 
audience felt that to be frank, except for me, felt that radiation would 
be the way forward.  And Dr Yellow was the oncologist, and that’s 
what we are offering to you as first line treatment.  Unless you have 
any reservations, then we can think about other options.   
Pt:  I’ll do as you say…. 
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Daughter:  Right.  So he would have to come into hospital every 
day?….he’s a really bad traveller.  He feels sick, and really bad 
travelling 
Pt:  You know when I come here I get all tensed up and travelling…. 
Daughter:  He doesn’t really go out the house to be honest. 
Mr Black: Really? Is it likely you may then stop the treatment midway 
for whatever reason, because that would backfire very badly. 
Pt:  I wouldn’t do that 
Daughter:  No he wouldn’t do that 
Mr Black:  I know you asked about the surgical option.  I promised 
people I wouldn’t say anything.  But it is feasible to take it out 
surgically, and there is an option available, but the consensus at the 
MDT was to go ahead with radiation.  Unless, as a family or yourself 
very strongly object to it and feel that you can’t go ahead with that, 
then of course the surgical options is always there.  But as a group we 
felt that the best way forward was to offer you radiation 
Pt:  Well. I’ll go with you 
(Vincent Lowry, Observation, MDT Clinic, 19
th
 January 2012) 
In the MDT discussion, Mr Black was clearly in favour of laser (referred to here as 
“surgery”).  Mr Black was instructed by the MDT meeting to deliver radiotherapy as a 
single treatment recommendation: the data reveals the inflexibility of this instruction.  
This limited his freedom to express his opinion; as a result of this Mr Black struggled to 
address the questions and concerns of the patient and his family as the clinic 
appointment progressed. The challenge faced by Mr Black with respect to the 
recommendation is similar to the one faced by the MDT as a whole when attempting to 
incorporate clinical guidelines (discussed in Chapter Two).  Is the recommendation a 
‘rule’ which should be adhered to at all costs, or is it to guide a conversation of the 
options available?  If it is the latter, then how should it be used in this way?  In these 
data, Mr Black struggles with the questions from the patient’s daughter about whether 
there are any other treatment options available.  In this way, the rigidity of the treatment 
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recommendation acts as a barrier to an open discussion between Mr Black, the patient 
and his daughter about the real options that exist to treat his cancer.  The discussion of 
the surgical option was limited to “it is feasible to take it out surgically” which would 
be offered only if the patient ‘strongly objected’ to radiotherapy.  However, without any 
means of knowing the risks, benefits and trade-offs, the patient is not provided with 
anything to form the basis of these objections.  
If patients are to be truly involved in the decisions about their care, and the MDT is to 
embrace an engaged model of decision making, the role of the team discussion, and 
hence the resultant recommendation needs to be clear.  I have already discussed the 
fundamental flaws with using the recommendation as a paternalistic ‘instruction’ for a 
treatment decision.  Here, the data show the difficulties of limiting the recommendation 
to ‘clinically best’ and then attempting to use the clinic appointment to build into the 
decision the patient’s preferences.  Therefore, the aim of the team discussion, the role of 
the recommendation, and the manner with which it is delivered to the patient needs 
close consideration by individual MDTs and clinic structures if patient participation in 
treatment decision making is going to be enacted.  I will discuss some of the methods 
for achieving this in Chapter Eight. 
7.3 Conclusion 
I have outlined two separate processes in MDT decision making; that of the clinicians 
and that of the patient.  In the clinician process, the MDT meets to produce a treatment 
recommendation and then this recommendation is delivered to the patient in the MDT 
clinic.  In the present chapter, I examined the patient work of decision making: patients 
base this work on the information and experience which is available to them and 
distribute it across people, places and time. 
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In its current form, decisions are usually made in the MDT clinic immediately following 
the MDT meeting and this patient work is rarely acknowledged.  If the patient work is 
not acknowledged, this does not mean it does not take place: instead patients may have 
to base it on limited experiential information, or perform the work after the decision has 
been made.  Thus, by not including this patient work in the decision making pathway, 
detrimental outcomes range from causing the patient and their family increased anxiety 
to patients using unrelated information to inform their decision. 
For patients to be truly engaged in decisions about their care, their work of decision 
making must be recognised and supported.  The MDT can support the patient work of 
decision making by proving information, support and time.  In this chapter, I have 
highlighted the numerous challenges to providing this.  Information giving is more 
complex than the presentation of large amount of verbal or written information.  
Patients must be allowed to engage with and understand the process and outcomes of 
treatment.  They must be given information in understandable and accessible forms, 
with representations of a range of patient experiences.  They must be informed of the 
uncertainties regarding the outcome and success of treatment.  In this way, uncertainty 
is regarded as an opportunity to gather the preferences of patients and build these into 
the decision rather than being seen as a barrier to patient involvement.  Patients must be 
given time to discuss this information with those around them, and weigh up and trade-
off options depending on how important the outcomes are to them, or how they fit into 
their way of life.    
If the MDT is to engage patients in decisions, acknowledging and supporting the patient 
work of decision making alone is not sufficient.  The MDT has to be clear about the aim 
and the outcome of the MDT meeting.  The resultant recommendation cannot be a 
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paternalistic instruction for treatment.  Neither can a ‘clinically best’ recommendation 
be produced, which the patient is then expected to build their own values and 
preferences into, partly due to the difficulties in defining ‘clinically best’.  The team 
need to be explicit about what the role of the patient is in the decision process and how 
they are going to support this role.  Also, although providing support to the patient to 
engage in decision making work could potentially create a lot of time and expense to 
organise in the first instance, the benefits to both patients and clinicians could 
potentially far outweigh the costs of this restructuring. 
In the next chapter I will discuss the findings in close relation to the objectives which I 
set out at the start of the thesis.  I will then discuss how these findings impact on the 
structure and function of the MDT, and outline the ways in which MDT working can 




Summary of Results 
Chapter Five: the MDT meeting, laying the foundation 
In this chapter I discussed the backstage interaction between MDT members in the 
MDT meeting; here, the MDT members use the information and evidence available to 
them with the aim of producing one or more treatment recommendations.  I argue that 
the team build an ‘evidential patient’, designed to reproduce the patient in the backstage 
via information.  They combine this with their interpretation of the research evidence 
and the previous experience of the team.  These discussions are framed by the 
atmosphere, history and culture of the team.  The variable interpretation of the relative 
importance or reliability of the pieces of information varies across the individuals in the 
team, and forms a loose hierarchy which is continually defined and re-defined through 
negotiation between the members.  Some information is less contestable, but certainly 
not immune to discussion, such as the size and extent of the tumour and clinical opinion 
of the team.  Other evidence (such as patient preference, social circumstances and use of 
research literature) varies in importance.  There was a perceived variation in the 
recommendations made by the team between centres, dependent on the atmosphere of 
the team and the experience of the individual members. 
Chapter Six: Delivering the Treatment Recommendation 
The aim of the backstage MDT discussion is to decide which treatment is ‘best’ for an 
individual patient.  Information about the patient’s values and preferences are central to 
this assessment of ‘best’, and yet the MDT faces difficulty in incorporating information 
of this nature into the backstage MDT discussion.  Nevertheless, when the assessment 
of ‘best’ has been made, the resultant MDT recommendation is delivered to the patient 
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by one or more selected member(s) of the MDT.  During this exchange between 
clinician and patient the aim of the proposed treatment is not always explicit and the 
description of the treatment options is often ‘framed’ in order to guide the patient to 
complying with the clinician’s recommendation.  The challenges in the assessment of 
‘best’ and how to effectively involve patients in decisions are most pronounced when 
there is treatment choice.  To offer choice is sometimes seen as exposing to a patient the 
uncertainty underpinning the treatment recommendation; this is something many 
members of the team feel is undesirable. 
Chapter Seven: Enabling Patient Choice 
Here I explored the patient’s perspective of the MDT decision process.  In a similar way 
to the MDT members, patients base their ‘work’ of decision making on the information 
and experience which is available to them at the time and distribute it across people, 
places and time.  Currently, decisions are made in the MDT clinic immediately 
following the MDT meeting and thus the patient work is rarely acknowledged.  This 
often has detrimental consequences: patients may have to base their work on limited 
experiential information (which may not be applicable to the clinical situation), or 
perform it after the decision has been made.   When patients were encouraged and 
facilitated by clinicians to engage in this work, they were able to interpret the 
information, discuss it with those around them and consider the effect that the treatment 
process or outcome may have on their day to day life.  For patients to be truly engaged 
in decisions about their care, their work of decision making must be recognised and 
supported.  The MDT should be clear about the role of the patient in the decision and 
how they are going to support this role.  Importantly, the MDT should be clear about the 
treatment recommendation and the way it is used in clinic to help decision making. 
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Chapter 8: Discussion 
Towards a new model of MDT working 
In this thesis I have presented a detailed analysis of the process of treatment 
recommendation and decision making in the HNC MDT, with a particular focus on 
patient engagement.  The data has highlighted that, despite being widely viewed as a 
UK standard of care, MDT working creates multiple barriers to effective patient 
involvement.  To maintain the status quo is unsatisfactory: attempting to involve 
patients in decisions, whilst working with an MDT structure which does not adequately 
allow this, can and does result in decisions which are not in line with the values and 
preferences of the patient. The MDT is therefore compelled to improve care in this 
setting: in the present chapter I outline the ways in which this may be achieved.  I 
discuss how the current model of MDT working encourages and perpetuates a 
paternalistic form of decision making.  I summarise and discuss the main findings with 
reference to the aims and objectives which I set out at the start of the thesis.  I draw on 
the wider literature to discuss how these barriers may be overcome in this setting and 
outline a new model of MDT working, with MDT members and patients working as 
partners to make individualised cancer treatment decisions.   
This thesis has one aim: to examine critically patient engagement in the MDT treatment 
decision making process in HNC.  There were three objectives of this work which I will 
use below to begin the discussion of my findings: 
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Objective 1: To examine critically the current function of the MDT meeting in 
head and neck cancer 
I discussed the function of the MDT in Chapter Five.  The MDT makes treatment 
recommendations based on the information and evidence which is available to members 
at the time of the meeting.  The patient is, however, absent from the MDT meeting and 
therefore all evidence that is incorporated into the discussion must be gathered before 
the meeting takes place. In order to represent the patient in the backstage, the team 
construct an ‘evidential patient’ out of a number of pieces of information about the 
patient.   This ‘evidential patient’ is designed to reproduce the patient in the MDT 
meeting room via information.  The pieces of information which form the evidential 
patient are hierarchical: all pieces of information are interpreted in different ways by 
individual members, indeed some are even manipulated to reinforce a particular opinion 
or line of action.  Thus, the hierarchy is continually negotiated and redefined by 
interaction between the members of the MDT.  The evidential patient is made up of 
multiple different pieces of information: the size, extent and spread of the cancer, 
comorbidity information, the clinical state of the patient (swallow/voice function) or 
information to provide a more holistic view of the patient such as their social situation 
or their values and preferences.   
The evidential patient is not the only source of information which the MDT draws upon 
during the meeting: the recommendation is also based on the MDT members’ clinical 
experience and their interpretation of the wider research literature.  At times, research 
findings from other centres are interpreted as being reliable and trustworthy, and as such 
are relied upon to inform a strong recommendation for an individual patient; at other 
times research findings are discarded due to concerns over their validity, or even 
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assumptions about the motivations of the authors.  Whether a piece of research should 
be trusted or discarded depends partly on the quality of the research; however in 
practice it also depends on the individual MDT member interpreting it and the argument 
that they are attempting to reinforce.   In contrast to the interpretation of research 
evidence, the clinical experience of the members of the MDT is less open to 
interrogation amongst the members; experience, anecdote and opinion are often 
therefore trusted as a reliable source of information.  This reliance on individual 
clinician’s experience creates a variation in recommendations made between MDTs 
both between and within centres depending on the individual clinicians present at any 
given MDT meeting.   
Thus, before the point is reached where the team can begin discussion of the treatment 
recommendation, the evidence underpinning the recommendation needs to be made 
available and mobilised.   This process of mobilisation represents an extra layer of 
complexity in the process of team decision making, a step before treatment 
recommendation, where the foundation blocks for the decision are put in place.    Some 
MDTs attempt to increase the ‘patient-centredness’ of their discussion by introducing as 
much information as possible about the patient into this backstage area.  However, 
much of this attempt to re-produce the “feel” of a patient (without the opportunity for 
face to face interaction) is potentially doomed to fail.   It is difficult to incorporate some 
information - for example, “the patient lives alone” - into a clinical recommendation 
without making an assumption.  Information about the preferences of the patient was 
variably presented and had a sometimes significant guiding influence on the backstage 
discussion and recommendation.  However, many MDT members treated this type of 
information with suspicion about its source or elicitation.  Not only this, but when 
preference information was presented in a similar manner as a T stage or pathology 
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result, there was an assumption that preference information can be incorporated into the 
discussion in this way.  However the preference of a patient is not an information 
commodity which can be passed from person to person in order to make a decision.   If 
MDT decisions are to incorporate patient preferences into the treatment decision, the 
nature of patient preferences and how they are formed needs to be explored.   
Patient preferences 
I have discussed how, in the MDT meeting, when patient preference information is 
available, it is often presented in a similar way to information such as the tumour stage 
or comorbidities.   However, preferences which are formed in life threatening situations, 
particularly cancer, are unlikely to be pre-formed or pre-existing (Lichtenstein and 
Slovic 2006).  Patients diagnosed with HNC are faced with considerable uncertainty, 
and as a result their preferences may be unstable (Epstein and Peters 2009).  This means 
patients are not deemed to opt for the treatment which maximises their expected utility 
(with resultant preferences to match), but rather that their expressed preferences are 
labile, dynamic, reversible and sensitive to option description.  When patients assess 
their preferences, they may rely on heuristics, emotion or intuition; preferences formed 
in this way are often more unstable and changeable  (Epstein and Gramling 2013).  The 
‘ordeal’ associated with treatment is difficult for a patient to imagine (Little et al. 2008); 
also, when this unimaginable health state is encountered, patients tend to rate their 
quality of life as being higher than they expected it to be (Ubel et al. 2005).  This means 
that when the patient meets the surgeon before the MDT meeting, the preference that 
they express is unlikely to be pre-existing or strongly held.  Hence, an attempt to 
include a preference as a stable piece of information making up the ‘evidential patient’ 
is misusing information of this nature.    
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A patient preference is formed from a process of interaction with their physician: it is 
constructed (Slovic 1995; Lichtenstein and Slovic 2006).  Preferences are constructed 
during elicitation and are therefore responsive to the way in which the options are 
presented, described or even framed by the physician.  Slovic describes the process of 
preference formation: 
“Construction strategies include anchoring and adjustment, relying on 
the prominent dimension, eliminating common elements, discarding 
non-essential differences, adding new attributes into the problem 
frame in order to bolster one alternative, or otherwise  restructuring 
the decision problem to create dominance and thus reduce conflict and 
indecision” (Slovic 1995, page 369) 
The response to this should not be to minimise the effect of the physician on this 
preference, as the interaction itself can be therapeutic (Epstein and Street 2011).  Rather, 
the acknowledgement that patient preference is the product of an interaction should be 
recognised in the structure of the clinic.  Epstein (2013) proposes that in life threatening 
disease, with complex choices in situations of uncertainty, models of decision making 
do not always acknowledge the instability of patient preferences and the process of 
construction.  He argues that a decision process should therefore place the relationship 
between patient and health care professional at its centre.   
In relation to MDT decision making, the recognition of ‘constructed’ preferences has 
significant implications for the way in which decisions are made in this setting.  If it is 
acknowledged that patient preferences are constructed from an interaction with 
clinician(s) then the structure of the decision making process should respect this.  
However, even if the resultant patient preferences are adequately incorporated into the 
decision making processes, this does not mean that patients are involved in their care.  If 
properly constructed patient preferences are to be central to the MDT decision process, 
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next it must be ensured that patients have a foundation on which to base them.  I will 
discuss how this should be achieved later in the chapter. 
Objective 2: to evaluate the experience and practice of decision-making by 
patients and clinicians and to elicit their views on current and preferred 
involvement in the treatment decision making process 
The outcome of the backstage MDT discussion is a treatment recommendation which is 
delivered to the patient in the MDT clinic.  The basis of the recommendation discussion 
is the MDT members’ consideration of which treatment option is ‘best’ for the 
individual patient.  MDT members do not always recognise that the ‘best’ treatment is 
not a single objective clinical fact which can be viewed as indisputable. Although a 
particular site and stage of tumour may have an established treatment modality which 
research evidence has shown to provide a superior survival, recommending this option 
without discussion with the patient may result in a treatment decision which does not 
adequately account for the values and preferences of the patient.  
The ‘best’ treatment for an individual patient is dependent on their aims for treatment, 
their values and their preferences.  I have discussed already how preferences are not 
fixed informational commodities, but rather are constructed through a process of 
interaction with members of the MDT and supporters.  This means that any decision of 
which treatment is ‘best’ for an individual patient can only be made after interaction 
with them.   In this section I will discuss the other key component of the MDT clinic 
interaction: the available treatment options. 
In Chapter Six I explored the reasons why the MDT may limit or withhold a discussion 
of alternative treatment options from patients.  Firstly, MDT teams may not 
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acknowledge that alternative treatment options exist: commonly, this is because the 
MDT assumes that the aim of the patient is cure and hence recommends radical 
treatments.  This leads to little or no discussion of palliative options, best supportive 
care or other non-curative options.  Secondly, the MDT as a group sometimes 
acknowledges that two (or more) options may be considered ‘best’; however, no one 
individual MDT member agrees that both could equally be regarded thus.  Because each 
individual has a clear preference for one or other option, the MDT is presented with 
difficulties when selecting a clinician to deliver the treatment options to the patient, as 
the chosen individual may only deliver their own view of ‘best’, or perhaps frame the 
discussion to reflect this.  This makes the choice of clinician to deliver the 
recommendation to the patient a proxy for the recommendation itself.  
The data presented in Chapter Six demonstrate that MDT members sometimes viewed 
the offering of treatment options to the patient as revealing uncertainty to the patient.  
However, many MDT members view their role as being one of providing expertise (and 
hence certainty); to offer treatment options is seen to be ‘not knowing what to do’.  The 
desire of MDT members to conceal uncertainty sometimes meant that treatment options 
were not discussed with the patient.  Thus, the perceived requirement to conceal 
uncertainty acted as an additional barrier to offering treatment options and hence 
involving patients in treatment decisions
8
.  Hence, the question of how to deal with 
                                                 
8
 I recognise that treatment choice exists even if alternative treatment options are not offered to 
the patient: the patient can choose not to accept a treatment recommendation, indeed they may 
choose not to attend clinic at all.  Equally, MDT members are not the only participants in the 




uncertainty and whether or not to present it to patients is central to any discussion of 
patient involvement in this setting. 
Clinical uncertainty 
HNC is a heterogeneous disease with low survival and a large range of treatment 
outcomes which have a significant effect on the quality of life of a patient; as a result 
the choice of treatment involves considerable uncertainty.  One source of this 
uncertainty is a distinct lack of prognostic data available to MDT members to guide 
decision making.  In the studied centres this lack of numerical prognostic information 
led some clinicians to treat more patients radically, so any patients who had a chance of 
survival were treated, at the expense of some patients who had a very low chance of 
survival being treated unnecessarily.  Other clinicians reacted to this lack of prognostic 
information by using more heuristic judgements to attempt to predict which patients 
were unlikely to survive treatment and hence which patients should not be offered 
radical management.  These alternative interpretations of the same problem (lack of 
prognostic information) led to a variation in the treatments offered between clinicians.   
A common reaction to uncertainty is to attempt to reduce it by providing data about the 
risk of treatment where it was previously absent.  Indeed some diseases and treatments 
have extensive, peer-reviewed research and outcome data to guide management 
decisions. Importantly however, even when this is available, uncertainty still exists.  For 
example, if the HNC community gathered the data available, and were able to inform a 
patient with laryngeal cancer that if they were to be treated, given their age, sex, cancer 
and comorbidities, their chance of survival would be 30%, this would be considered by 
many to reduce the uncertainty associated with treatment, or perhaps even eliminate it.  
However, there is considerable difficulty in applying an objective probability estimate 
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(30%) to a single event (survival) in an individual patient (Han 2013); arguably there 
cannot be a ‘frequency’ of a single event.  This stated risk is postdictive, rather than 
predictive and as such is a record of past events in similar patients rather than a true 
prediction of the future (Politi et al. 2007).  The issue of how population based risk data 
applies to an individual patient is described as ‘first order’ or ‘probability’ uncertainty 
(Han et al. 2011).  An expression of probability is a description of the degree of 
confidence of an event happening in an individual with similar characteristics: an 
expression of personal confidence in numbers.  However, it is not possible to have ‘30% 
survival’: the patient will either survive or not (Thomson et al. 2005).  These 
probabilities are interpreted by individual patients (Han 2013); this interpretation is 
affected by factors such as their prior beliefs, their interpretation of the context in which 
the physicians beliefs were formed, the perceived credibility of the clinician, the 
patient’s understanding of the risk, how it was provided and the context in which the 
information was given (Fox and Irwin 1998).  These interpretations must be taken into 
account and explored when risk information such as this is being given.   
First order uncertainty can be reduced to an extent by ensuring that the presentation of 
risk information is clear.  Strategies to achieve this include presenting the absolute risk 
of an event occurring (rather than a relative risk), a common denominator when 
comparing treatments, a clear reference class and an accompanying time frame (Paling 
2003).  However, first order uncertainty when using risk estimates is the not the only 
type of clinical uncertainty. 
‘Second order’ uncertainty or ambiguity refers to either imprecision of the expressed 
probability estimates or disagreement about their validity or evidence base (Han et al. 
2011).  Communicating ambiguity is challenging; a common method is confidence 
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intervals, although there is disagreement regarding the optimum interval range, clinical 
usefulness and patient interpretation of these (Han 2013).  The GRADE system presents 
the evidence for the effectiveness of an intervention with a qualitative indicator of the 
strength of the recommendation and the quality of the evidence, allowing patients and 
clinicians to judge the probability and ambiguity of the evidence simultaneously 
(Balshem et al. 2011).  However, separating the likelihood of an event from the 
confidence in it occurring is difficult: for example it is challenging to express to patients 
that there is a low confidence that something is highly likely (Han 2013).  Also, it can 
be argued that ambiguity cannot exist, as an expression of probability cannot be viewed 
as a true ‘fact’ (Han et al. 2011).  In addition to probability and ambiguity, there are 
multiple other potential sources of uncertainty, all of which are present in HNC.  
Whereas probability and ambiguity encompass the likelihood of an event, ‘complexity’ 
encompasses the severity and the effect that it will have on the patient’s life.  Thus 
complexity is both objective and subjective: it depends not only the outcome itself, but 
the perceived effect of the outcome on the patient and their supporters and their 
judgement of its severity and its effect on relationships, work etc. (Han et al. 2011). 
Concealing uncertainty 
In the centres included in this research, members of the MDT often attempted to present 
a ‘front’ of certainty.  In order to achieve this, the uncertainty associated with treatment 
was sometimes concealed in the backstage, and not revealed to the patient.  This is an 
understandable reaction and is not uncommon (Parascandola et al. 2002).  Uncertainty 
is abstract and difficult for patients to conceptualise and understand, hence 
communication of uncertainty may be time and resource intensive, and may lead to 
increased confusion for patients.  Patients sometimes have a preference for known risks 
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and avoid decisions with unknown risks: so called “ambiguity aversion”.  This persists 
even when the odds favour the ambiguous option (Ritov and Baron 1990).  Uncertainty 
can lead to a heightened perception of risk and worry for patients (Viscusi et al. 1991; 
Han et al. 2011) or decreased satisfaction with decisions (Politi et al. 2007).  A 
combination of these negative reactions to uncertainty may lead to patients withdrawing 
from involvement in decision making.  Therefore is concealing uncertainty as far as 
possible preferential?  In order to answer this question, it must first be considered 
whether adequate concealment is indeed possible.  Concealing uncertainty is not 
eliminating it; a clinician may conceal uncertainties about risk information but the 
patient may still be uncertain about their interpretation of this data or the effects of 
treatment on their quality of life or relationships.  Not only this, but to conceal 
uncertainty is to ignore the potential positive effects on the decision consultation.  
Revealing uncertainty may lead to an increase in patient information gathering, or a 
renewed interest in engaging with the decision process.  Ambiguity (as described above) 
may be used positively, to facilitate the discussion about how the probabilities presented 
are not necessarily “true” for that individual, or even as a source of hope that a 
particular side effect may not happen to that patient (Han 2013). Uncertainty could act 
as a useful cue to gather the values and preferences of patient and build these into the 
decision. This means that instead of being viewed as a barrier, the existence of 
uncertainty could be viewed as an opportunity to further involve patients (Han et al. 
2011).    
Informing patients about uncertainty associated with treatment is respecting their 
autonomy: it allows patients to judge for themselves the strength of a recommendation 
and therefore whether to accept it.  Indeed, to provide a picture of certainty is 
potentially to provide an inaccurate or even misleading picture of risk (Edwards 2003).  
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Hence, the concealment of uncertainty is not a solution for dealing with uncertainty in 
decision making.  This means that if patients are to be adequately informed, an open 
discussion of the clinical uncertainty which underpins the recommendation and decision 
is required. 
Communication of uncertainty 
If it is accepted that uncertainty should no longer remain a backstage concept and 
instead be presented to the patient, next it must be considered how this uncertainty 
should be presented to the patient and used to make treatment decisions.  It must be 
understood that decisions under conditions of uncertainty involve different cognitive 
pathways than decisions with better known outcomes and risks.  Indeed, the use of 
utility optimisation and statistical thinking in decisions with imperfect information can 
lead to decisions which are worse than those using heuristics alone (Gigerenzer and 
Gaissmaier 2011).  In situations of uncertainty, this makes logic less useful that the 
brain’s adaptive ‘toolbox’ of heuristic processing (Volz and Gigerenzer 2012).  
However, decisions in situations of uncertainty are common in everyday life and as 
such are well-rehearsed in human decision making (Volz and Gigerenzer 2012).  Thus, 
when making decision under conditions of uncertainty, rather than denying or 
eliminating the role of instinct and heuristics, these should be explicit, challenged and 
discussed.  In a similar way to the discussion above about eliciting patient preferences, 
this makes the discussion of uncertainty a dynamic interaction between patient and 
physician, rather than a presentation of risk and uncertainty information alone.   
There are relatively few methods developed of communicating uncertainty to patients 
visually (Han et al. 2011).  Han et al (2012) developed visual dynamic random icon 
arrays to demonstrate an uncertainty for a 9% risk of colon cancer.  This consisted of 
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100 icons, nine of which were highlighted; the highlighted icons were randomly 
distributed, and this random distribution changed every two seconds, in an attempt to 
represent the uncertainty of outcome.  Ancker et al (2009) attempted to reproduce the 
uncertainty and also the ‘feeling’ of risk by using game graphic icons.  Users 
‘discovered’ if icons were affected by a health outcome by clicking on them and 
affected outcomes were randomly allocated.  The authors found that the use of 
interactive graphics helped patients to understand not only what the risk was, but also 
how it felt.  This in turn helped to demonstrate high risk and reduce anxiety of low risk.  
Although these methods of representing the ‘randomness’ of clinical outcomes change 
patients’ perception of risk, the effect on patient understanding is not known (Han 
2013). 
In the settings under study, MDT members relied on verbal communication when 
discussing the risks and uncertainties associated with treatment and very few 
communication adjuncts were used.  Potentially, the discussion of the risk and 
uncertainty associated with treatment could be improved by using adjuncts to 
communication such as those described above.  Decisions aids are also an established 
tool to help improve communication which provides a platform for discussion of the 
clinical uncertainties. Decision aids are “tools designed to help people participate in 
decision making about health care options [which] provide information on the options 
and help patients clarify and communicate the personal value they associate with 
different features of the options” (IPDAS 2012).   Decision aids are designed to be used 
before, during or after a clinical consultation by the patient with or without a clinician.  
In a systematic review of 115 randomised controlled trials studying the effectiveness of 
decision aids, the use of a decision aid was associated with improved patient 
knowledge, lower decisional conflict, a decreased proportion of patients who were 
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passive in decision making and fewer patients remaining undecided.  There was also a 
reported increase in patient satisfaction with the decision making encounter and 
improved perception of risk (Stacey et al. 2014).  If MDT members were provided with 
a tool to facilitate the communication of risk, then this may improve communication of 
uncertainty, and consequently improve patient involvement.   
So far in this section, I have described the difficulties of concealing and communicating 
uncertainty.  However, to complete this discussion, the effect of uncertainty on the 
clinician should also be considered.  A physician’s reluctance to deal with uncertainty 
can lead to over-investigation in the pursuit of certainty, or indeed a refusal to talk about 
the future (“there is no way of telling”) (Smith et al. 2013).  A higher intolerance of 
clinical uncertainty in clinicians is associated with their fear of death or dying (Merrill 
et al. 1998) and often leads to misplaced optimism about the future in terminally ill 
patients (Christakis and Lamont 2000) .  There is a large variation in clinicians’ 
reluctance to disclose uncertainty and uncertainty related stress (Gerrity et al. 1990).  A 
reluctance to discuss uncertainty was associated with physicians not recruiting eligible 
patients to trials (Taylor et al. 1984) and a reluctance  to engage with SDM (Politi and 
Legare 2010).  The attitude of physicians to uncertainty in turn affects the number of 
expressions of uncertainty to patients during clinic appointments (Gordon et al. 2000).    
The relationship of the physician’s reaction to uncertainty and the decision made is 
complex but important: it has been suggested that the physician’s reaction to uncertainty 
has a greater effect on patient satisfaction in decision making than the patient’s reaction 
(Politi et al. 2011).  Whether the development of better tools to share uncertainty would 
modify these factors remains to be seen, however if communication of uncertainty is to 
be commonplace, the effect of this interaction on patients, clinicians and the decision 
made requires scrutiny. 
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Objective 3: To use the findings from objectives one and two to determine the 
requirements for decision support in the context of the MDT. 
The data presented in this thesis demonstrate that the complexities and uncertainties of 
treating HNC and the consequences of treatment led many clinicians and patients to 
conclude that patients cannot and perhaps should not be more involved decisions about 
their care.  Hence, a paternalistic model of decision making is dominant in this setting.  
In the paternalistic model, the evidence is discussed in the MDT meeting, and a clear 
treatment recommendation is delivered to the patient.  As the patient is often not 
supported in decision making, they have very little to draw upon to make the decision.  
This results in patients requesting and then accepting this recommendation from the 
MDT, which endorses the paternalistic (‘expert’) decision process and allows it to 
continue unchallenged.   Although some clinicians and patients advocate an increased 
role for patients in treatment decision making, the paternalistic model predominates as 
MDT working lends itself well to this model.  The two main reasons for this 
predominance are uncertainty about how the MDT can adequately incorporate patient 
preferences and difficulties in understanding how to support patients in making 
decisions.  This results in (sometimes strong) disagreement between members of the 
MDT as to what the role of the patient is in the treatment decision, how a patient should 
be involved and hence what the aim of the MDT meeting discussion is.  
The behaviour of the MDT members appeared to be strongly influenced by the attitude 
of the MDT members and in Chapter Five I describe a distinct difference in the 
‘atmosphere’ of the MDT from centre to centre, based on my observations.  The MDT 
atmosphere appeared to be influenced by the make up of the group, such as the 
personalities present, the leadership style and previous discussions.  The atmosphere 
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was also influenced by the setting in which the discussion took place: the layout and set 
up of the room, the time available and the number of patients.  The atmosphere 
impacted on how the discussions unfolded and how individual members, especially 
allied healthcare professionals, engaged with the team during the backstage discussion.  
A particularly combative or hostile atmosphere often silenced allied health professional 
members, and with it the information and expertise that they brought.  Allied health 
professionals were included in some centres with exercises such as ‘round the table’, led 
by the chairperson at the end of the meeting, where all members were encouraged, one 
by one, to raise questions or issues to the group.  Importantly, by affecting the 
behaviour of the MDT members, team atmosphere seemed to significantly shape not 
only the discussion which unfolded but also the recommendations the MDT made and 
how these recommendations were delivered to the patient in clinic. 
Paternalistic MDT members found their argument for paternalism supported when 
patients were offered treatment options, but not then given supplementary support to 
help to make this decision.  In the studied centres, this led to either a request from the 
patient to the clinician for clear guidance, and hence a reversion to paternalism, or a 
decision made by the patient based on limited experiential information which may not 
have been relevant to the situation at hand.  However, the paternalistic model assumes a 
passive role for the patient in accepting the treatment recommendation; this is not 
always the case.  Patients sometimes refuse or question the recommendation being put 
to them, providing a rare challenge to paternalism in this setting. Offering treatment 
options to patients without supporting them in their choice is delegation of the decision 
and abandonment of the patient. Thus, if patients are to be involved in a treatment 
decision, acknowledging and then offering choice is not enough.  Instead, patients need 
to be supported in making decisions.   To offer treatment options and support choice is 
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to value the autonomy of the patient.  Hence, before continuing with my discussion of 
decision support, I shall discuss the way in which the MDT may respect the autonomy 
of the patient 
Patient autonomy 
Respecting the autonomy of a patient is a legal, ethical and moral requisite.  Patients are 
encouraged to make autonomous decisions, and this is seen to improve quality, 
accountability and choice (DoH 2010B).  Although it is clear that the autonomy of the 
patent should be respected, this concerns more than merely allowing and offering choice 
(Entwistle et al. 2010).  For example, to offer treatment options would be to respect the 
autonomy of the patient, however this may constitute “naïve consumerism” (merely 
giving patients what they ask for) or “abandonment” (delegation of the decision to the 
patient) (Epstein and Peters 2009).  In relation to the data presented in this thesis, the 
concern amongst MDT members that offering choice is delegating and abandoning the 
patient is a significant barrier to choice being offered in the first instance.  Also, to offer 
choice without supporting and enabling that choice may alienate groups of patients who 
are vulnerable, marginalised or who lack confidence (Davies and Elwyn 2008); these 
are the patients who are in most need of support and the group who often present with 
HNC.  Thus, if patient autonomy is to be  respected, the independence of the patient 
should perhaps be de-emphasised, and their relationship with the doctor and other 
members of the healthcare team emphasised (Struhkamp 2005).  A consideration of this 
‘relational autonomy’ recognises that humans are not self-sufficient and independent, 
meaning that involving patients in decisions requires more than presenting options and 
awaiting a verdict.  Relational autonomy emphasises the importance of the interaction 
with the clinician, encouraging questions, correcting misunderstanding, constructing 
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preferences and allowing disagreement (Entwistle et al. 2010).  In this way, autonomy 
is generated through interaction with others.  
In relation to decision making, Rapley (2008) describes how patients demonstrate a 
relational autonomy by distributing their decision across multiple encounters with 
different doctors, supporters and family members.  Some encounters are prolonged 
dialogues, others short chance meetings.  In this way patients turn to others for 
knowledge, understanding, dependency and for support and care during the time of 
illness.  This takes place over a period of time and involves gleaning information from a 
range of sources.  The recognition of the ‘mundane’ patient work of decision making 
not only alters the way in which the autonomy of a patient should be considered but also 
highlights the way in which patient preferences are formed through a process of 
interaction with others.   
The data presented in this thesis strengthens this viewpoint.  For the patient, a lot of the 
‘work’ of decision making took place away from the clinic setting, distributed amongst 
people, encounters, places and information sources.  Patients performed this work in 
their own homes or communities, with family members and other supporters, after the 
clinic appointment.  Patients interpreted the information if it was provided to them, but 
combined it with a host of other considerations when choosing which treatment option 
to pursue.  They interacted and negotiated with their supporters to interpret the options 
which were available to them and considered the process, risks and uncertainties of 
treatment options in the context of their everyday and family life.  
If this work is not supported by the MDT it does not mean that it is not performed.  
Patients instead use anything that they have available to them to form the basis of the 
decision: this is often limited, experiential information which is not clinically 
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applicable.  Also, if the decision is made immediately in the MDT clinic, much of this 
work must be performed after the decision has been made.  This sometimes leads to 
increased anxiety and confusion and other times results in decisions which are not in 
line with patient preferences, or in line with ill-formed preferences (Elwyn et al. 2012).    
In this thesis, I have demonstrated that the provision of information is central to offering 
support to patients.  However, in this disease and setting, information giving presents a 
far greater challenge than merely presenting a patient and their supporters with verbal 
and written information, or indeed meeting a single patient. Instead, information needs 
to be provided with opportunity, encouragement and support to interpret, engage with 
and understand this information.  Here, I will discuss the ways in which the MDT may 
provide the patient with this. 
Information giving 
Information giving is central to patient involvement in decision making, not only to 
guide patients expectations of disease (Llewellyn et al. 2005), but also to facilitate the 
process of preference construction (Slovic 1995).   Providing accurate treatment related 
information to patients presents clinicians with significant difficulties.  Data presented 
in this thesis highlight the uncertainty surrounding the prognosis and expected outcome 
of treatment for an individual patient.  Although information on outcome figures may 
sometimes be available nationally, clinicians did not always feel that this was applicable 
at the local level due to differences in patient characteristics.  Additionally, these data 
were often not routinely collected at the level of the hospital or geographical region, 
impacting on the availability of information of this nature.  Not only this, but even if 
accurate outcome data were available, there exists debate over which outcome measure 
most accurately represents the functional  outcome after treatment for HNC, with 
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established outcome measures often not representing patient experience or patient 
perception of the symptom (van der Molen et al. 2009).  This causes difficulties when 
researching the differences between different treatments and when providing patients 
with comparative information about the effect that treatment may have on them.  This 
lack of comparative and prognostic data creates challenges when discussing which 
treatment is ‘better’ with regard to survival, function or quality of life which, in turn, 
may add to the framing effect from the presenting clinician. 
At the same time, information giving is about more than the provision of copious 
amounts of written information (Semple and McGowan 2002).  The data presented in 
this thesis demonstrates that currently, patients are provided with a large amount of 
treatment related information, but this is usually only after the treatment decision had 
been made.  Patients were rarely supported to understand and interpret this material 
which often led to either the information being discarded or misunderstood.  Hence, 
even if comprehensive information about the risk and uncertainty of treatment is 
provided, patients should also be supported in its understanding and interpretation.  
Patients should be provided with information about the aspects of treatment which are 
important to them, or practical in their situation.  In the next section I will discuss a 
possible method of providing such support: decision coaching. 
Decision coaching  
The role of a decision coach is to assess the decisional needs of the patient and then 
support the patient through decision making, using decision aids and adjuncts if 
available.  The decision coach can monitor the progress of the patient in their decision 
and identify barriers to the implementation of the decision (Stacey et al. 2008).  
Decision coaching or decision navigating can be provided by a member of the team who 
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is “trained in decision support and [is] supportive but relatively neutral in the decision” 
(Stacey et al. 2008, page 28).  In the cancer centres included in this thesis, a variation on 
the decision coach role was often provided by the Clinical Nurse Specialist.  However 
the guidance sometimes offered instead functioned as an added opportunity for the 
MDT to bias the patient’s decision.  These nurses do not fulfil the role of decision coach 
as outlined in the literature as they are not trained in decision support; also the structure 
of the MDT does not currently support nurses to take a decision coach role 
Decision coaches can help to improve confidence in decision making and prepare for 
the decision consultation (O'Connor et al. 2008) with positive effects on knowledge, 
information recall and participation in decision making (Coulter and Ellins 2007).   
However, in a recently published systematic review, only 10 randomised controlled 
studies were identified and thus conclusions about the effectiveness of decision coaches 
were limited.  The authors found that although decision coaching can improve patient 
knowledge, it is difficult to unpick how much of this improvement is due to decision 
coaching, and how much to the decision aid which is often simultaneously used.  The 
effect on other outcomes such as cost effectiveness, values-choice concurrence and 
patient satisfaction varies, with some studies reporting a positive effect, and others 
reporting no difference (Stacey et al. 2012).  A variation on the role of decision coach is 
decision “navigator”: a navigator meets the patient before the clinical appointment and 
prepares them for the consultation with the physician.  The training of the navigators is 
based on the SCOPED checklist for consultations (Situation, Choices, Objectives, 
People, Evaluation, and Decisions) (Belkora 2014).  In a large randomised controlled 
study of the use of navigators in prostate cancer, navigators provided pre-consultation 
preparation, accompanied the patient to the clinic appointment and produced recorded 
and written documentation of the consultation.  ‘Navigated’ patients were more 
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confident in making decisions about cancer treatment and had less decisional regret than 
those who received usual care (Hacking et al. 2013).  If a decision coach or navigator 
role is included in team decision making, the MDT must incorporate this individual: 
such models have previously been developed.  
Shared decision making in healthcare teams  
In Chapter Two, I examined the effectiveness of shared decision making (SDM) as a 
method of delivering patient centred healthcare and outlined the strong clinical and 
ethical argument for SDM as a method of engaging patients in treatment decisions.  
Therefore, before I discuss further how the MDT may improve patient engagement in 
decision making I will consider the work which has already been done around SDM and 
healthcare teams.  First, I will discuss an SDM model which has already been proposed 
for involving patients in healthcare teams; this model incorporates a ‘decision coach’ 
role as discussed above.  Second, I will discuss the role of team training in promoting an 
environment of SDM in a healthcare teams. 
Inter-Professional Shared Decision Making (IP-SDM) is in its infancy (Legare et al. 
2008) as the majority of the research on SDM concentrates on the physician/patient 
dyad (Makoul and Clayman 2006).  In two recent systematic reviews of measures to 
help the implementation of SDM, only 3/40 studies focussed on the interdisciplinary 
approach (Legare et al. 2010; Legare et al. 2012).   Stacey et al (2010) performed a 
large literature review and theory analysis which identified no models of SDM in the 
interprofessional context.  This led the same group to develop a conceptual model for an 





This model is based on various assumptions: the definition of ‘inter-professional’ is 
when “professionals from different disciplines collaborate to provide an integrated and 
cohesive approach to patient care” (Legare et al. 2011, page 18).  The model assumes 
that all members of the team understand and agree that SDM is the optimal method of 
achieving patient-centred care, and are aware of the steps required to enact it (and of 
their role in each step).  The model also acknowledges a view of relational autonomy of 
the patient, in stating that that the team of the patient (family and supporters) and their 
preferences should be involved in the shared deliberation.  In this model, the rows 
represent the experience of the patient as they move through the decision process, and 
the columns are the people involved in the step.  The model outlines the six steps of 
SDM in teams.  This is a conceptual model, providing a platform on which to base 
further research about how interprofessional teams collaborate with each other and the 
patient, and the relationships which are essential for SDM to take place in a team 
Figure 6: inter-professional shared decision making model, from Legare, 2011 
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setting.  In order to achieve inclusiveness, the model lacks detail as to how each step 
may work in practice, but it acts as a useful framework for considering how patients 
may be involved in their care when working in teams (Legare et al. 2011).  When 
validating this model with 79 stakeholders, the main barriers for the implementation of 
SDM in an inter-professional team were seen to be time, resources for implementation, 
organisational structures and imbalance of power within the team.  The main facilitators 
were inter-professional training and the sharing of knowledge within the team.  
However, only half of the 79 stakeholders felt that the model was clear, while 41% felt 
they would be willing to test it in the clinical setting (Legare et al. 2011)..  
The proposed conceptual model is, by the authors’ own admission, more a recognition 
of the individual roles and inclusive environment needed to implement SDM than a 
guide of how a healthcare team should engage a patient in the clinical setting.  
Importantly, the model highlights the people, processes and shared understandings 
which are required if patient involvement in decisions is to be improved.  However, the 
majority of the work done in developing this model was in the primary care setting and 
the reference to an interprofessional team is not necessarily the same as an MDT.  
Interprofessional teams involve multiple professionals taking part in the care of the 
patient, potentially at different time points and different parts of the healthcare system 
(e.g. primary and secondary care).  The MDT is a unique example of interprofessional 
care: it involves a single interaction or a series of interactions which usually take place 
at one time point or over a short space of time.  This means that a lot of the steps shown 
occur simultaneously in the MDT meeting and clinic rather than sequentially; indeed 
this is one of the reasons why difficulties in patient engagement arise.  When studying 
MDT decision making, the central effect of the interaction of the members of the team 
with each other must also be acknowledged, as well as the interaction of the members 
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with the patient.  This thesis has provided a level of detail for the individual steps in the 
model above in relation to the MDT, and in doing so has added to it by casting light on 
the barriers which exist between the steps.  However, this model could not be applied to 
the MDT without adaptation. Also, as I have already briefly discussed; imposing a new 
model of working is not sufficient alone to change the behaviour of the team.  If the 
MDT is to effectively implement a more patient centred approach to decision making, a 
shared understanding of how to do this effectively needs to be in place.  Team training 
potentially has a role in achieving this 
Team training 
Team training potentially has a role in achieving more patient centred care however, 
few IP-SDM training programs exist: in a review of 80 training programs in 14 
countries and 10 languages, only five were aimed at a professional group other than 
doctors only, and only one adopted an inter-professional approach (Legare et al. 2012).  
Also, a recent systematic review of the effect of inter-professional training on team 
interaction and patient related outcomes was inconclusive (Reeves et al. 2010).  
Although the included papers showed inter-professional training to potentially decrease 
the clinical error rate (Morey et al. 2002), improve teamwork (Young et al. 2005) and 
increase patient satisfaction (Campbell et al. 2001), the six studies identified were of 
variable quality with heterogeneity of methodology.    
Korner et al (2012) developed one of the only training models aimed at inter-
professional teams, which divided SDM into ‘internal’ and ‘external’ participation.  
‘External’ participation involved communicating treatment options with the patient, 
discussing values and preferences and delivering a treatment recommendation.  
‘Internal’ participation concerned the communication within the team needed to create 
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shared decisions; this included training on communication and cooperation within the 
team, feedback between members, leadership style and tools to facilitate 
communication.  This training program was evaluated positively by the included teams, 
and implemented successfully, however the authors did not investigate the effect of the 
training on the process or outcome of decision making.   
Hence, although team training in SDM seems to make sense, there are few training 
programs available and even fewer studies evaluating its effect on the decision making 
process, patient experience and outcome.  At the same time, team training is in its 
infancy, so the obvious paucity of studies assessing the effectiveness of training in 
teams should not lead automatically to the conclusion that it is of no benefit, rather that 
the benefits are unknown.  Also, whilst recognising there is a need to better evaluate 
such specific team SDM training, more broad communication training is known to 
develop key communication skills in clinicians (Fallowfield et al. 2002).  Similar 
training techniques are therefore likely to be useful for improving communication (and 
patient involvement) in the MDT setting. 
Role of the recommendation 
Finally, if the MDT is to embrace patient centred care as a routine way of working, the 
role of the backstage MDT interaction and the resultant recommendation needs to be 
scrutinised.  If the MDT meeting and clinic follows a paternalistic pathway, the way in 
which this recommendation is used is clear: it is delivered to the patient with an 
assumption that it will be accepted.  However, if patients are involved in decision 
making, the data presented in this thesis highlights a unique problem with the MDT 
recommendation: its inflexibility.  In the clinician/patient dyad the recommendation can 
be adjusted and changed depending on the ongoing interaction with the patient and the 
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preferences expressed.  An MDT recommendation on the other hand, presents the 
members of the MDT with difficulty when trying to combine it with the preferences of 
the patient.  Is it a rule which must be adhered to?  If the patient disagrees with the 
recommendation, what action should the MDT member take?  It is not possible to 
provide an absolute answer to these questions, as it will vary from team to team and 
patient to patient.  However, the role of the recommendation and the way it is delivered 
to the patient needs to be explicit and agreed within each team.  Importantly, the 
recommendation should not be delivered until after the physician has discussed the 
options available and ascertained the values of the patient.  Also, after the 
recommendation has been given, the way in which the recommendation was generated 
and the values which underpin it must be explicitly discussed (Epstein et al. 2004).  
Through the course of this discussion, I have highlighted the steps which need to be 
taken to acknowledge a treatment choice, offer it to a patient and then support the 
patient in making a decision about their care.  The interaction between members of the 
MDT and the patient has been central to this discussion: it is a therapeutic relationship 
where preferences are constructed, risk and uncertainty are communicated and the 
process of decision making takes place.  As a conclusion to this discussion, I will 
outline the ways in which the MDT might change in order to achieve a more patient-




A new model of MDT working 
The MDT must be aware of the barriers to offering choice to patients and the 
importance of the interaction between physician and patient; this interaction should be 
central to the structure of the clinic.  At the end of Chapter Seven, I presented a model 
of decision making in the MDT which allows interaction of the team with each other 
and with the patient and acknowledges and supports the patient work of decision 




Firstly, I will discuss the assumptions which underlie this model.  Members of the team 
must agree that the patient is to be involved in the decision if the patient desires it.  
Figure 7: a new model of multidisciplinary working 
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Then, members should be aware of the steps which are required to involve a patient in a 
decision and the role that they, as an MDT member, should have in this.  Team training 
may have a role in establishing these assumptions.  Lastly, they must be aware of the 
barriers to decision making in this setting and how these should be overcome if choice 
is to be offered to the patient in clinic. 
At the centre of this model of MDT working is the interaction between MDT members 
and the patient and their supporters.  This interaction takes place within the MDT clinic, 
and is driven by the outputs of two work processes: the MDT meeting and patient work.  
The MDT meeting is the interaction of the team members with each other (mainly in the 
backstage), and the product of this is usually a treatment recommendation.  Patient work 
is the interaction of the patient with the MDT and their own supporters, and the product 
of this work is a patient preference.  I will discuss each of the steps in the decision 
process, in turn, below. 
The MDT meeting 
The aim of this meeting should be one or more treatment recommendations or a 
communication of alternative treatment options.  The members of the MDT should 
discuss the clinical information about the patient, review the radiology and pathology 
reports and discuss which treatment options are available for a particular patient.  The 
MDT should allow a patient a role in choosing the best option for them as an individual.  
At all times, the aim of the treatment recommendation and the values which underpin 
the discussion should be explicit.  This includes a consideration that survival at all costs 
is not always the patient’s main aim of treatment.  It should be clear that the MDT 
discussion is not a discussion of which option is ‘best’ for a particular patient as this 
assessment cannot be made backstage in the MDT meeting.  Instead it should be clear 
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what the recommendation is, why it was formed and which values underpin it.  The 
team should also explicitly state how it should be used in the MDT clinic and the MDT 
member who delivers the recommendation should be clear about how and when it is 
delivered in relation to the description of the options and the patient’s preferences. 
Patient work 
The aim of patient work is to form preferences which are stable and in line with their 
values and beliefs.  The patient work can take place at any time: it may be spread 
between information sources, places and people.  The MDT members should recognise 
this and enable it by providing support, resources and personnel to discuss the treatment 
options, communicate the risk and uncertainty, elicit preferences and explore them: a 
decision aid may support this work.  Some of the work may take place during the clinic 
appointments, some between the patient and their supporters and some between the 
patient, their supporters and a member of the MDT.    The team may consider providing 
an individual who is independent of the clinical team to act as a decision coach or 
navigator. 
Interaction 
The aim of the interaction between the MDT members and the patient is to form a 
treatment decision.  Here, the MDT members help the patient to construct their 
treatment preference, give information about the risks and benefits of treatment options 
and discuss the uncertainty and risk associated with the choice of treatment.  The 
treatment recommendation should be delivered, together with the reason for the 
recommendation, its aim and a discussion of why other options are not recommended.  
The timing of the delivery of the treatment recommendation is challenging: on one 
237 
 
hand, if could be delivered after the description of the options.  This could present 
difficulties in combining the recommendation and the patient view.  Alternatively, the 
recommendation could be given at an early stage to inform the patient preferences: 
however this must be done with the acknowledgement that this recommendation was 
formed without the patient perspective.   Again, a decision aid may work in facilitating 
this discussion. 
This interaction can happen once, or multiple times in relation to the patient and staff 
work.  For example, the MDT member and patient may have a first consultation 
focussed on information exchange and a second concentrated on decision making (with 
support between the appointments). As I discussed in Chapter Seven, the provision of 
time has prognostic and logistical barriers.  The disease being treated is unrelenting, the 
make-up of the MDT meeting changes from week to week, and patients are often 
referred to the clinic as part of the cancer waiting times national strategy, which dictates 
that treatment must be started with 62 days of their first presentation.  Thus, although 
providing time is beneficial, the organisational barriers must be acknowledged and 
overcome in order for time provision to be routine practice. 
Importantly, this model does not have a time line.  The three work processes (MDT 
meeting, patient work and interaction) should take place, but there is no requirement for 
them to take place in any particular order.  This allows flexibility for various teams to 
format their clinic in various ways.  The patient may be enabled to come to the initial 
consultation more informed and prepared for the discussion.  The MDT meeting may 
take place in a small ‘combined clinic’ setting around the interaction with the patient.  I 
observed this practice during informal observations in other centres.  A small group of 
treating physicians of various specialities meet together briefly, and then meet the 
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patient as a group.  They can then leave the patient to continue backstage discussions 
which are then delivered to the patient again or the patient is allowed into the backstage.  
This structure breaks down the barrier between the backstage and frontstage, allows 
maximal interaction with the patient, and is dynamic, so the decision making model can 
be guided by the preference of the patient.  It allows short, interlinked discussions to 
take place in quick succession between the physicians with or without the patient with a 
resultant recommendation which is more dynamic and therefore responsive to the 
patient needs.  The result of this interaction and discussion could then be delivered to a 
larger MDT on a different occasion.  
The patient work can take place before the MDT meeting, after it, or within the clinic 
appointment.  The patient may legitimately delegate all or some of the responsibility of 
the decision to the members of the team, or turn down the opportunity to distribute this 
work.  MDT members should encourage the patient to engage in this work, but the 
patient must be able to exercise a right to take very little part in the decision if required. 
There is flexibility in the model above to allow patients to attend their own MDT 
meeting if required.  As I discussed in Chapter Three, this idea is popular amongst 
patient advocates (Butow et al. 2007), but not clinicians (Butow et al. 2007; NCAT 
2009).  There is little data documenting the patient experience of involvement in MDTs, 
as it is rarely routine practice: small studies have concluded that patients attending their 
own MDT allows for better information giving but not necessarily improved 
involvement in decision making (Choy et al. 2007; Bellardita et al. 2011).   This means 
the area of patients attending their own meeting is relatively unfamiliar as an 
intervention, making conclusions about its worth difficult.  However, the concept of a 
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well-prepared and supported patient attending a sympathetic MDT is worth further 
exploration. 
The model allows MDTs to identify the processes required to enable patients to become 
involved in decisions about their care.  It is flexible enough to act as a guide for the 
organisation and format of team decision making, but at the same time clearly states the 
essential work processes which should take place.  If this model is to be enacted in 
practice, the barriers to offering and supporting choice need to be acknowledged and 
overcome.  Only by achieving this, can the MDT begin to move towards improving the 
process of patient engagement. 
Strengths and weaknesses 
This data presented in this thesis provides an in depth account of the process of decision 
making in MDTs, with a particular focus on patient engagement in this process.  The 
analysis of observational data provides a detailed, in depth description of the backstage 
activity of the staff participants and, when combined with the staff interviews, a novel 
insight into the challenges facing MDTs when involving patients in decisions.  My role 
as a clinician researcher allowed me to understand the complex MDT discussions and 
enabled informal and formal interviews with participants which were perhaps more 
frank than they would be with a non-clinician researcher. 
However, the methods of data collection, analysis and sampling also present limitations 
which should be acknowledged.  This thesis highlights significant problems with patient 
participation in MDT decision making, and because of this, patient interaction with the 
team can sometimes be minimal.  As I detail in Chapter Four, data were analysed using 
a theoretical basis of symbolic interactionism, where interaction between participants is 
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the unit of study.  Sometimes the lack of patient interaction with the MDT members in 
decision making consultations led to difficulties when attempting to gather data on the 
patient experience of making decisions.  To an extent, I tried to counteract this by 
conducting interviews with the patients themselves, but this presented more problems.  
If patients delegate the decision to the members of the MDT, their process of decision 
making may have been very short; merely a process of asking somebody else to make 
the decision for them.  This sometimes made for challenging interviews when trying to 
discuss a patient’s process of decision making, as they sometimes had no such account 
to draw upon.  With this in mind, I sought to gather further data about the patient 
experience by conducting semi-structured interviews with two groups of patients at 
various time points. However, this only went part of the way to providing a richness and 
depth to the account of the patients’ decisions.  I followed up group one after an average 
of nine months, however patients were hard to reach at this time: they were often still 
suffering the acute effects of radical cancer treatment and, understandably, were not 
interested in talking to a researcher.  Protective carers usually took phone calls rather 
than the patients themselves which sometimes compounded this effect.  When I did 
manage to interview patients from this group, they usually gave a detailed account of 
the process of treatment and rehabilitation, but often did not see the decision as a 
defined ‘event’ to be expanded upon.  I encountered the same problem with group two 
patients (who had received treatment within the last five years).  Group two were a 
difficult group to access; I was reliant on patient names being given to me by the 
clinical team and the selected patients were often happy with their treatment and felt 




With respect to data collection, my sampling criteria meant that some interesting 
decisions and patients will have been missed.  One of my criteria was a “patient with a 
decision to make”.  In specifying this, a group of patients - those who are offered just 
one option which they must accept or turn down - which make up a significant 
proportion of the clinic, were omitted.  Importantly, this group is not absent from the 
thesis as sometimes I included patients for whom treatment options existed, but only 
one option was actually presented to the patient in clinic.  However, the experience of 
these patients, in accepting or refusing the clear treatment recommendation is under 
represented.   
Finally, data collection occurred over three centres, each with a more “classical” 
structure of MDT clinic (as I have described through the course of the Chapter Seven 
and Chapter Eight).  It is assumed, but not clear, if this structure is indeed universal 
amongst other centres and cancer areas.  Thus some of the issues highlighted in this 




Chapter 9: Conclusion 
The MDT was introduced after the Calman-Hine report highlighted the value of 
centralisation of cancer care (Calman and Hine 1995).  In subsequent NICE Improving 
Outcomes Guidance in various cancer subsites, the obligation to make every cancer 
decision using an MDT was repeatedly reinforced (NICE 2004).  MDT decision making 
is now the gold standard of care in cancer treatment delivery in the UK.  However, 
despite the central importance of the MDT in cancer care and the significant cost 
associated (Taylor et al. 2010), evidence for its effectiveness is sparse (Fleissig et al. 
2006).  There is no proven effect on survival (Hong et al. 2010), and although it is 
established that different decisions are made within an MDT than by individual 
clinicians, it is unknown as to whether these decisions are better (Blazeby et al. 2006).  
There is little doubt that the MDT is popular amongst its members (NCAT 2009): 
indeed this may be a primary reason for its longevity.  However, it is difficult to 
ascertain how much input allied health professionals have on the resultant treatment 
recommendation: is the MDT discussion truly ‘multidisciplinary’ or is it merely an 
‘observed conversation’?   
Patient involvement in decision making is ethically, morally and clinically necessary.  
HNC has a low survival (DAHNO 2011), and patients face a significant functional 
trade-off if they are to achieve cure (Abendstein et al. 2005).  The data presented in this 
thesis highlight the multiple barriers to effective patient involvement that MDT working 
presents.  Indeed, it could be argued that, with respect to patient involvement in 
decisions, the MDT paradigm is a backwards step from the physician-patient dyad.  The 
format of the meeting and clinic often leads to strong recommendations and decisions of 
‘best’ being made in the backstage without the patient, primarily focused on a bias 
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towards cure, and ill-informed by patient preferences.  Concerns about decision 
delegation and risk communication discourage clinicians from offering choice to 
patients and lack of relevant knowledge and experience lead patients to delegate the 
decision to the MDT members.  This encourages and perpetuates the paternalistic 
process, with apparent assent from both patients and staff.  
Progression towards patient centred decisions in an MDT clinic cannot be achieved by 
introducing increasing amounts of information about the patient into the backstage.  
Instead, the interaction between MDT members and patients should be central to the 
structure of the clinic.  The product of the backstage MDT discussion, the 
recommendation, suffers from inflexibility, creating problems when attempting to 
combine it with the values and preferences of the patient.  These values and preferences 
are difficult to represent adequately in the traditional MDT structure, and therefore to 
incorporate into the decisions.  There is little understanding of the patient work of 
decision making, and thus patients are not adequately supported in making decisions 
about their care. 
If MDT working is to remain the gold standard of care, it should continually adapt to 
meet the needs of the patient population that it serves.  If patient involvement is to be 
improved, close consideration should be given to the structure of the clinic, the content 
and aim of the MDT backstage discussion, the support provided to patients and the 
central importance of the interaction between members of the MDT and the patient.  
Moreover, a wider consideration of the quality of care that the MDT provides, coupled 
with a desire to continually improve this standard of provision, should perhaps lead 
MDT members to reflect on whether their current mode of working is achieving the 
high standard of individualised care required for every cancer patient. 
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Appendix 1: Glossary 
CNS  Clinical Nurse Specialist 
CT scan Computed tomography scan, a detailed cross-sectional scan which is 
performed on all patients with head and neck cancer to delineate the size and spread of 
the cancer 
ENT  Ear Nose and Throat, the surgical speciality which encompasses the 
treatment of head and neck cancer 
EUA  Examination under anaesthetic 
HNC  Head and neck cancer 
HPV  Human Papilloma Virus 
IP-SDM Interprofessional shared decision making 
Larynx The voicebox 
Max Facs Maxillofacial surgery 
MDT  Multidisciplinary team, the collection of professionals who gather to 
make treatment recommendations 
MRI  Magnetic Resonance Imaging, a detailed cross sectional scan using 
strong electromagnets.  Provides details of different internal structures than the CT scan. 
M stage Metastasis stage.  Denotes the presence of distant metastases (rare in 
head and neck cancer). If no metastases are present, the tumour is graded M0, if the 
cancer has spread to distant structures (most often the lung) it is graded M1. 
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NCAT  National Cancer Action Team 
NHS  National Health Service 
NICE  National Institute for Health and Clinical Excellence 
N stage Nodal stage.  The number, position and size of the lymph nodes that the 
cancer has spread to: graded between N0 (no detectable spread to lymph nodes) and N3 
Oncology Medical speciality concerned the treatment of cancer 
PET CT Positron emission tomography computed tomograph scan: similar to a 
CT scan, but highlights groups of cancer cells by changing their colour on the scan 
Pharynx The anatomical area at the back of the mouth and nose which links the 
mouth to the oesophagus and windpipe.  Consists of nasopharynx (back of the nose), 
oropharynx (back of the mouth, where the tonsil and the back of the tongue is) and 
hypopharynx (lower down in the throat, at the top of the oesophagus, behind the 
voicebox) 
SALT  Speech and language therapist 
SCC  Squamous cell carcinoma, the most common histological diagnosis of 
head and neck cancer 
SDM  Shared decision making 
T stage Tumour stage.  Concerns the size, position and local invasion of the 
tumour: graded between T1 (small tumours) and T4 (large, invasive tumours).   
Total laryngectomy Complete removal of the voice box  
268 
 













Appendix 3: Interview Guides 
Staff Interview Schedule 
Introduce researcher and purpose of the study 
Obtain consent to proceed and to record the conversation 
 What do you see as the best way of making decisions in head and neck cancer? 
 The MDT 
o What is it for?  What is its primary aim? 
o What works well, and what works not so well? 
o How could it be improved? 
o No decision about me without me in the MDT…. Is this possible? 
 Treatment decision 
o Why do you regard a treatment as the best for a patient? 
o What factors do you take into account when making treatment decisions? 
 Patient involvement in decisions/shared decision making 
o What does it mean to you? 
o Do you think there are barriers to patient involvement?  What are they?  
Why do they exist? 
o Why do clinicians struggle to involve their patients effectively? 
o Do you think we need to improve patient involvement?  Why? 
 Uncertainty/conflict 
o Is it a problem or is it healthy/required? 
o How should uncertainty and conflict be presented to the patient?  Should 
they know that you don’t know? 
o If there are options, how should they be communicated? 
 Decision for treatment 
o What is the role of the patient in the treatment decision? 
o How much of a role should the patient have?  Can patients know 
enough? 
o How much of a role should a patient have in the decision 
 Should we give power of vito? 
 Should you allow a patient to make a decision which is 
considered wrong? 
 how much should a patient know before treatment 
o How much of a role should the family have 
 Palliation/prognosis 
o Do we palliate enough? Do we treat too many people radically? 
o What are the barriers to good palliation? 
o Do you think we have a range of palliative options available to us? 
o Do you have prognostic information available to you? 




New patient interview 1 schedule 
Introduce researcher and purpose of the study 
Obtain consent to proceed and to record the conversation 
The interview will cover the following broad areas: 
 Previous experience of making healthcare decisions 
o What does shared decision making mean? 
o Have you had to make big healthcare decisions before? 
 Experience of making this decision 
o What was your process of making the decision?  Talk me though it 
o What did you draw upon? 
o What factors did you take into account? 
o Did you turn to anybody/anything for information or help? 
o How did you come to your final decision? 
o What was the MDT like? 
o Did you understand what was going on? 
o Could it be improved? 
 Information given about the disease and treatment options 
o Do you think you had enough information? 
o Where do you get your information from? 
o Do you think you need more information? 
o Did you understand all the information 
 Patient involvement in the decision about care 
o Should patients be involved in decisions about their care? 
o How should we involve patients? 
o Were you involved? How? 
o Would you have liked more say/less say? 
o How this made the participant feel, and further exploration 
 What are your expectations of treatment? 
o Are you expecting side effects?  What sort? 
o Do you have any idea of your prognosis?  Do you want to know? 
o Where will you be in 6 months time? 







New patient interview 2 schedule/retrospective patient interview schedule 
Introduce researcher and purpose of the study 
Obtain consent to proceed and to record the conversation 
 Experience of the treatment 
o What has happened so far, story of the treatment 
o Correlation with expectations – worse, better 
 New normal 
o Do you have a good quality of life? 
o How do you cope with swallowing? 
o How is your voice, how do you get on with communication? 
 MDT and decision process 
o When you look back did you understand the treatment decision? 
o Did you understand the consequences of the decision? 
o Did you have enough information to base the decision on? 
o Should they have allowed you more or less control over the decision? 
o Do you wish the decision had been made differently? 
o Do you feel you made the right or the wrong decision? 
o Do you have any regrets? 
o How could they improve the clinic/the decision process? 
o In the perfect world, how do you think treatment decisions should be 
made? 
 Palliation/prognosis 
o Were you ever aware of the chances of the treatment being successful? 
o Would you want to be aware? 
o Was palliation ever an option for you?  Is it now? 
 Information giving 
o Do you think you had enough information about treatment? 
o Did you understand what you were entering yourself into? 
o Should they give more information?  Could they? 
 
